

**DISSERTATION TITLE: A KNOWLEDGE-BASED SYSTEM FOR INTELLIGENT
SUPPORT IN PHARMACOGENOMICS EVIDENCE ASSESSMENT: ONTOLOGY-DRIVEN
EVIDENCE REPRESENTATION, RETRIEVAL, CLASSIFICATION AND
INTERPRETATION**

APPENDICE

**APPENDIX 1: LIST OF RESEARCH ARTICLES SELECTED FOR DERIVING CONCEPTUAL
MODEL OF PHARMACOGENOMICS EVIDENCE ASSESSMENT..... A1**

APPENDIX 2: INSTANTIATION OF INDIVIDUAL PUBLICATIONS A5

APPENDIX 3: INSTANTIATION OF INDIVIDUAL STUDIES A9

APPENDIX 4: INSTANTIATION OF INDIVIDUAL EVIDENCE..... A25

APPENDIX 1: LIST OF RESEARCH ARTICLES SELECTED FOR DERIVING CONCEPTUAL MODEL OF PHARMACOGENOMICS EVIDENCE ASSESSMENT

| PMID | Citation of Article |
|----------|--|
| 10509530 | Ogg MS, Brennan P, Meade T, Humphries SE. CYP2C9*3 allelic variant and bleeding complications. <i>Lancet</i> . 1999 Sep 25;354(9184):1124. |
| 11127854 | Margaglione M, Colaizzo D, D'Andrea G, Brancaccio V, Ciampa A, Grandone E, Di Minno G. Genetic modulation of oral anticoagulation with warfarin. <i>Thromb Haemost</i> . 2000 Nov;84(5):775-8. |
| 11926893 | Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. <i>JAMA</i> . 2002 Apr 3;287(13):1690-8. |
| 15841315 | Voorra D, Eby C, Linder MW, Milligan PE, Bukaveckas BL, McLeod HL, Maloney W, Clohisy J, Burnett RS, Grosso L, Gatchel SK, Gage BF. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. <i>Thromb Haemost</i> . 2005 Apr;93(4):700-5. |
| 15888487 | Yuan HY, Chen JJ, Lee MT, Wung JC, Chen YF, Charng MJ, Lu MJ, Hung CR, Wei CY, Chen CH, Wu JY, Chen YT. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. <i>Hum Mol Genet</i> . 2005 Jul 1;14(13):1745-51. Epub 2005 May 11. |
| 16160068 | Hillman MA, Wilke RA, Yale SH, Vidaillet HJ, Caldwell MD, Glurich I, Berg RL, Schmelzer J, Burmester JK. A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. <i>Clin Med Res</i> . 2005 Aug;3(3):137-45. |
| 17653141 | Limdi NA, McGwin G, Goldstein JA, Beasley TM, Arnett DK, Adler BK, Baird MF, Acton RT. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. <i>Clin Pharmacol Ther</i> . 2008 Feb;83(2):312-21. Epub 2007 Jul 25. |
| 17851566 | Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. <i>Clin Pharmacol Ther</i> . 2008 Mar;83(3):460-70. Epub 2007 Sep 12. |
| 17982182 | Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. <i>N Engl J Med</i> . 2007 Nov 15;357(20):2001-15. Epub 2007 Nov 4. |
| 17989110 | Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP, Kahn SF, May HT, Samuelson KM, Muhlestein JB, Carlquist JF; Couma-Gen Investigators. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. <i>Circulation</i> . 2007 Nov 27;116(22):2563-70. Epub 2007 Nov 7. |
| 18305455 | Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, Milligan PE, Grice G, Lenzini P, Rettie AE, Aquilante CL, Grosso L, Marsh S, Langae T, Farnett LE, Voorra D, Veenstra DL, Glynn RJ, Barrett A, McLeod HL. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. <i>Clin Pharmacol Ther</i> . 2008 Sep;84(3):326-31. doi:10.1038/clpt.2008.10. Epub 2008 Feb 27. Erratum in: <i>Clin Pharmacol Ther</i> . 2008 Sep;84(3):430. |
| 18482659 | Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, Stratz C, Schmiebusch P, Bestehorn HP, Büttner HJ, Neumann FJ. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. <i>J Am Coll Cardiol</i> . 2008 May 20;51(20):1925-34. doi:10.1016/j.jacc.2007.12.056. |
| 18577829 | Malek LA, Kisiel B, Spiewak M, Grabowski M, Filipiak KJ, Kostrzewa G, Huczek Z, Ploski R, Opolski G. Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel. <i>Circ J</i> . 2008 Jul;72(7):1165-9. |
| 19106083 | Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, Steg PG, Ferrières J, Danchin N, Becquemont L; French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. <i>N Engl J Med</i> . 2009 Jan 22;360(4):363-75. doi:10.1056/NEJMoa0808227. Epub 2008 Dec 22. |
| 19106084 | Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS. Cytochrome p-450 polymorphisms and response to clopidogrel. <i>N Engl J Med</i> . 2009 Jan 22;360(4):354-62. doi:10.1056/NEJMoa0809171. Epub 2008 Dec 22. |
| 19108880 | Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, Payot L, Brugier D, Cayla G, Beygui F, Bensimon G, Funck-Brentano C, Montalescot G. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. <i>Lancet</i> . 2009 Jan 24;373(9660):309-17. doi:10.1016/S0140-6736(08)61845-0. Epub 2008 Dec 26. |
| 19177029 | Huang SW, Chen HS, Wang XQ, Huang L, Xu DL, Hu XJ, Huang ZH, He Y, Chen KM, Xiang DK, Zou XM, Li Q, Ma LQ, Wang HF, Chen BL, Li L, Jia YK, Xu XM. Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. <i>Pharmacogenet Genomics</i> . 2009 Mar;19(3):226-34. doi:10.1097/FPC.0b013e328326e0c7. |
| 19193675 | Sibbing D, Stegherr J, Latz W, Koch W, Mehilli J, Dörrler K, Morath T, Schömig A, Kastrati A, von Beckerath N. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. <i>Eur Heart J</i> . 2009 Apr;30(8):916-22. doi:10.1093/eurheartj/ehp041. Epub 2009 Feb 4. |
| 19228618 | International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA. Estimation of the warfarin dose with clinical and pharmacogenetic data. <i>N Engl J Med</i> . 2009 Feb 19;360(8):753-64. doi:10.1056/NEJMoa0809329. Erratum in: <i>N Engl J Med</i> . 2009 Oct 15;361(16):1613. Dosage error in article text. |
| 19268736 | Giusti B, Gori AM, Marcucci R, Saracini C, Sestini I, Paniccia R, Buonamici P, Antonucci D, Abbate R, Gensini GF. |

| | |
|----------|---|
| | Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. <i>Am J Cardiol.</i> 2009 Mar 15;103(6):806-11. doi:10.1016/j.amjcard.2008.11.048. Epub 2009 Jan 24. |
| 19414633 | Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias WL, Braunwald E, Sabatine MS. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. <i>Circulation.</i> 2009 May 19;119(19):2553-60. doi:10.1161/CIRCULATIONAHA.109.851949. Epub 2009 May 4. |
| 19706858 | Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson Q, Pollin TI, Post W, Parsa A, Mitchell BD, Faraday N, Herzog W, Gurbel PA. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. <i>JAMA.</i> 2009 Aug 26;302(8):849-57. doi:10.1001/jama.2009.1232. |
| 19717846 | Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators, Freij J, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. <i>N Engl J Med.</i> 2009 Sep 10;361(11):1045-57. doi:10.1056/NEJMoa0904327. Epub 2009 Aug 30. |
| 20083681 | Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, Morath T, Schömig A, von Beckerath N, Kastrati A. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. <i>Circulation.</i> 2010 Feb 2;121(4):512-8. doi:10.1161/CIRCULATIONAHA.109.885194. Epub 2010 Jan 18. |
| 20375999 | Lenzini P, Wadelius M, Kimmel S, Anderson JL, Jorgensen AL, Pirmohamed M, Caldwell MD, Limdi N, Burmester JK, Dowd MB, Anchaisuksiri P, Bass AR, Chen J, Eriksson N, Rane A, Lindh JD, Carlquist JF, Horne BD, Grice G, Milligan PE, Eby C, Shin J, Kim H, Kurnik D, Stein CM, McMillin G, Pendleton RC, Berg RL, Deloukas P, Gage BF. Integration of genetic, clinical, and INR data to refine warfarin dosing. <i>Clin Pharmacol Ther.</i> 2010 May;87(5):572-8. doi:10.1038/clpt.2010.13. Epub 2010 Apr 7. |
| 20381283 | Epstein RS, Moyer TP, Aubert RE, O Kane DJ, Xia F, Verbrugge RR, Gage BF, Teagarden JR. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). <i>J Am Coll Cardiol.</i> 2010 Jun 22;55(25):2804-12. doi:10.1016/j.jacc.2010.03.009. Epub 2010 Apr 8. |
| 20492467 | Sorich MJ, Vitry A, Ward MB, Horowitz JD, McKinnon RA. Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. <i>J Thromb Haemost.</i> 2010 Aug;8(8):1678-84. doi:10.1111/j.1538-7836.2010.03923.x. Epub 2010 May 21. |
| 20708365 | Bonello L, Armero S, Ait Mokhtar O, Mancini J, Aldebert P, Saut N, Bonello N, Barragan P, Arques S, Giacomoni MP, Bonello-Burignat C, Bartholomei MN, Dignat-George F, Camoin-Jau L, Paganelli F. Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism. <i>J Am Coll Cardiol.</i> 2010 Nov 9;56(20):1630-6. doi:10.1016/j.jacc.2010.07.004. Epub 2010 Aug 12. |
| 20801494 | Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, Simon T, Antman EM, Braunwald E, Sabatine MS. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. <i>Lancet.</i> 2010 Oct 16;376(9749):1312-9. doi:10.1016/S0140-6736(10)61273-1. |
| 20801498 | Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, Horrow J, Husted S, Katus H, Steg PG, Shah SH, Becker RC; PLATO investigators. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. <i>Lancet.</i> 2010 Oct 16;376(9749):1320-8. doi:10.1016/S0140-6736(10)61274-3. |
| 20826260 | Tiroch KA, Sibbing D, Koch W, Roosen-Runge T, Mehilli J, Schömig A, Kastrati A. Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events. <i>Am Heart J.</i> 2010 Sep;160(3):506-12. doi:10.1016/j.ahj.2010.06.039. |
| 20833683 | Harmsze AM, van Werkum JW, Ten Berg JM, Zwart B, Bouman HJ, Breet NJ, van 't Hof AW, Ruven HJ, Hackeng CM, Klungel OH, de Boer A, Deneer VH. CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study. <i>Eur Heart J.</i> 2010 Dec;31(24):3046-53. doi:10.1093/eurheartj/ehq321. Epub 2010 Sep 10. |
| 20924183 | Małek LA, Przyłuski J, Spiewak M, Kłopotowski M, Kostrzewa G, Kruk M, Płoski R, Witkowski A, Rużyło W. Cytochrome P450 2C19 polymorphism, suboptimal reperfusion and all-cause mortality in patients with acute myocardial infarction. <i>Cardiology.</i> 2010;117(2):81-7. doi:10.1159/000320093. Epub 2010 Oct 6. |
| 20979470 | Paré G, Mehta SR, Yusuf S, Anand SS, Connolly SJ, Hirsh J, Simonsen K, Bhatt DL, Fox KA, Eikelboom JW. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. <i>N Engl J Med.</i> 2010 Oct 28;363(18):1704-14. doi:10.1056/NEJMoa1008410. Epub 2010 Aug 29. |
| 21099121 | Sawada T, Shinke T, Shite J, Honjo T, Haraguchi Y, Nishio R, Shinohara M, Toh R, Ishida T, Kawamori H, Kozuki A, Inoue T, Hariki H, Hirata K. Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel. <i>Circ J.</i> 2011;75(1):99-105. Epub 2010 Nov 16. |
| 21168310 | Yamamoto K, Hokimoto S, Chitose T, Morita K, Ono T, Kaikita K, Tsujita K, Abe T, Deguchi M, Miyagawa H, Saruwatari J, Sumida H, Sugiyama S, Nakagawa K, Ogawa H. Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy. <i>J Cardiol.</i> 2011 Mar;57(2):194-201. doi:10.1016/j.jjcc.2010.10.007. Epub 2010 Dec 17. |
| 21170047 | Bouman HJ, Schömig E, van Werkum JW, Velder J, Hackeng CM, Hirschhäuser C, Waldmann C, Schmalz HG, ten Berg JM, Taubert D. Paraoxonase-1 is a major determinant of clopidogrel efficacy. <i>Nat Med.</i> 2011 Jan;17(1):110-6. doi:10.1038/nm.2281. Epub 2010 Dec 19. Erratum in: <i>Nat Med.</i> 2011 Sep;17(9):1153. |
| 21272753 | Finkelman BS, Gage BF, Johnson JA, Brensinger CM, Kimmel SE. Genetic warfarin dosing: tables versus algorithms. <i>J Am Coll Cardiol.</i> 2011 Feb 1;57(5):612-8. doi:10.1016/j.jacc.2010.08.643. |
| 21334530 | Hulot JS, Collet JP, Montalescot G. Genetic substudy of the PLATO trial. <i>Lancet.</i> 2011 Feb 19;377(9766):637, author reply 637-8. doi:10.1016/S0140-6736(11)60227-4. |
| 21423021 | Burmester JK, Berg RL, Yale SH, Rottscheit CM, Glurich IE, Schmelzer JR, Caldwell MD. A randomized controlled trial of genotype-based Coumadin initiation. <i>Genet Med.</i> 2011 Jun;13(6):509-18. doi:10.1097/GIM.0b013e31820ad77d. |
| 21511218 | Collet JP, Hulot JS, Anzaha G, Pena A, Chastre T, Caron C, Silvain J, Cayla G, Bellemain-Appaix A, Vignalou JB, Galier S, |

| | |
|----------|--|
| | Barthélémy O, Beygui F, Gallois V, Montalescot G; CLOVIS-2 Investigators. High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2). <i>JACC Cardiovasc Interv</i> . 2011 Apr;4(4):392-402. doi:10.1016/j.jcin.2011.03.002. |
| 21527445 | Sibbing D, Koch W, Massberg S, Byrne RA, Mehilli J, Schulz S, Mayer K, Bernlochner I, Schömig A, Kastrati A. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. <i>Eur Heart J</i> . 2011 Jul;32(13):1605-13. doi:10.1093/eurheartj/ehr155. Epub 2011 Apr 28. |
| 21679849 | Campo G, Parrinello G, Ferraresi P, Lunghi B, Tebaldi M, Miccoli M, Marchesini J, Bernardi F, Ferrari R, Valgimigli M. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. <i>J Am Coll Cardiol</i> . 2011 Jun 21;57(25):2474-83. doi:10.1016/j.jacc.2010.12.047. |
| 21700758 | Oh IY, Park KW, Kang SH, Park JJ, Na SH, Kang HJ, Koo BK, Jeong YH, Hwang JY, Kwak CH, Park Y, Hwang SJ, Ko YG, Shin DJ, Jang Y, Kim HS. Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents. <i>Heart</i> . 2012 Jan;98(2):139-44. doi:10.1136/hrt.2011.227272. Epub 2011 Jun 23. |
| 21778720 | Yan SD, Chen M, Li Q, Liu XJ, Peng Y, Chai H, Xu YN, Wei JF, Huang DJ. The value of combining CYP2C19*2 polymorphism with classic risk factors in prediction of clinical prognosis in acute coronary syndrome patients. <i>Cardiology</i> . 2011;119(1):15-20. doi:10.1159/000329048. Epub 2011 Jul 16. |
| 21854540 | Harmsze AM, van Werkum JW, Souverein PC, Breet NJ, Bouman HJ, Hackeng CM, Ruven HJ, ten Berg JM, Klungel OH, de Boer A, Deneer VH. Combined influence of proton-pump inhibitors, calcium-channel blockers and CYP2C19*2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention. <i>J Thromb Haemost</i> . 2011 Oct;9(10):1892-901. doi:10.1111/j.1538-7836.2011.04483.x. |
| 21862109 | Ono T, Kaikita K, Hokimoto S, Iwashita S, Yamamoto K, Miyazaki Y, Horio E, Sato K, Tsujita K, Abe T, Deguchi M, Tayama S, Sumida H, Sugiyama S, Yamabe H, Nakamura S, Nakagawa K, Ogawa H. Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention. <i>Thromb Res</i> . 2011 Dec;128(6):e130-6. doi:10.1016/j.thromres.2011.07.028. Epub 2011 Aug 20. |
| 22028352 | Cayla G, Hulot JS, O'Connor SA, Pathak A, Scott SA, Gruel Y, Silvain J, Vignalou JB, Huerre Y, de la Briolle A, Allanic F, Beygui F, Barthélémy O, Montalescot G, Collet JP. Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. <i>JAMA</i> . 2011 Oct 26;306(16):1765-74. doi:10.1001/jama.2011.1529. |
| 22045970 | Jeong YH, Tantry US, Kim IS, Koh JS, Kwon TJ, Park Y, Hwang SJ, Bliden KP, Kwak CH, Hwang JY, Gurbel PA. Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin. <i>Circ Cardiovasc Interv</i> . 2011 Dec 1;4(6):585-94. doi:10.1161/CIRCINTERVENTIONS.111.962555. Epub 2011 Nov 1. |
| 22088240 | Tang XF, He C, Yuan JQ, Meng XM, Yang YJ, Qin XW, Qiao SB, Liu HB, Wu YJ, Yao M, Chen J, You SJ, Wu Y, Li JJ, Dai J, Chen JL, Gao RL, Chen ZJ. [Impact of cytochrome P450 2C19 polymorphisms on outcome of cardiovascular events in clopidogrel-treated Chinese patients after percutaneous coronary intervention]. <i>Zhonghua Xin Xue Guan Bing Za Zhi</i> . 2011 Jul;39(7):617-20. Chinese. |
| 22088980 | Mega JL, Hochholzer W, Frelinger AL 3rd, Kluk MJ, Angiolillo DJ, Kereiakes DJ, Isserman S, Rogers WJ, Ruff CT, Contant C, Pencina MJ, Scirica BM, Longtine JA, Michelson AD, Sabatine MS. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. <i>JAMA</i> . 2011 Nov 23;306(20):2221-8. doi:10.1001/jama.2011.1703. Epub 2011 Nov 16. |
| 22116003 | Tello-Montoliu A, Jover E, Marín F, Bernal A, Lozano ML, Sánchez-Vega B, Pastor FJ, Hurtado JA, Valdés M, Vicente V, Rivera J. Influence of CYP2C19 polymorphisms in platelet reactivity and prognosis in an unselected population of non ST elevation acute coronary syndrome. <i>Rev Esp Cardiol (Engl Ed)</i> . 2012 Mar;65(3):219-26. doi:10.1016/j.recesp.2011.07.013. Epub 2011 Nov 23. English, Spanish. |
| 22190063 | Delaney JT, Ramirez AH, Bowton E, Pulley JM, Basford MA, Schildcrout JS, Shi Y, Zink R, Oetjens M, Xu H, Cleator JH, Jahangir E, Ritchie MD, Masys DR, Roden DM, Crawford DC, Denny JC. Predicting clopidogrel response using DNA samples linked to an electronic health record. <i>Clin Pharmacol Ther</i> . 2012 Feb;91(2):257-63. doi:10.1038/clpt.2011.221. Epub 2011 Dec 21. |
| 22377481 | Teixeira R, Monteiro P, Marques G, Pego J, Lourenço M, Tavares C, Reboredo A, Monteiro S, Gonçalves F, Ferreira MJ, Freitas M, Ribeiro G, Providência LA. CYP2C19*2 and prognosis after an acute coronary syndrome: Insights from a Portuguese center. <i>Rev Port Cardiol</i> . 2012 Apr;31(4):265-73. doi:10.1016/j.repc.2012.02.001. Epub 2012 Feb 28. |
| 22390861 | Marcucci R, Giusti B, Panizza R, Gori AM, Saracini C, Valente S, Giglioli C, Parodi G, Antonucci D, Gensini GF, Abbate R. High on-treatment platelet reactivity by ADP and increased risk of MACE in good clopidogrel metabolizers. <i>Platelets</i> . 2012;23(8):586-93. doi:10.3109/09537104.2012.658106. Epub 2012 Mar 5. |
| 22431865 | Anderson JL, Horne BD, Stevens SM, Woller SC, Samuelson KM, Mansfield JW, Robinson M, Barton S, Brunisholz K, Mower CP, Huntinghouse JA, Rollo JS, Siler D, Bair TL, Knight S, Muhlestein JB, Carlquist JF. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). <i>Circulation</i> . 2012 Apr 24;125(16):1997-2005. doi:10.1161/CIRCULATIONAHA.111.070920. Epub 2012 Mar 19. |
| 22450429 | Bhatt DL, Paré G, Eikelboom JW, Simonsen KL, Emison ES, Fox KA, Steg PG, Montalescot G, Bhakta N, Hacke W, Flather MD, Mak KH, Cacoub P, Creager MA, Berger PB, Steinhilb SR, Murugesan G, Mehta SR, Kottke-Marchant K, Lincoff AM, Topol EJ; CHARISMA Investigators. The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. <i>Eur Heart J</i> . 2012 Sep;33(17):2143-50. Epub 2012 Mar 26. |
| 22464343 | Roberts JD, Wells GA, Le May MR, Labinaz M, Glover C, Froeschl M, Dick A, Marquis JF, O'Brien E, Goncalves S, Druce I, Stewart A, Gollob MH, So DY. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. <i>Lancet</i> . 2012 May 5;379(9827):1705-11. doi:10.1016/S0140-6736(12)60161-5. Epub 2012 Mar 29. |
| 22624833 | Price MJ, Murray SS, Angiolillo DJ, Lillie E, Smith EN, Tisch RL, Schork NJ, Teirstein PS, Topol EJ; GIFT Investigators. |

| | |
|----------------|---|
| | Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study. <i>J Am Coll Cardiol</i> . 2012 May 29;59(22):1928-37. doi:10.1016/j.jacc.2011.11.068. |
| 22836303 | Borgman MP, Pendleton RC, McMillin GA, Reynolds KK, Vazquez S, Freeman A, Wilson A, Valdes R Jr, Linder MW. Prospective pilot trial of PerMIT versus standard anticoagulation service management of patients initiating oral anticoagulation. <i>Thromb Haemost</i> . 2012 Sep;108(3):561-9. doi:10.1160/TH12-03-0159. Epub 2012 Jul 26. |
| 22927772 | Wang M, Lang X, Cui S, Fei K, Zou L, Cao J, Wang L, Zhang S, Wu X, Wang Y, Ji Q. Clinical application of pharmacogenetic-based warfarin-dosing algorithm in patients of Han nationality after rheumatic valve replacement: a randomized and controlled trial. <i>Int J Med Sci</i> . 2012;9(6):472-9. doi:10.7150/ijms.4637. Epub 2012 Aug 10. |
| 22990067 | Wu H, Qian J, Xu J, Sun A, Sun W, Wang Q, Ge J. Effects of CYP2C19 variant alleles on postclopidogrel platelet reactivity and clinical outcomes in an actual clinical setting in China. <i>Pharmacogenet Genomics</i> . 2012 Dec;22(12):887-90. doi:10.1097/FPC.0b013e328359253a. |
| 23001453 | Zou JJ, Xie HG, Chen SL, Tan J, Lin L, Zhao YY, Xu HM, Lin S, Zhang J, Wang GJ. Influence of CYP2C19 loss-of-function variants on the antiplatelet effects and cardiovascular events in clopidogrel-treated Chinese patients undergoing percutaneous coronary intervention. <i>Eur J Clin Pharmacol</i> . 2013 Apr;69(4):771-7. doi:10.1007/s00228-012-1392-5. Epub 2012 Sep 22. |
| 23850318 | Xie X, Ma YT, Yang YN, Li XM, Zheng YY, Ma X, Fu ZY, Ba Bayinsilema, Li Y, Yu ZX, Chen Y, Chen BD, Liu F, Huang Y, Liu C, Baituola G. Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: a randomized control trial. <i>Int J Cardiol</i> . 2013 Oct 9;168(4):3736-40. doi:10.1016/j.ijcard.2013.06.014. Epub 2013 Jul 11. |
| 24251360 | Verhoef TI, Ragia G, de Boer A, Barallon R, Kolovou G, Kolovou V, Konstantinides S, Le Cessie S, Maltezos E, van der Meer FJ, Redekop WK, Remkes M, Rosendaal FR, van Schie RM, Tavidou A, Tziakas D, Wadelius M, Manolopoulos VG, Maitland-van der Zee AH; EU-PACT Group. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. <i>N Engl J Med</i> . 2013 Dec 12;369(24):2304-12. doi:10.1056/NEJMoa1311388. Epub 2013 Nov 19. |
| 24251361 | Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, Gage BF, Rosenberg YD, Eby CS, Madigan RA, McBane RB, Abdel-Rahman SZ, Stevens SM, Yale S, Mohler ER 3rd, Fang MC, Shah V, Horenstein RB, Limdi NA, Muldowney JA 3rd, Gujral J, Delafontaine P, Desnick RJ, Ortel TL, Billett HH, Pendleton RC, Geller NL, Halperin JL, Goldhaber SZ, Caldwell MD, Califf RM, Ellenberg JH; COAG Investigators. A pharmacogenetic versus a clinical algorithm for warfarin dosing. <i>N Engl J Med</i> . 2013 Dec 12;369(24):2283-93. doi:10.1056/NEJMoa1310669. Epub 2013 Nov 19. |
| 24251363 | Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, Kesteven P, Christersson C, Wahlström B, Stafberg C, Zhang JE, Leathart JB, Kohnke H, Maitland-van der Zee AH, Williamson PR, Daly AK, Avery P, Kamali F, Wadelius M; EU-PACT Group. A randomized trial of genotype-guided dosing of warfarin. <i>N Engl J Med</i> . 2013 Dec 12;369(24):2294-303. doi:10.1056/NEJMoa1311386. Epub 2013 Nov 19. |
| Not applicable | Mega JL, Thakuria JV, Cannon CP, Sabatine MS. Sequence variations in CYP metabolism genes and cardiovascular outcomes following treatment with clopidogrel: insights from the CLARITY-TIMI 28 genomic study. In: <i>J Am Coll Cardiol</i> 2008: Abstract 51, p. A206-A206. |
| Not applicable | Anderson JL. Carriage of the CYP2C19*2 allele increases one-year risk of myocardial infarction among recipients of drug-eluting stents treated with clopidogrel. <i>J Am Coll Cardiol</i> 2009;53:A1-A99. |
| Not applicable | Worral A. The presence of the CYP p450 C19*2 allele is associated with impaired response to clopidogrel as measured by the verifynow P2Y12 near-patient testing device in patients undergoing coronary angiography. <i>Eur Heart J</i> 2009;30:301-585. |
| Not applicable | Komarov A, Shakhmatova O, Donnikov A, Ilyushchenko T, Dzhililova G, Panchenko E. Carrying of P450 2C19*2 polymorphism and use of proton pump inhibitors increase risk of adverse outcomes after elective PCI in Russian patients with CAD. <i>European Journal of Cardiovascular Prevention & Rehabilitation</i> 2011;18:S100-S125. |
| Not applicable | Nishio R, Shinke T, Shite J, Sawada T, Toh R, Haraguchi Y, Otake H, Matsumoto D, Kawamori H, Nakagawa M, Nagoshi R, Kozuki A, Inoue T, Hariki H, Taniguchi Y, Hiranuma N, Hirata K-i. Impact of Cytochrome P450 2C19*2 polymorphism on the target lesion outcome after drug-eluting stent implantation in Japanese patients receiving clopidogrel. <i>Journal of the American College of Cardiology</i> 2011;57:E1299. |
| Not applicable | Yuan J, Tang XF, Yang YJ, Gao RL. Association between cytochrome P450 2C19 681G>A polymorphisms and risk of cardiovascular events in coronary heart disease with clopidogrel in Chinese. <i>Eur Heart J</i> 2011;32 (suppl 1):1-312. |

APPENDIX 2: INSTANTIATION OF INDIVIDUAL PUBLICATIONS

| Name of individual | Assertion of individual |
|--------------------|-------------------------------------|
| pub_10509530 | hasPMID pmid10509530 |
| | hasPubYear 1999 |
| | hasPublicationType some Letter |
| pub_11127854 | hasPMID pmid11127854 |
| | hasPubYear 2000 |
| | hasPublicationType some FullArticle |
| pub_11926893 | hasPMID pmid11926893 |
| | hasPubYear 2002 |
| | hasPublicationType some FullArticle |
| pub_15841315 | hasPMID pmid15841315 |
| | hasPubYear 2005 |
| | hasPublicationType some FullArticle |
| pub_15888487 | hasPMID pmid15888487 |
| | hasPubYear 2005 |
| | hasPublicationType some FullArticle |
| pub_16160068 | hasPMID pmid16160068 |
| | hasPubYear 2005 |
| | hasPublicationType some FullArticle |
| pub_17653141 | hasPMID pmid17653141 |
| | hasPubYear 2007 |
| | hasPublicationType some FullArticle |
| pub_17851566 | hasPMID pmid17851566 |
| | hasPubYear 2007 |
| | hasPublicationType some FullArticle |
| pub_17982182 | hasPMID pmid17982182 |
| | hasPubYear 2007 |
| | hasPublicationType some FullArticle |
| pub_17989110 | hasPMID pmid17989110 |
| | hasPubYear 2007 |
| | hasPublicationType some FullArticle |
| pub_18305455 | hasPMID pmid18305455 |
| | hasPubYear 2008 |
| | hasPublicationType some FullArticle |
| pub_18482659 | hasPMID pmid18482659 |
| | hasPubYear 2008 |
| | hasPublicationType some FullArticle |
| pub_18577829 | hasPMID pmid18577829 |
| | hasPubYear 2008 |
| | hasPublicationType some FullArticle |
| pub_19106083 | hasPMID pmid19106083 |
| | hasPubYear 2008 |
| | hasPublicationType some FullArticle |
| pub_19106084 | hasPMID pmid19106084 |
| | hasPubYear 2008 |
| | hasPublicationType some FullArticle |
| pub_19108880 | hasPMID pmid19108880 |
| | hasPubYear 2008 |
| | hasPublicationType some FullArticle |
| pub_19177029 | hasPMID pmid19177029 |
| | hasPubYear 2009 |
| | hasPublicationType some FullArticle |
| pub_19193675 | hasPMID pmid19193675 |
| | hasPubYear 2009 |
| | hasPublicationType some FullArticle |
| pub_19228618 | hasPMID pmid19228618 |
| | hasPubYear 2009 |
| | hasPublicationType some FullArticle |
| pub_19268736 | hasPMID pmid19268736 |
| | hasPubYear 2009 |
| | hasPublicationType some FullArticle |
| pub_19414633 | hasPMID pmid19414633 |
| | hasPubYear 2009 |

| | |
|--------------|-------------------------------------|
| | hasPublicationType some FullArticle |
| pub_19706858 | hasPMID pmid19706858 |
| | hasPubYear 2009 |
| | hasPublicationType some FullArticle |
| pub_19717846 | hasPMID pmid19717846 |
| | hasPubYear 2009 |
| | hasPublicationType some FullArticle |
| pub_20083681 | hasPMID pmid20083681 |
| | hasPubYear 2010 |
| | hasPublicationType some FullArticle |
| pub_20375999 | hasPMID pmid20375999 |
| | hasPubYear 2010 |
| | hasPublicationType some FullArticle |
| pub_20381283 | hasPMID pmid20381283 |
| | hasPubYear 2010 |
| | hasPublicationType some FullArticle |
| pub_20492467 | hasPMID pmid20492467 |
| | hasPubYear 2010 |
| | hasPublicationType some FullArticle |
| pub_20708365 | hasPMID pmid20708365 |
| | hasPubYear 2010 |
| | hasPublicationType some FullArticle |
| pub_20801494 | hasPMID pmid20801494 |
| | hasPubYear 2010 |
| | hasPublicationType some FullArticle |
| pub_20801498 | hasPMID pmid20801498 |
| | hasPubYear 2010 |
| | hasPublicationType some FullArticle |
| pub_20826260 | hasPMID pmid20826260 |
| | hasPubYear 2010 |
| | hasPublicationType some FullArticle |
| pub_20833683 | hasPMID pmid20833683 |
| | hasPubYear 2010 |
| | hasPublicationType some FullArticle |
| pub_20924183 | hasPMID pmid20924183 |
| | hasPubYear 2010 |
| | hasPublicationType some FullArticle |
| pub_20979470 | hasPMID pmid20979470 |
| | hasPubYear 2010 |
| | hasPublicationType some FullArticle |
| pub_21099121 | hasPMID pmid21099121 |
| | hasPubYear 2010 |
| | hasPublicationType some FullArticle |
| pub_21168310 | hasPMID pmid21168310 |
| | hasPubYear 2010 |
| | hasPublicationType some FullArticle |
| pub_21170047 | hasPMID pmid21170047 |
| | hasPubYear 2010 |
| | hasPublicationType some FullArticle |
| pub_21272753 | hasPMID pmid21272753 |
| | hasPubYear 2011 |
| | hasPublicationType some FullArticle |
| pub_21334530 | hasPMID pmid21334530 |
| | hasPubYear 2011 |
| | hasPublicationType some Letter |
| pub_21423021 | hasPMID pmid21423021 |
| | hasPubYear 2011 |
| | hasPublicationType some FullArticle |
| pub_21511218 | hasPMID pmid21511218 |
| | hasPubYear 2011 |
| | hasPublicationType some FullArticle |
| pub_21527445 | hasPMID pmid21527445 |
| | hasPubYear 2011 |
| | hasPublicationType some FullArticle |
| pub_21679849 | hasPMID pmid21679849 |
| | hasPubYear 2011 |

| | |
|--------------|-------------------------------------|
| | hasPublicationType some FullArticle |
| pub_21700758 | hasPMID pmid21700758 |
| | hasPubYear 2011 |
| | hasPublicationType some FullArticle |
| pub_21778720 | hasPMID pmid21778720 |
| | hasPubYear 2011 |
| | hasPublicationType some FullArticle |
| pub_21854540 | hasPMID pmid21854540 |
| | hasPubYear 2011 |
| | hasPublicationType some FullArticle |
| pub_21862109 | hasPMID pmid21862109 |
| | hasPubYear 2011 |
| | hasPublicationType some FullArticle |
| pub_22028352 | hasPMID pmid22028352 |
| | hasPubYear 2011 |
| | hasPublicationType some FullArticle |
| pub_22045970 | hasPMID pmid22045970 |
| | hasPubYear 2011 |
| | hasPublicationType some FullArticle |
| pub_22088240 | hasPMID pmid22088240 |
| | hasPubYear 2011 |
| | hasPublicationType some FullArticle |
| pub_22088980 | hasPMID pmid22088980 |
| | hasPubYear 2011 |
| | hasPublicationType some FullArticle |
| pub_22116003 | hasPMID pmid22116003 |
| | hasPubYear 2011 |
| | hasPublicationType some FullArticle |
| pub_22190063 | hasPMID pmid22190063 |
| | hasPubYear 2011 |
| | hasPublicationType some FullArticle |
| pub_22377481 | hasPMID pmid22377481 |
| | hasPubYear 2012 |
| | hasPublicationType some FullArticle |
| pub_22390861 | hasPMID pmid22390861 |
| | hasPubYear 2012 |
| | hasPublicationType some FullArticle |
| pub_22431865 | hasPMID pmid22431865 |
| | hasPubYear 2012 |
| | hasPublicationType some FullArticle |
| pub_22450429 | hasPMID pmid22450429 |
| | hasPubYear 2012 |
| | hasPublicationType some FullArticle |
| pub_22464343 | hasPMID pmid22464343 |
| | hasPubYear 2012 |
| | hasPublicationType some FullArticle |
| pub_22624833 | hasPMID pmid22624833 |
| | hasPubYear 2012 |
| | hasPublicationType some FullArticle |
| pub_22836303 | hasPMID pmid22836303 |
| | hasPubYear 2012 |
| | hasPublicationType some FullArticle |
| pub_22927772 | hasPMID pmid22927772 |
| | hasPubYear 2012 |
| | hasPublicationType some FullArticle |
| pub_22990067 | hasPMID pmid22990067 |
| | hasPubYear 2012 |
| | hasPublicationType some FullArticle |
| pub_23001453 | hasPMID pmid23001453 |
| | hasPubYear 2012 |
| | hasPublicationType some FullArticle |
| pub_23850318 | hasPMID pmid23850318 |
| | hasPubYear 2013 |
| | hasPublicationType some FullArticle |
| pub_24251360 | hasPMID pmid24251360 |
| | hasPubYear 2013 |

| | |
|-------------------|--|
| | hasPublicationType some FullArticle |
| pub_24251361 | hasPMID pmid24251361 |
| | hasPubYear 2013 |
| | hasPublicationType some FullArticle |
| pub_24251363 | hasPMID pmid24251363 |
| | hasPubYear 2013 |
| | hasPublicationType some FullArticle |
| pub_Mega_2008 | hasPubYear 2008 |
| | hasPublicationType some ConferenceAbstract |
| pub_Anderson_2009 | hasPubYear 2009 |
| | hasPublicationType some ConferenceAbstract |
| pub_Worrall_2009 | hasPubYear 2009 |
| | hasPublicationType some ConferenceAbstract |
| pub_Komarov_2011 | hasPubYear 2011 |
| | hasPublicationType some ConferenceAbstract |
| pub_Nisho_2011 | hasPubYear 2011 |
| | hasPublicationType some ConferenceAbstract |
| pub_Yuan_2011 | hasPubYear 2011 |
| | hasPublicationType some ConferenceAbstract |

APPENDIX 3: INSTANTIATION OF INDIVIDUAL STUDIES

| Name of individual | Assertion of individual |
|---|--|
| stu_1_pub_10509530 | isReportedIn pub_10509530 |
| | hasDrugTherapyOI some (WarfarinTherapy and (hasDrugTherapyStrategy some (PharmacologicallyMonitoredDrugDosing and (hasDrugRegimen some WarfarinInitialDose2.5mg_day) and (monitorsPharmacodynamicsParameter some INR)))) |
| | hasDrugTherapyRef some Placebo |
| | hasStudyPopulation some (Patient and (hasIndicationByDrug some Warfarin) and (hasRisk some CoronaryArteryDisease)) |
| stu_1_pub_11127854 | isReportedIn pub_11127854 |
| | hasDrugTherapyObserved some (WarfarinTherapy and (hasDrugTherapyStrategy some (PharmacologicallyMonitoredDrugDosing and (hasDrugRegimen some WarfarinInitialDose5mg_day) and (monitorsPharmacodynamicsParameter some INR)))) |
| | hasStudyPopulation some (Patient and (hasDisease some (CoronaryArteryDisease or Thromboembolism)) and (hasIndicationByDrug some Warfarin)) |
| | hasStudyType some (ObservationalStudy and (hasStudyDesign some (Cohort and (hasTimePerspective some Retrospective)))) |
| stu_1_pub_11926893 | isReportedIn pub_11926893 |
| | hasDrugTherapyObserved some (WarfarinTherapy and (hasDrugTherapyStrategy some (PharmacologicallyMonitoredDrugDosing and (hasDrugRegimen some WarfarinInitialDose5mg_day) and (monitorsPharmacodynamicsParameter some INR)))) |
| | hasStudyPopulation some (Patient and (hasDisease some (AtrialFibrillation or DVTandPE or DilatedCardiomyopathy)) and (hasIndicationByDrug some Warfarin) and (hasProcedure some HeartValveReplacement)) |
| | hasStudyType some (ObservationalStudy and (hasStudyDesign some (Cohort and (hasTimePerspective some Retrospective)))) |
| stu_1_pub_15841315 | isReportedIn pub_15841315 |
| | hasDrugTherapyOI some (WarfarinTherapy and (hasDrugTherapyStrategy some (GenotypeGuidedDrugDosing and ((considersGeneticVariant exactly 1 CYP2C9star2) and (considersGeneticVariant exactly 1 CYP2C9star3) and (considersGeneticVariant exactly 2 GeneticVariant)))) |
| | not (hasDrugTherapyRef some DrugTherapy) |
| | hasStudyPopulation some (Patient and (hasIndicationByDrug some Warfarin) and (hasProcedure some (KneeArthroplasty or TotalHipArthroplasty))) |
| stu_1_pub_15888487 | isReportedIn pub_15888487 |
| | hasDrugTherapyObserved some (WarfarinTherapy and (hasDrugTherapyStrategy some (PharmacologicallyMonitoredDrugDosing and (hasDrugRegimen some WarfarinInitialDoseStandard) and (monitorsPharmacodynamicsParameter some INR)))) |
| | hasStudyPopulation some (Patient and (hasDisease some (AtrialFibrillation or DeepVeinThrombosis or Stroke)) and (hasIndicationByDrug some Warfarin) and (hasProcedure some HeartValveReplacement)) |
| | hasStudyType some (ObservationalStudy and (hasStudyDesign some (Cohort and (hasTimePerspective some Retrospective)))) |
| stu_1_pub_16160068 | isReportedIn pub_16160068 |
| | hasDrugTherapyOI some (WarfarinTherapy and (hasDrugTherapyStrategy some (GenotypeGuidedDrugDosing and ((considersGeneticVariant exactly 1 CYP2C9star2) and (considersGeneticVariant exactly 1 CYP2C9star3) and (considersGeneticVariant exactly 2 GeneticVariant)))) |
| | hasDrugTherapyRef some (WarfarinTherapy and (hasDrugTherapyStrategy some (PharmacologicallyMonitoredDrugDosing and (hasDrugRegimen some WarfarinInitialDose5mg_day) and (monitorsPharmacodynamicsParameter some INR)))) |
| | hasStudyPopulation some (Patient and (hasDisease some (AtrialFibrillation or DVTandPE)) and (hasIndicationByDrug some Warfarin) and (hasProcedure some (HeartValveReplacement or KneeArthroplasty))) |
| | hasStudyType some (InterventionalStudy and (hasStudyDesign some (ParallelGroup and (hasAllocationScheme some Randomization)))) |
| | hasROBA_Cochrane_RandomSequenceGeneration roba_low |
| | hasROBA_Cochrane_AllocationConcealment roba_low |
| hasROBA_Cochrane_BlindingParticipantPersonnel roba_high | |
| hasROBA_Cochrane_BlindingOutcomeAssessment roba_unclear | |
| hasROBA_Cochrane_IncompleteOutcomeData roba_low | |
| hasROBA_Cochrane_SelectiveReporting roba_unclear | |
| stu_1_pub_17653141 | isReportedIn pub_17653141 |
| | hasDrugTherapyObserved some (WarfarinTherapy and (hasDrugTherapyStrategy some (PharmacologicallyMonitoredDrugDosing and (hasDrugRegimen some WarfarinInitialDose5mg_day) and |

| | |
|--------------------|--|
| | <p>(monitorsPharmacodynamicsParameter some INR))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some (DeepVeinThrombosis or MyocardialInfarction or PulmonaryEmbolism or Stroke or TransientIschemicAttack)) and (hasIndicationByDrug some Warfarin))</p> <p>hasStudyType some (ObservationalStudy and (hasStudyDesign some (Cohort and (hasTimePerspective some Prospective))))</p> |
| stu_1_pub_17851566 | <p>isReportedIn pub_17851566</p> <p>hasDrugTherapyOI some (WarfarinTherapy and (hasDrugTherapyStrategy some (GenotypeGuidedDrugDosing and ((considersGeneticVariant exactly 1 CYP2C9star2) and (considersGeneticVariant exactly 1 CYP2C9star3) and (considersGeneticVariant exactly 2 GeneticVariant))))))</p> <p>hasDrugTherapyRef some (WarfarinTherapy and (hasDrugTherapyStrategy some ClinicallyGuidedDrugDosing))</p> <p>hasStudyPopulation some (Patient and (hasDisease some (AtrialFibrillation or DVTandPE or DeepVeinThrombosis or PulmonaryEmbolism)) and (hasIndicationByDrug some Warfarin))</p> <p>hasStudyType some (InterventionalStudy and (hasStudyDesign some (ParallelGroup and (hasAllocationScheme some Randomization))))</p> <p>hasROBA_Cochrane_RandomSequenceGeneration roba_high</p> <p>hasROBA_Cochrane_AllocationConcealment roba_high</p> <p>hasROBA_Cochrane_BlindingParticipantPersonnel roba_low</p> <p>hasROBA_Cochrane_BlindingOutcomeAssessment roba_unclear</p> <p>hasROBA_Cochrane_IncompleteOutcomeData roba_low</p> <p>hasROBA_Cochrane_SelectiveReporting roba_low</p> |
| stu_1_pub_17982182 | <p>isReportedIn pub_17982182</p> <p>hasDrugTherapyOI some (PrasugrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and ((hasDrugRegimen some PrasugrelLD60mgOnce) and (hasDrugRegimen some PrasugrelMD10mg))))))</p> <p>hasDrugTherapyRef some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and ((hasDrugRegimen some ClopidogrelLD300mgOnce) and (hasDrugRegimen some ClopidogrelMD75mg))))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some AcuteCoronarySyndrome) and (hasIndicationByDrug some (Clopidogrel or Prasugrel)) and (hasProcedure some PCIWithStent))</p> <p>hasStudyType some (InterventionalStudy and (hasStudyDesign some (ParallelGroup and (hasAllocationScheme some Randomization))))</p> |
| stu_1_pub_17989110 | <p>isReportedIn pub_17989110</p> <p>hasDrugTherapyOI some (WarfarinTherapy and (hasDrugTherapyStrategy some (GenotypeGuidedDrugDosing and ((considersGeneticVariant exactly 1 CYP2C9star2) and (considersGeneticVariant exactly 1 CYP2C9star3) and (considersGeneticVariant exactly 1 VKORC1_C1173T) and (considersGeneticVariant exactly 3 GeneticVariant))))))</p> <p>hasDrugTherapyRef some (WarfarinTherapy and (hasDrugTherapyStrategy some (PharmacologicallyMonitoredDrugDosing and (hasDrugRegimen some WarfarinInitialDose10mg_day) and (monitorsPharmacodynamicsParameter some INR))))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some (AtrialFibrillation or DVTandPE or DeepVeinThrombosis or PulmonaryEmbolism)) and (hasIndicationByDrug some Warfarin) and (hasProcedure some OrthopedicSurgery))</p> <p>hasStudyType some (InterventionalStudy and (hasStudyDesign some (ParallelGroup and (hasAllocationScheme some Randomization))))</p> <p>hasROBA_Cochrane_RandomSequenceGeneration roba_low</p> <p>hasROBA_Cochrane_AllocationConcealment roba_unclear</p> <p>hasROBA_Cochrane_BlindingParticipantPersonnel roba_low</p> <p>hasROBA_Cochrane_BlindingOutcomeAssessment roba_low</p> <p>hasROBA_Cochrane_IncompleteOutcomeData roba_low</p> <p>hasROBA_Cochrane_SelectiveReporting roba_low</p> |
| stu_1_pub_18305455 | <p>isReportedIn pub_18305455</p> <p>hasDrugTherapyOI some (WarfarinTherapy and (hasDrugTherapyStrategy some (GenotypeGuidedDrugDosing and ((considersGeneticVariant exactly 1 CYP2C9star2) and (considersGeneticVariant exactly 1 CYP2C9star3) and (considersGeneticVariant exactly 1 VKORC1_G-1639A) and (considersGeneticVariant exactly 3 GeneticVariant))))))</p> <p>hasDrugTherapyRef some (WarfarinTherapy and (hasDrugTherapyStrategy some ClinicallyGuidedDrugDosing))</p> <p>hasStudyPopulation some (Patient and (hasIndicationByDrug some Warfarin))</p> <p>hasStudyType some (InterventionalStudy and (hasStudyDesign some InterventionVsSimulation))</p> |
| stu_1_pub_18482659 | <p>isReportedIn pub_18482659</p> <p>hasDrugTherapyObserved some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and ((hasDrugRegimen some ClopidogrelLD600mgOnce) and (hasDrugRegimen some ClopidogrelMD75mg))))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some CoronaryArteryDisease) and (hasIndicationByDrug some Clopidogrel) and (hasProcedureAll some (PCIWithStent and (hasProcedureDescriptor some Elective))) and (hasProcedureMinority some PCIWithDES))</p> <p>hasStudyType some (ObservationalStudy and (hasStudyDesign some (Cohort and (hasTimePerspective some Prospective))))</p> <p>hasROBA_QUADAS2_PatientSelection roba_high</p> |

| | |
|--------------------|--|
| | <p>hasROBA_QUADAS2_OutcomeAssessment roba_low hasROBA_QUADAS2_GeneticTesting roba_low hasROBA_QUADAS2_FlowAndTiming roba_low</p> |
| stu_1_pub_18577829 | <p>isReportedIn pub_18577829</p> <p>hasDrugTherapyObserved some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and ((hasDrugRegimen some ClopidogrelMD75mg) and (hasDrugRegimen some (ClopidogrelLD300mgOnce or ClopidogrelLD600mgOnce))))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some AcuteCoronarySyndrome) and (hasIndicationByDrug some Clopidogrel) and (hasProcedureAll some PCIWithStent))</p> <p>hasStudyType some (ObservationalStudy and (hasStudyDesign some (Cohort and (hasTimePerspective some Prospective))))</p> <p>hasROBA_QUADAS2_PatientSelection roba_low hasROBA_QUADAS2_OutcomeAssessment roba_unclear hasROBA_QUADAS2_GeneticTesting roba_high hasROBA_QUADAS2_FlowAndTiming roba_low</p> |
| stu_1_pub_19106083 | <p>isReportedIn pub_19106083</p> <p>hasDrugTherapyObserved some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and ((hasDrugRegimen some ClopidogrelLD300mgOnce) and (hasDrugRegimen some ClopidogrelMD75mg))))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some (MyocardialInfarction and (hasDiseaseStatus some Acute))) and (hasIndicationByDrug some Clopidogrel) and (hasProcedureMajority some PCI))</p> <p>hasStudyType some (ObservationalStudy and (hasStudyDesign some (Cohort and (hasTimePerspective some Prospective))))</p> <p>hasROBA_QUADAS2_PatientSelection roba_low hasROBA_QUADAS2_OutcomeAssessment roba_low hasROBA_QUADAS2_GeneticTesting roba_high hasROBA_QUADAS2_FlowAndTiming roba_low</p> |
| stu_1_pub_19106084 | <p>isReportedIn pub_19106084</p> <p>hasDrugTherapyRef some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and ((hasDrugRegimen some ClopidogrelLD300mgOnce) and (hasDrugRegimen some ClopidogrelMD75mg))))))</p> <p>not (hasDrugTherapyOI some DrugTherapy)</p> <p>hasStudyPopulation some (Patient and (hasDisease some AcuteCoronarySyndrome) and (hasIndicationByDrug some Clopidogrel) and (hasProcedure some PCIWithStent))</p> <p>hasStudyType some (InterventionalStudy and (hasStudyDesign some (ParallelGroup and (hasAllocationScheme some Randomization))))</p> <p>hasROBA_Cochrane_RandomSequenceGeneration roba_unclear hasROBA_Cochrane_AllocationConcealment roba_unclear hasROBA_Cochrane_BlindingParticipantPersonnel roba_low hasROBA_Cochrane_BlindingOutcomeAssessment roba_low hasROBA_Cochrane_IncompleteOutcomeData roba_low hasROBA_Cochrane_SelectiveReporting roba_low</p> <p>hasROBA_QUADAS2_PatientSelection roba_low hasROBA_QUADAS2_OutcomeAssessment roba_unclear hasROBA_QUADAS2_GeneticTesting roba_unclear hasROBA_QUADAS2_FlowAndTiming roba_low</p> |
| stu_1_pub_19108880 | <p>isReportedIn pub_19108880</p> <p>hasDrugTherapyObserved some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and (hasDrugRegimen some ClopidogrelMD75mg))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some (MyocardialInfarction and (hasDiseaseStatus some Acute))) and (hasIndicationByDrug some Clopidogrel) and (hasProcedureMajority some PCIWithStent) and (hasProcedureMinority some PCIWithDES))</p> <p>hasStudyType some (ObservationalStudy and (hasStudyDesign some (Cohort and (hasTimePerspective some Prospective))))</p> <p>hasROBA_QUADAS2_PatientSelection roba_low hasROBA_QUADAS2_OutcomeAssessment roba_low hasROBA_QUADAS2_GeneticTesting roba_high hasROBA_QUADAS2_FlowAndTiming roba_low</p> |
| stu_1_pub_19177029 | <p>isReportedIn pub_19177029</p> <p>hasDrugTherapyOI some (WarfarinTherapy and (hasDrugTherapyStrategy some (GenotypeGuidedDrugDosing and ((considersGeneticVariant exactly 1 CYP2C9star3) and (considersGeneticVariant exactly 1 VKORC1_C1173T) and (considersGeneticVariant exactly 2 GeneticVariant))))))</p> <p>hasDrugTherapyRef some (WarfarinTherapy and (hasDrugTherapyStrategy some (PharmacologicallyMonitoredDrugDosing and (hasDrugRegimen some WarfarinInitialDose2.5mg_day) and (monitorsPharmacodynamicsParameter some INR))))</p> <p>hasStudyPopulation some (Patient and (hasIndicationByDrug some Warfarin) and (hasProcedure some HeartValveReplacement))</p> <p>hasStudyType some (InterventionalStudy and (hasStudyDesign some (ParallelGroup and (hasAllocationScheme some Randomization))))</p> |

| | |
|---------------------|---|
| | <p>hasROBA_Cochrane_RandomSequenceGeneration roba_unclear hasROBA_Cochrane_AllocationConcealment roba_unclear hasROBA_Cochrane_BlindingParticipantPersonnel roba_high hasROBA_Cochrane_BlindingOutcomeAssessment roba_unclear hasROBA_Cochrane_IncompleteOutcomeData roba_unclear hasROBA_Cochrane_SelectiveReporting roba_low</p> |
| stu_1_pub_19193675 | <p>isReportedIn pub_19193675 hasDrugTherapyObserved some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and (hasDrugRegimen some ClopidogrelLD600mgOnce)))) hasStudyPopulation some (Patient and (hasDisease some CoronaryArteryDisease) and (hasIndicationByDrug some Clopidogrel) and (hasProcedure some PCIWithStent) and (hasProcedureMinority some PCIWithDES)) hasStudyType some (ObservationalStudy and (hasStudyDesign some (Cohort and (hasTimePerspective some Prospective)))) hasROBA_QUADAS2_PatientSelection roba_high hasROBA_QUADAS2_OutcomeAssessment roba_low hasROBA_QUADAS2_GeneticTesting roba_unclear hasROBA_QUADAS2_FlowAndTiming roba_low</p> |
| stus_1_pub_19228618 | <p>isReportedIn pub_19228618 hasDrugTherapyOI some (WarfarinTherapy and (hasDrugTherapyStrategy some (GenotypeGuidedDrugDosing and ((considersGeneticVariant exactly 1 CYP2C9star2) and (considersGeneticVariant exactly 1 CYP2C9star3) and (considersGeneticVariant exactly 1 VKORC1_G-1639A) and (considersGeneticVariant exactly 3 GeneticVariant)))))) hasDrugTherapyRef some (WarfarinTherapy and (hasDrugTherapyStrategy some ClinicallyGuidedDrugDosing)) hasStudyPopulation some (Patient and (hasDisease some (AtrialFibrillation or DeepVeinThrombosis or DilatedCardiomyopathy or PulmonaryEmbolism or Stroke)) and (hasIndicationByDrug some Warfarin) and (hasProcedure some (HeartValveReplacement or OrthopedicSurgery))) hasStudyType some (SimulationStudy and (hasStudyDesign some SimulationVsSimulation))</p> |
| stu_1_pub_19268736 | <p>isReportedIn pub_19268736 hasDrugTherapyObserved some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and ((hasDrugRegimen some ClopidogrelLD600mgOnce) and (hasDrugRegimen some ClopidogrelMD75mg)))))) hasStudyPopulation some (Patient and (hasDisease some AcuteCoronarySyndrome) and (hasIndicationByDrug some Clopidogrel) and (hasProcedure some PCIWithDES)) hasStudyType some (ObservationalStudy and (hasStudyDesign some (Cohort and (hasTimePerspective some Prospective)))) hasROBA_QUADAS2_PatientSelection roba_low hasROBA_QUADAS2_OutcomeAssessment roba_low hasROBA_QUADAS2_GeneticTesting roba_high hasROBA_QUADAS2_FlowAndTiming roba_low</p> |
| stu_1_pub_19414633 | <p>isReportedIn pub_19414633 hasDrugTherapyOI some (PrasugrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and ((hasDrugRegimen some PrasugrelLD60mgOnce) and (hasDrugRegimen some PrasugrelMD10mg)))))) not (hasDrugTherapyRef some DrugTherapy) hasStudyPopulation some (Patient and (hasDisease some AcuteCoronarySyndrome) and (hasIndicationByDrug some Prasugrel) and (hasProcedure some PCI)) hasStudyType some (InterventionalStudy and (hasStudyDesign some (ParallelGroup and (hasAllocationScheme some Randomization))))</p> |
| stu_1_pub_19706858 | <p>isReportedIn pub_19706858 hasDrugTherapyObserved some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and ((hasDrugRegimen some ClopidogrelMD75mg) and (hasDrugRegimen some (ClopidogrelLD300mgOnce or ClopidogrelLD600mgOnce)))))) hasStudyPopulation some (Patient and (hasDisease some CoronaryArteryDisease) and (hasIndicationByDrug some Clopidogrel) and (hasProcedureAll some (PCI and (hasProcedureDescriptor some Elective)))) hasStudyType some (ObservationalStudy and (hasStudyDesign some (Cohort and (hasTimePerspective some Prospective)))) hasROBA_QUADAS2_PatientSelection roba_low hasROBA_QUADAS2_OutcomeAssessment roba_low hasROBA_QUADAS2_GeneticTesting roba_high hasROBA_QUADAS2_FlowAndTiming roba_low</p> |
| stu_1_pub_19717846 | <p>isReportedIn pub_19717846 hasDrugTherapyOI some (TicagrelorTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and ((hasDrugRegimen some TicagrelorLD180mgOnce) and (hasDrugRegimen some TicagrelorMD90mgbid)))))) hasDrugTherapyRef some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and ((hasDrugRegimen some ClopidogrelLD300mgOnce) and (hasDrugRegimen some ClopidogrelMD75mg)))))) hasStudyPopulation some (Patient and (hasDisease some AcuteCoronarySyndrome) and (hasIndicationByDrug some (Clopidogrel or Ticagrelor)) and (hasProcedureMajority some PCIWithStent)) hasStudyType some (InterventionalStudy and (hasStudyDesign some (ParallelGroup and</p> |

| | |
|---------------------|---|
| | (hasAllocationScheme some Randomization)))) |
| stu_1_pub_20083681 | isReportedIn pub_20083681 hasDrugTherapyObserved some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and ((hasDrugRegimen some ClopidogrelLD600mgOnce) and (hasDrugRegimen some ClopidogrelMD75mg)))))) hasStudyPopulation some (Patient and (hasDisease some CoronaryArteryDisease) and (hasIndicationByDrug some Clopidogrel) and (hasProcedure some PCIWithDES)) hasStudyType some (ObservationalStudy and (hasStudyDesign some (Cohort and (hasTimePerspective some Prospective)))) hasROBA_QUADAS2_PatientSelection roba_low hasROBA_QUADAS2_OutcomeAssessment roba_low hasROBA_QUADAS2_GeneticTesting roba_high hasROBA_QUADAS2_FlowAndTiming roba_low |
| stus_1_pub_20375999 | isReportedIn pub_20375999 hasDrugTherapyOI some (WarfarinTherapy and (hasDrugTherapyStrategy some (GenotypeGuidedDrugDosing and ((considersGeneticVariant exactly 1 CYP2C9star2) and (considersGeneticVariant exactly 1 CYP2C9star3) and (considersGeneticVariant exactly 1 VKORC1_G-1639A) and (considersGeneticVariant exactly 3 GeneticVariant)))))) hasDrugTherapyRef some (WarfarinTherapy and (hasDrugTherapyStrategy some ClinicallyGuidedDrugDosing)) hasStudyPopulation some (Patient and (hasDisease some (AtrialFibrillation or DeepVeinThrombosis or PulmonaryEmbolism or Stroke)) and (hasIndicationByDrug some Warfarin) and (hasProcedure some (HeartValveReplacement or OrthopedicSurgery))) hasStudyType some (SimulationStudy and (hasStudyDesign some SimulationVsSimulation)) |
| stu_1_pub_20381283 | isReportedIn pub_20381283 hasDrugTherapyOI some (WarfarinTherapy and (hasDrugTherapyStrategy some (GenotypeInformedDrugDosing and ((considersGeneticVariant exactly 1 CYP2C9star2) and (considersGeneticVariant exactly 1 CYP2C9star3) and (considersGeneticVariant exactly 1 VKORC1_G-1639A) and (considersGeneticVariant exactly 3 GeneticVariant)))))) hasDrugTherapyRef some (WarfarinTherapy and (hasDrugTherapyStrategy some (PharmacologicallyMonitoredDrugDosing and (hasDrugRegimen some WarfarinInitialDose5mg_day) and (monitorsPharmacodynamicsParameter some INR)))) hasStudyPopulation some (Patient and (hasDisease some (AtrialFibrillation or DeepVeinThrombosis or PulmonaryEmbolism)) and (hasIndicationByDrug some Warfarin)) hasStudyType some (InterventionalStudy and (hasStudyDesign some InterventionVsHistoricalUsualCare)) hasROBA_Cochrane_RandomSequenceGeneration roba_high hasROBA_Cochrane_AllocationConcealment roba_high hasROBA_Cochrane_BlindingParticipantPersonnel roba_high hasROBA_Cochrane_BlindingOutcomeAssessment roba_unclear hasROBA_Cochrane_IncompleteOutcomeData roba_low hasROBA_Cochrane_SelectiveReporting roba_low |
| stus_1_pub_20492467 | isReportedIn pub_20492467 hasDrugTherapyOI some (PrasugrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and ((hasDrugRegimen some PrasugrelLD60mgOnce) and (hasDrugRegimen some PrasugrelMD10mg)))))) hasDrugTherapyRef some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and ((hasDrugRegimen some ClopidogrelLD300mgOnce) and (hasDrugRegimen some ClopidogrelMD75mg)))))) hasStudyPopulation some (Patient and (hasDisease some (NSTE_MI or UnstableAngina)) and (hasIndicationByDrug some (Clopidogrel or Prasugrel)) and (hasProcedure some PCI)) hasStudyType some (SecondaryAnalysis and (hasStudyDesign some (ParallelGroup and (hasAllocationScheme some Randomization)))) hasROBA_QUADAS2_PatientSelection roba_low hasROBA_QUADAS2_OutcomeAssessment roba_unclear hasROBA_QUADAS2_GeneticTesting roba_unclear hasROBA_QUADAS2_FlowAndTiming roba_low |
| stu_1_pub_20708365 | isReportedIn pub_20708365 hasDrugTherapyOI some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and (hasDrugRegimen some (ClopidogrelLD600Four or ClopidogrelLD600Three or ClopidogrelLD600mgTwice)))))) hasDrugTherapyRef some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and (hasDrugRegimen some ClopidogrelLD600mgOnce)))) hasStudyPopulation some (Patient and (hasDisease some NSTE_MI) and (hasIndicationByDrug some Clopidogrel) and (hasProcedure some PCIWithStent)) hasStudyType some (InterventionalStudy and (hasStudyDesign some BeforeAfter)) hasROBA_QUADAS2_PatientSelection roba_low hasROBA_QUADAS2_OutcomeAssessment roba_unclear hasROBA_QUADAS2_GeneticTesting roba_unclear hasROBA_QUADAS2_FlowAndTiming roba_low |
| stu_1_pub_20801494 | isReportedIn pub_20801494 |

| | |
|--------------------|--|
| | <p>hasDrugTherapyOI some (PrasugrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and ((hasDrugRegimen some PrasugrelLD60mgOnce) and (hasDrugRegimen some PrasugrelMD10mg))))))</p> <p>hasDrugTherapyRef some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and ((hasDrugRegimen some ClopidogrelLD300mgOnce) and (hasDrugRegimen some ClopidogrelMD75mg))))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some AcuteCoronarySyndrome) and (hasIndicationByDrug some (Clopidogrel or Prasugrel)) and (hasProcedure some PCIWithStent))</p> <p>hasStudyType some (InterventionalStudy and (hasStudyDesign some (ParallelGroup and (hasAllocationScheme some Randomization))))</p> <p>hasROBA_Cochrane_RandomSequenceGeneration roba_unclear hasROBA_Cochrane_AllocationConcealment roba_unclear hasROBA_Cochrane_BlindingParticipantPersonnel roba_low hasROBA_Cochrane_BlindingOutcomeAssessment roba_low hasROBA_Cochrane_IncompleteOutcomeData roba_high hasROBA_Cochrane_SelectiveReporting roba_high</p> <p>hasROBA_QUADAS2_PatientSelection roba_low hasROBA_QUADAS2_OutcomeAssessment roba_unclear hasROBA_QUADAS2_GeneticTesting roba_unclear hasROBA_QUADAS2_FlowAndTiming roba_low</p> |
| stu_1_pub_20801498 | <p>isReportedIn pub_20801498</p> <p>hasDrugTherapyOI some (TicagrelorTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and ((hasDrugRegimen some TicagrelorLD180mgOnce) and (hasDrugRegimen some TicagrelorMD90mgbid))))))</p> <p>hasDrugTherapyRef some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and ((hasDrugRegimen some ClopidogrelLD300mgOnce) and (hasDrugRegimen some ClopidogrelMD75mg))))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some AcuteCoronarySyndrome) and (hasIndicationByDrug some (Clopidogrel or Ticagrelor)) and (hasProcedureMajority some PCIWithStent))</p> <p>hasStudyType some (InterventionalStudy and (hasStudyDesign some (ParallelGroup and (hasAllocationScheme some Randomization))))</p> <p>hasROBA_Cochrane_RandomSequenceGeneration roba_unclear hasROBA_Cochrane_AllocationConcealment roba_unclear hasROBA_Cochrane_BlindingParticipantPersonnel roba_low hasROBA_Cochrane_BlindingOutcomeAssessment roba_low hasROBA_Cochrane_IncompleteOutcomeData roba_low hasROBA_Cochrane_SelectiveReporting roba_low</p> <p>hasROBA_QUADAS2_PatientSelection roba_low hasROBA_QUADAS2_OutcomeAssessment roba_unclear hasROBA_QUADAS2_GeneticTesting roba_high hasROBA_QUADAS2_FlowAndTiming roba_low</p> |
| stu_1_pub_20826260 | <p>isReportedIn pub_20826260</p> <p>hasDrugTherapyObserved some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and ((hasDrugRegimen some ClopidogrelLD600mgOnce) and (hasDrugRegimen some ClopidogrelMD75mg))))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some (MyocardialInfarction and (hasDiseaseStatus some Acute))) and (hasIndicationByDrug some Clopidogrel) and (hasProcedureAll some PCIWithDES))</p> <p>hasStudyType some (ObservationalStudy and (hasStudyDesign some (Cohort and (hasTimePerspective some Prospective))))</p> <p>hasROBA_QUADAS2_OutcomeAssessment roba_unclear hasROBA_QUADAS2_PatientSelection roba_low hasROBA_QUADAS2_GeneticTesting roba_unclear hasROBA_QUADAS2_FlowAndTiming roba_low</p> |
| stu_1_pub_20833683 | <p>isReportedIn pub_20833683</p> <p>hasDrugTherapyObserved some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and (hasDrugRegimen some ClopidogrelMD75mg))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some CoronaryArteryDisease) and (hasIndicationByDrug some Clopidogrel) and (hasProcedure some PCIWithStent))</p> <p>hasStudyType some (ObservationalStudy and (hasStudyDesign some CaseControl))</p> <p>hasROBA_QUADAS2_PatientSelection roba_high hasROBA_QUADAS2_OutcomeAssessment roba_unclear hasROBA_QUADAS2_GeneticTesting roba_unclear hasROBA_QUADAS2_FlowAndTiming roba_low</p> |
| stu_1_pub_20924183 | <p>isReportedIn pub_20924183</p> <p>hasDrugTherapyObserved some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and (hasDrugRegimen some ClopidogrelStandardDose))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some (MyocardialInfarction and (hasDiseaseStatus some Acute))) and (hasIndicationByDrug some Clopidogrel) and (hasProcedure some PCIWithStent))</p> <p>hasStudyType some (ObservationalStudy and (hasStudyDesign some (Cohort and (hasTimePerspective some Prospective))))</p> <p>hasROBA_QUADAS2_PatientSelection roba_low hasROBA_QUADAS2_OutcomeAssessment roba_unclear</p> |

| | |
|---------------------|--|
| | <p>hasROBA_QUADAS2_GeneticTesting roba_unclear hasROBA_QUADAS2_FlowAndTiming roba_low</p> |
| stu_1_pub_20979470 | <p>isReportedIn pub_20979470 hasDrugTherapyOI some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and (hasDrugRegimen some ClopidogrelMD75mg)))) hasDrugTherapyRef some Placebo hasStudyPopulation some (Patient and (hasDisease some NSTEMI) and (hasIndicationByDrug some Clopidogrel) and (hasProcedureMinority some PCI)) hasStudyType some (InterventionalStudy and (hasStudyDesign some (ParallelGroup and (hasAllocationScheme some Randomization)))) hasROBA_Cochrane_RandomSequenceGeneration roba_low hasROBA_Cochrane_AllocationConcealment roba_low hasROBA_Cochrane_BlindingParticipantPersonnel roba_low hasROBA_Cochrane_BlindingOutcomeAssessment roba_low hasROBA_Cochrane_IncompleteOutcomeData roba_low hasROBA_Cochrane_SelectiveReporting roba_low hasROBA_QUADAS2_PatientSelection roba_low hasROBA_QUADAS2_OutcomeAssessment roba_unclear hasROBA_QUADAS2_GeneticTesting roba_unclear hasROBA_QUADAS2_FlowAndTiming roba_low</p> |
| stu_1_pub_21099121 | <p>isReportedIn pub_21099121 hasDrugTherapyObserved some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and (hasDrugRegimen some ClopidogrelLD300mgOnce) and (hasDrugRegimen some ClopidogrelMD75mg)))) hasStudyPopulation some (Patient and (hasDisease some CoronaryArteryDisease) and (hasIndicationByDrug some Clopidogrel) and (hasProcedure some PCIWithDES)) hasStudyType some (ObservationalStudy and (hasStudyDesign some (Cohort and (hasTimePerspective some Prospective)))) hasROBA_QUADAS2_PatientSelection roba_unclear hasROBA_QUADAS2_OutcomeAssessment roba_unclear hasROBA_QUADAS2_GeneticTesting roba_unclear hasROBA_QUADAS2_FlowAndTiming roba_low</p> |
| stus_1_pub_21168310 | <p>isReportedIn pub_21168310 hasDrugTherapyObserved some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and (hasDrugRegimen some ClopidogrelLD300mgOnce) and (hasDrugRegimen some ClopidogrelMD75mg)))) hasStudyPopulation some (Patient and (hasDisease some (CoronaryArteryDisease and (hasDiseaseStatus some Stable))) and (hasIndicationByDrug some Clopidogrel) and (hasProcedureAll some (PCIWithStent and (hasProcedureDescriptor some Elective)))) hasStudyType some (ObservationalStudy and (hasStudyDesign some (Cohort and (hasTimePerspective some Prospective)))) hasROBA_QUADAS2_PatientSelection roba_low hasROBA_QUADAS2_OutcomeAssessment roba_unclear hasROBA_QUADAS2_GeneticTesting roba_unclear hasROBA_QUADAS2_FlowAndTiming roba_low</p> |
| stu_1_pub_21170047 | <p>isReportedIn pub_21170047 hasDrugTherapyObserved some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and (hasDrugRegimen some ClopidogrelLD600mgOnce) and (hasDrugRegimen some ClopidogrelMD75mg)))) hasStudyPopulation some (Patient and (hasDisease some AcuteCoronarySyndrome) and (hasIndicationByDrug some Clopidogrel) and (hasProcedure some PCIWithStent)) hasStudyType some (ObservationalStudy and (hasStudyDesign some (Cohort and (hasTimePerspective some Prospective)))) hasROBA_QUADAS2_PatientSelection roba_unclear hasROBA_QUADAS2_OutcomeAssessment roba_low hasROBA_QUADAS2_GeneticTesting roba_low hasROBA_QUADAS2_FlowAndTiming roba_low</p> |
| stu_1_pub_21272753 | <p>isReportedIn pub_21272753 hasDrugTherapyOI some (WarfarinTherapy and (hasDrugTherapyStrategy some (GenotypeGuidedDrugDosing and ((considersGeneticVariant exactly 1 CYP2C9star2) and (considersGeneticVariant exactly 1 CYP2C9star3) and (considersGeneticVariant exactly 1 VKORC1_G-1639A) and (considersGeneticVariant exactly 3 GeneticVariant)))))) hasDrugTherapyRef some (WarfarinTherapy and (hasDrugTherapyStrategy some (PharmacologicallyMonitoredDrugDosing and (hasDrugRegimen some WarfarinInitialDose5mg_day) and (monitorsPharmacodynamicsParameter some INR)))) hasStudyPopulation some (Patient and (hasIndicationByDrug some Warfarin)) hasStudyType some (SimulationStudy and (hasStudyDesign some SimulationVsSimulation))</p> |
| stu_1_pub_21334530 | <p>isReportedIn pub_21334530</p> |

| | |
|--------------------|---|
| | <p>hasDrugTherapyOI some (TicagrelorTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and ((hasDrugRegimen some TicagrelorLD180mgOnce) and (hasDrugRegimen some TicagrelorMD90mgbid))))))</p> <p>hasDrugTherapyRef some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and ((hasDrugRegimen some ClopidogrelLD300mgOnce) and (hasDrugRegimen some ClopidogrelMD75mg))))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some AcuteCoronarySyndrome) and (hasIndicationByDrug some (Clopidogrel or Ticagrelor)) and (hasProcedure some PCIWithStent))</p> <p>hasStudyType some (InterventionalStudy and (hasStudyDesign some (ParallelGroup and (hasAllocationScheme some Randomization))))))</p> |
| stu_1_pub_21423021 | <p>isReportedIn pub_21423021</p> <p>hasDrugTherapyOI some (WarfarinTherapy and (hasDrugTherapyStrategy some (GenotypeGuidedDrugDosing and ((considersGeneticVariant exactly 1 CYP2C9star2) and (considersGeneticVariant exactly 1 CYP2C9star3) and (considersGeneticVariant exactly 1 VKORC1_G-1639A) and (considersGeneticVariant exactly 1 rs2108622) and (considersGeneticVariant exactly 4 GeneticVariant))))))</p> <p>hasDrugTherapyRef some (WarfarinTherapy and (hasDrugTherapyStrategy some ClinicallyGuidedDrugDosing))</p> <p>hasStudyPopulation some (Patient and (hasDisease some (AtrialFibrillation or Thromboembolism)) and (hasIndicationByDrug some Warfarin) and (hasProcedure some HeartValveReplacement))</p> <p>hasStudyType some (InterventionalStudy and (hasStudyDesign some (ParallelGroup and (hasAllocationScheme some Randomization))))))</p> <p>hasROBA_Cochrane_RandomSequenceGeneration roba_low</p> <p>hasROBA_Cochrane_AllocationConcealment roba_low</p> <p>hasROBA_Cochrane_BlindingParticipantPersonnel roba_low</p> <p>hasROBA_Cochrane_BlindingOutcomeAssessment roba_unclear</p> <p>hasROBA_Cochrane_IncompleteOutcomeData roba_high</p> <p>hasROBA_Cochrane_SelectiveReporting roba_low</p> |
| stu_1_pub_21511218 | <p>isReportedIn pub_21511218</p> <p>hasDrugTherapyOI some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and (hasDrugRegimen some ClopidogrelLD900mgOnce))))</p> <p>hasDrugTherapyRef some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and (hasDrugRegimen some ClopidogrelLD300mgOnce))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some (MyocardialInfarction and (hasDiseaseStatus some Stable))) and (hasIndicationByDrug some Clopidogrel) and (hasProcedure some PCI))</p> <p>hasStudyType some (InterventionalStudy and (hasStudyDesign some (CrossOver and (hasAllocationScheme some Randomization))))))</p> <p>hasROBA_Cochrane_RandomSequenceGeneration roba_low</p> <p>hasROBA_Cochrane_AllocationConcealment roba_low</p> <p>hasROBA_Cochrane_BlindingParticipantPersonnel roba_high</p> <p>hasROBA_Cochrane_BlindingOutcomeAssessment roba_high</p> <p>hasROBA_Cochrane_IncompleteOutcomeData roba_low</p> <p>hasROBA_Cochrane_SelectiveReporting roba_low</p> <p>hasROBA_QUADAS2_PatientSelection roba_low</p> <p>hasROBA_QUADAS2_OutcomeAssessment roba_high</p> <p>hasROBA_QUADAS2_GeneticTesting roba_unclear</p> <p>hasROBA_QUADAS2_FlowAndTiming roba_low</p> |
| stu_1_pub_21527445 | <p>isReportedIn pub_21527445</p> <p>hasDrugTherapyObserved some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and (hasDrugRegimen some ClopidogrelStandardDose))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some CoronaryArteryDisease) and (hasIndicationByDrug some Clopidogrel) and (hasProcedure some PCIWithStent))</p> <p>hasStudyType some (ObservationalStudy and (hasStudyDesign some CaseControl))</p> <p>hasROBA_QUADAS2_PatientSelection roba_high</p> <p>hasROBA_QUADAS2_OutcomeAssessment roba_low</p> <p>hasROBA_QUADAS2_GeneticTesting roba_unclear</p> <p>hasROBA_QUADAS2_FlowAndTiming roba_low</p> |
| stu_1_pub_21679849 | <p>isReportedIn pub_21679849</p> <p>hasDrugTherapyObserved some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and ((hasDrugRegimen some ClopidogrelLD600mgOnce) and (hasDrugRegimen some ClopidogrelMD75mg))))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some NSTEMI) and (hasIndicationByDrug some Clopidogrel) and (hasProcedure some PCIWithDES))</p> <p>hasStudyType some (ObservationalStudy and (hasStudyDesign some (Cohort and (hasTimePerspective some Prospective))))))</p> <p>hasROBA_QUADAS2_PatientSelection roba_low</p> <p>hasROBA_QUADAS2_OutcomeAssessment roba_unclear</p> <p>hasROBA_QUADAS2_GeneticTesting roba_low</p> <p>hasROBA_QUADAS2_FlowAndTiming roba_low</p> |
| stu_1_pub_21700758 | <p>isReportedIn pub_21700758</p> <p>hasDrugTherapyObserved some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose</p> |

| | |
|--------------------|--|
| | <p>and ((hasDrugRegimen some ClopidogrelMD75mg) and (hasDrugRegimen some (ClopidogrelLD300mgOnce or ClopidogrelLD600mgOnce))))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some CoronaryArteryDisease) and (hasIndicationByDrug some Clopidogrel) and (hasProcedure some PCIWithDES))</p> <p>hasStudyType some (ObservationalStudy and (hasStudyDesign some (Cohort and (hasTimePerspective some Prospective))))</p> <p>hasROBA_QUADAS2_PatientSelection roba_unclear hasROBA_QUADAS2_OutcomeAssessment roba_unclear hasROBA_QUADAS2_GeneticTesting roba_unclear hasROBA_QUADAS2_FlowAndTiming roba_low</p> |
| stu_1_pub_21778720 | <p>isReportedIn pub_21778720</p> <p>hasDrugTherapyObserved some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and (hasDrugRegimen some ClopidogrelStandardDose))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some AcuteCoronarySyndrome) and (hasIndicationByDrug some Clopidogrel))</p> <p>hasStudyType some (ObservationalStudy and (hasStudyDesign some (Cohort and (hasTimePerspective some Prospective))))</p> <p>hasROBA_QUADAS2_PatientSelection roba_low hasROBA_QUADAS2_OutcomeAssessment roba_low hasROBA_QUADAS2_GeneticTesting roba_unclear hasROBA_QUADAS2_FlowAndTiming roba_low</p> |
| stu_1_pub_21854540 | <p>isReportedIn pub_21854540</p> <p>hasDrugTherapyObserved some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and ((hasDrugRegimen some ClopidogrelMD75mg) and (hasDrugRegimen some (ClopidogrelLD300mgOnce or ClopidogrelLD600mgOnce))))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some CoronaryArteryDisease) and (hasIndicationByDrug some Clopidogrel) and (hasProcedureAll some (PCIWithStent and (hasProcedureDescriptor some Elective))))</p> <p>hasStudyType some (ObservationalStudy and (hasStudyDesign some (Cohort and (hasTimePerspective some Prospective))))</p> <p>hasROBA_QUADAS2_PatientSelection roba_low hasROBA_QUADAS2_OutcomeAssessment roba_low hasROBA_QUADAS2_GeneticTesting roba_unclear hasROBA_QUADAS2_FlowAndTiming roba_low</p> |
| stu_1_pub_21862109 | <p>isReportedIn pub_21862109</p> <p>hasDrugTherapyObserved some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and (hasDrugRegimen some ClopidogrelLD300mgOnce) and (hasDrugRegimen some ClopidogrelMD75mg))))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some (CoronaryArteryDisease and (hasDiseaseStatus some Stable))) and (hasIndicationByDrug some Clopidogrel) and (hasProcedureAll some (PCI and (hasProcedureDescriptor some Elective))))</p> <p>hasStudyType some (ObservationalStudy and (hasStudyDesign some (Cohort and (hasTimePerspective some Prospective))))</p> <p>hasROBA_QUADAS2_PatientSelection roba_low hasROBA_QUADAS2_OutcomeAssessment roba_unclear hasROBA_QUADAS2_GeneticTesting roba_unclear hasROBA_QUADAS2_FlowAndTiming roba_low</p> |
| stu_1_pub_22028352 | <p>isReportedIn pub_22028352</p> <p>hasDrugTherapyObserved some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and (hasDrugRegimen some ClopidogrelStandardDose))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some CoronaryArteryDisease) and (hasIndicationByDrug some Clopidogrel) and (hasProcedure some PCIWithStent))</p> <p>hasStudyType some (ObservationalStudy and (hasStudyDesign some CaseControl))</p> <p>hasROBA_QUADAS2_PatientSelection roba_high hasROBA_QUADAS2_OutcomeAssessment roba_unclear hasROBA_QUADAS2_GeneticTesting roba_unclear hasROBA_QUADAS2_FlowAndTiming roba_low</p> |
| stu_1_pub_22045970 | <p>isReportedIn pub_22045970</p> <p>hasDrugTherapyObserved some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and (hasDrugRegimen some (ClopidogrelLD600mgOnce and ClopidogrelMD75mg))))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some (MyocardialInfarction and (hasDiseaseStatus some Acute))) and (hasIndicationByDrug some Clopidogrel) and (hasProcedure some PCIWithDES))</p> <p>hasStudyType some (ObservationalStudy and (hasStudyDesign some (Cohort and (hasTimePerspective some Prospective))))</p> <p>hasROBA_QUADAS2_PatientSelection roba_low hasROBA_QUADAS2_OutcomeAssessment roba_low hasROBA_QUADAS2_GeneticTesting roba_low hasROBA_QUADAS2_FlowAndTiming roba_low</p> |
| stu_1_pub_22088240 | <p>isReportedIn pub_22088240</p> |

| | |
|--------------------|---|
| | <p>hasDrugTherapyObserved some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and (hasDrugRegimen some ClopidogrelStandardDose))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some CoronaryArteryDisease) and (hasIndicationByDrug some Clopidogrel) and (hasProcedure some PCIWithStent))</p> <p>hasStudyType some (ObservationalStudy and (hasStudyDesign some (Cohort and (hasTimePerspective some Prospective))))</p> |
| stu_1_pub_22088980 | <p>isReportedIn pub_22088980</p> <p>hasDrugTherapyOI some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and (hasDrugRegimen some ClopidogrelMD150mg))))</p> <p>hasDrugTherapyRef some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and (hasDrugRegimen some ClopidogrelMD75mg))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some (CardiovascularDisease and (hasDiseaseStatus some Stable))) and (hasIndicationByDrug some Clopidogrel) and (hasProcedure some PCI))</p> <p>hasStudyType some (InterventionalStudy and (hasStudyDesign some (CrossOver and (hasAllocationScheme some Randomization))))</p> <p>hasROBA_Cochrane_RandomSequenceGeneration roba_low</p> <p>hasROBA_Cochrane_AllocationConcealment roba_low</p> <p>hasROBA_Cochrane_BlindingParticipantPersonnel roba_low</p> <p>hasROBA_Cochrane_BlindingOutcomeAssessment roba_low</p> <p>hasROBA_Cochrane_IncompleteOutcomeData roba_low</p> <p>hasROBA_Cochrane_SelectiveReporting roba_low</p> <p>hasROBA_QUADAS2_PatientSelection roba_low</p> <p>hasROBA_QUADAS2_OutcomeAssessment roba_high</p> <p>hasROBA_QUADAS2_GeneticTesting roba_unclear</p> <p>hasROBA_QUADAS2_FlowAndTiming roba_low</p> |
| stu_1_pub_22116003 | <p>isReportedIn pub_22116003</p> <p>hasDrugTherapyObserved some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and (hasDrugRegimen some ClopidogrelStandardDose))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some NSTEMI) and (hasIndicationByDrug some Clopidogrel) and (hasProcedureMajority some PCIWithStent))</p> <p>hasStudyType some (ObservationalStudy and (hasStudyDesign some (Cohort and (hasTimePerspective some Prospective))))</p> <p>hasROBA_QUADAS2_PatientSelection roba_low</p> <p>hasROBA_QUADAS2_OutcomeAssessment roba_unclear</p> <p>hasROBA_QUADAS2_GeneticTesting roba_unclear</p> <p>hasROBA_QUADAS2_FlowAndTiming roba_high</p> |
| stu_1_pub_22190063 | <p>isReportedIn pub_22190063</p> <p>hasDrugTherapyObserved some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and (hasDrugRegimen some ClopidogrelStandardDose))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some MyocardialInfarction) and (hasIndicationByDrug some Clopidogrel) and (hasProcedure some PCIWithDES))</p> <p>hasStudyType some (ObservationalStudy and (hasStudyDesign some (Cohort and (hasTimePerspective some Retrospective))))</p> <p>hasROBA_QUADAS2_PatientSelection roba_high</p> <p>hasROBA_QUADAS2_OutcomeAssessment roba_low</p> <p>hasROBA_QUADAS2_GeneticTesting roba_unclear</p> <p>hasROBA_QUADAS2_FlowAndTiming roba_low</p> |
| stu_1_pub_22377481 | <p>isReportedIn pub_22377481</p> <p>hasDrugTherapyObserved some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and (hasDrugRegimen some ClopidogrelMD75mg))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some AcuteCoronarySyndrome) and (hasIndicationByDrug some Clopidogrel) and (hasProcedure some PCIWithDES))</p> <p>hasStudyType some (ObservationalStudy and (hasStudyDesign some (Cohort and (hasTimePerspective some Prospective))))</p> <p>hasROBA_QUADAS2_PatientSelection roba_low</p> <p>hasROBA_QUADAS2_OutcomeAssessment roba_unclear</p> <p>hasROBA_QUADAS2_GeneticTesting roba_unclear</p> <p>hasROBA_QUADAS2_FlowAndTiming roba_low</p> |
| stu_1_pub_22390861 | <p>isReportedIn pub_22390861</p> <p>hasDrugTherapyObserved some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and ((hasDrugRegimen some ClopidogrelLD600mgOnce) and (hasDrugRegimen some ClopidogrelMD75mg))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some AcuteCoronarySyndrome) and (hasIndicationByDrug some Clopidogrel) and (hasProcedure some PCIWithStent))</p> <p>hasStudyType some (ObservationalStudy and (hasStudyDesign some (Cohort and (hasTimePerspective some Prospective))))</p> <p>hasROBA_QUADAS2_PatientSelection roba_low</p> <p>hasROBA_QUADAS2_OutcomeAssessment roba_unclear</p> |

| | |
|--------------------|---|
| | <p>hasROBA_QUADAS2_GeneticTesting roba_unclear hasROBA_QUADAS2_FlowAndTiming roba_low</p> |
| stu_1_pub_22431865 | <p>isReportedIn pub_22431865</p> <p>hasDrugTherapyOI some (WarfarinTherapy and (hasDrugTherapyStrategy some (GenotypeGuidedDrugDosing and ((considersGeneticVariant exactly 1 CYP2C9star2) and (considersGeneticVariant exactly 1 CYP2C9star3) and (considersGeneticVariant exactly 1 VKORC1_G-1639A) and (considersGeneticVariant exactly 3 GeneticVariant))))))</p> <p>hasDrugTherapyRef some (WarfarinTherapy and (hasDrugTherapyStrategy some (PharmacologicallyMonitoredDrugDosing and (hasDrugRegimen some WarfarinInitialDose5mg_day) and (monitorsPharmacodynamicsParameter some INR))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some (AtrialFibrillation or DVTandPE or DeepVeinThrombosis or PulmonaryEmbolism)) and (hasIndicationByDrug some Warfarin) and (hasProcedure some OrthopedicSurgery))</p> <p>hasStudyType some (InterventionalStudy and (hasStudyDesign some InterventionVsConcurrentUsualCare))</p> <p>hasROBA_Cochrane_RandomSequenceGeneration roba_high hasROBA_Cochrane_AllocationConcealment roba_high hasROBA_Cochrane_BlindingParticipantPersonnel roba_low hasROBA_Cochrane_BlindingOutcomeAssessment roba_low hasROBA_Cochrane_IncompleteOutcomeData roba_low hasROBA_Cochrane_SelectiveReporting roba_low</p> |
| stu_1_pub_22450429 | <p>isReportedIn pub_22450429</p> <p>hasDrugTherapyOI some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and (hasDrugRegimen some ClopidogrelStandardDose))))</p> <p>hasDrugTherapyRef some Placebo</p> <p>hasStudyPopulation some (Patient and (hasDisease some ((CardiovascularDisease or CerebrovascularDisorder) and (hasDiseaseStatus some Stable))) and (hasIndicationByDrug some Clopidogrel) and (hasRisk some (CardiovascularDisease and CerebrovascularDisorder)))</p> <p>hasStudyType some (InterventionalStudy and (hasStudyDesign some (ParallelGroup and (hasAllocationScheme some Randomization))))</p> <p>hasROBA_Cochrane_RandomSequenceGeneration roba_low hasROBA_Cochrane_AllocationConcealment roba_low hasROBA_Cochrane_BlindingParticipantPersonnel roba_low hasROBA_Cochrane_BlindingOutcomeAssessment roba_low hasROBA_Cochrane_IncompleteOutcomeData roba_low hasROBA_Cochrane_SelectiveReporting roba_low</p> <p>hasROBA_QUADAS2_PatientSelection roba_low hasROBA_QUADAS2_OutcomeAssessment roba_unclear hasROBA_QUADAS2_GeneticTesting roba_unclear hasROBA_QUADAS2_FlowAndTiming roba_low</p> |
| stu_1_pub_22464343 | <p>isReportedIn pub_22464343</p> <p>hasDrugTherapyOI some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (GenotypeGuidedDrugSelection and ((considersGeneticVariant exactly 1 CYP2C19star2) and (considersGeneticVariant exactly 1 GeneticVariant)) and (hasDrugTherapyAlternative some PrasugrelTherapy))))</p> <p>hasDrugTherapyRef some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and (hasDrugRegimen some ClopidogrelMD75mg))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some (NSTE_MI or (CoronaryArteryDisease and (hasDiseaseStatus some Stable)))) and (hasIndicationByDrug some Clopidogrel) and (hasProcedure some PCIWithDES))</p> <p>hasStudyType some (InterventionalStudy and (hasStudyDesign some (ParallelGroup and (hasAllocationScheme some Randomization))))</p> <p>hasROBA_Cochrane_RandomSequenceGeneration roba_low hasROBA_Cochrane_AllocationConcealment roba_low hasROBA_Cochrane_BlindingParticipantPersonnel roba_high hasROBA_Cochrane_BlindingOutcomeAssessment roba_unclear hasROBA_Cochrane_IncompleteOutcomeData roba_low hasROBA_Cochrane_SelectiveReporting roba_low</p> <p>hasROBA_QUADAS2_PatientSelection roba_low hasROBA_QUADAS2_OutcomeAssessment roba_high hasROBA_QUADAS2_GeneticTesting roba_unclear hasROBA_QUADAS2_FlowAndTiming roba_low</p> |
| stu_1_pub_22624833 | <p>isReportedIn pub_22624833</p> <p>hasDrugTherapyOI some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and ((hasDrugRegimen some ClopidogrelLD600mgTwice) and (hasDrugRegimen some ClopidogrelMD150mg))))))</p> <p>hasDrugTherapyRef some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and ((hasDrugRegimen some ClopidogrelLD600mgOnce) and (hasDrugRegimen some ClopidogrelMD75mg))))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some (AcuteCoronarySyndrome or (CoronaryArteryDisease and (hasDiseaseStatus some Stable)))) and (hasIndicationByDrug some Clopidogrel) and (hasProcedure some PCIWithDES))</p> |

| | |
|--------------------|--|
| | <p>hasStudyType some (InterventionalStudy and (hasStudyDesign some (ParallelGroup and (hasAllocationScheme some Randomization))))</p> <p>hasROBA_QUADAS2_PatientSelection roba_low hasROBA_QUADAS2_OutcomeAssessment roba_low hasROBA_QUADAS2_GeneticTesting roba_unclear hasROBA_QUADAS2_FlowAndTiming roba_low</p> |
| stu_1_pub_22836303 | <p>isReportedIn pub_22836303</p> <p>hasDrugTherapyOI some (WarfarinTherapy and (hasDrugTherapyStrategy some (GenotypeGuidedDrugDosing and ((considersGeneticVariant exactly 1 CYP2C9star2) and (considersGeneticVariant exactly 1 CYP2C9star3) and (considersGeneticVariant exactly 1 VKORC1_G-1639A) and (considersGeneticVariant exactly 3 GeneticVariant))))))</p> <p>hasDrugTherapyRef some (WarfarinTherapy and (hasDrugTherapyStrategy some (PharmacologicallyMonitoredDrugDosing and (hasDrugRegimen some WarfarinInitialDose5mg_day) and (monitorsPharmacodynamicsParameter some INR))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some (AtrialFibrillation or DeepVeinThrombosis or Stroke)) and (hasIndicationByDrug some Warfarin))</p> <p>hasStudyType some (InterventionalStudy and (hasStudyDesign some (ParallelGroup and (hasAllocationScheme some Randomization))))</p> <p>hasROBA_Cochrane_RandomSequenceGeneration roba_unclear hasROBA_Cochrane_AllocationConcealment roba_unclear hasROBA_Cochrane_BlindingParticipantPersonnel roba_high hasROBA_Cochrane_BlindingOutcomeAssessment roba_unclear hasROBA_Cochrane_IncompleteOutcomeData roba_high hasROBA_Cochrane_SelectiveReporting roba_low</p> |
| stu_1_pub_22927772 | <p>isReportedIn pub_22927772</p> <p>hasDrugTherapyOI some (WarfarinTherapy and (hasDrugTherapyStrategy some (GenotypeGuidedDrugDosing and ((considersGeneticVariant exactly 1 CYP2C9star3) and (considersGeneticVariant exactly 1 VKORC1_C1173T) and (considersGeneticVariant exactly 2 GeneticVariant))))))</p> <p>hasDrugTherapyRef some (WarfarinTherapy and (hasDrugTherapyStrategy some (PharmacologicallyMonitoredDrugDosing and (hasDrugRegimen some WarfarinInitialDose2.5mg_day) and (monitorsPharmacodynamicsParameter some INR))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some RheumaticHeartDisease) and (hasIndicationByDrug some Warfarin) and (hasProcedure some HeartValveReplacement))</p> <p>hasStudyType some (InterventionalStudy and (hasStudyDesign some (ParallelGroup and (hasAllocationScheme some Randomization))))</p> <p>hasROBA_Cochrane_RandomSequenceGeneration roba_low hasROBA_Cochrane_AllocationConcealment roba_unclear hasROBA_Cochrane_BlindingParticipantPersonnel roba_unclear hasROBA_Cochrane_BlindingOutcomeAssessment roba_unclear hasROBA_Cochrane_IncompleteOutcomeData roba_low hasROBA_Cochrane_SelectiveReporting roba_low</p> |
| stu_1_pub_22990067 | <p>isReportedIn pub_22990067</p> <p>hasDrugTherapyObserved some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and ((hasDrugRegimen some ClopidogrelLD300mgOnce) and (hasDrugRegimen some ClopidogrelMD75mg))))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some AcuteCoronarySyndrome) and (hasIndicationByDrug some Clopidogrel) and (hasProcedure some PCIWithDES))</p> <p>hasStudyType some (ObservationalStudy and (hasStudyDesign some (Cohort and (hasTimePerspective some Prospective))))</p> |
| stu_1_pub_23001453 | <p>isReportedIn pub_23001453</p> <p>hasDrugTherapyObserved some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and ((hasDrugRegimen some ClopidogrelLD300mgOnce) and (hasDrugRegimen some ClopidogrelMD75mg))))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some CoronaryArteryDisease) and (hasIndicationByDrug some Clopidogrel) and (hasProcedure some PCIWithDES))</p> <p>hasStudyType some (ObservationalStudy and (hasStudyDesign some (Cohort and (hasTimePerspective some Prospective))))</p> <p>hasROBA_QUADAS2_PatientSelection roba_low hasROBA_QUADAS2_OutcomeAssessment roba_unclear hasROBA_QUADAS2_GeneticTesting roba_unclear hasROBA_QUADAS2_FlowAndTiming roba_low</p> |
| stu_1_pub_23850318 | <p>isReportedIn pub_23850318</p> <p>hasDrugTherapyOI some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (GenotypeGuidedDrugSelection and ((considersGeneticVariant exactly 1 CYP2C19star2) and (considersGeneticVariant exactly 1 CYP2C19star3) and (considersGeneticVariant exactly 2 GeneticVariant) and (hasDrugTherapyAlternative some (CilostazolTherapy and ClopidogrelDoseEscalation))))))</p> <p>hasDrugTherapyRef some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and ((hasDrugRegimen some ClopidogrelLD300mgOnce) and (hasDrugRegimen some ClopidogrelMD75mg))))))</p> |

| | |
|-------------------------|---|
| | <p>hasStudyPopulation some (Patient and (hasDisease some AcuteCoronarySyndrome) and (hasIndicationByDrug some Clopidogrel) and (hasProcedure some PCIWithDES))</p> <p>hasStudyType some (InterventionalStudy and (hasStudyDesign some (ParallelGroup and (hasAllocationScheme some Randomization))))</p> |
| stu_1_pub_24251360 | <p>isReportedIn pub_24251360</p> <p>hasDrugTherapyOI some ((AcenocoumarolTherapy or PhenprocoumonTherapy) and (hasDrugTherapyStrategy some (GenotypeGuidedDrugDosing and ((considersGeneticVariant exactly 1 CYP2C9star2) and (considersGeneticVariant exactly 1 CYP2C9star3) and (considersGeneticVariant exactly 1 VKORC1_G-1639A) and (considersGeneticVariant exactly 3 GeneticVariant))))))</p> <p>hasDrugTherapyRef some ((AcenocoumarolTherapy or PhenprocoumonTherapy) and (hasDrugTherapyStrategy some ClinicallyGuidedDrugDosing))</p> <p>hasStudyPopulation some (Patient and (hasDisease some (AtrialFibrillation or Thromboembolism)) and (hasIndicationByDrug some (Acenocoumarol or Phenprocoumon)))</p> <p>hasStudyType some (InterventionalStudy and (hasStudyDesign some (ParallelGroup and (hasAllocationScheme some Randomization))))</p> |
| stu_1_pub_24251361 | <p>isReportedIn pub_24251361</p> <p>hasDrugTherapyOI some (WarfarinTherapy and (hasDrugTherapyStrategy some (GenotypeGuidedDrugDosing and ((considersGeneticVariant exactly 1 CYP2C9star2) and (considersGeneticVariant exactly 1 CYP2C9star3) and (considersGeneticVariant exactly 1 VKORC1_G-1639A) and (considersGeneticVariant exactly 3 GeneticVariant))))))</p> <p>hasDrugTherapyRef some (WarfarinTherapy and (hasDrugTherapyStrategy some ClinicallyGuidedDrugDosing))</p> <p>hasStudyPopulation some (Patient and (hasDisease some (AtrialFibrillation or DVTandPE or DeepVeinThrombosis or PulmonaryEmbolism)) and (hasIndicationByDrug some Warfarin))</p> <p>hasStudyType some (InterventionalStudy and (hasStudyDesign some (ParallelGroup and (hasAllocationScheme some Randomization))))</p> <p>hasROBA_Cochrane_RandomSequenceGeneration roba_low</p> <p>hasROBA_Cochrane_AllocationConcealment roba_low</p> <p>hasROBA_Cochrane_BlindingParticipantPersonnel roba_low</p> <p>hasROBA_Cochrane_BlindingOutcomeAssessment roba_low</p> <p>hasROBA_Cochrane_IncompleteOutcomeData roba_low</p> <p>hasROBA_Cochrane_SelectiveReporting roba_low</p> |
| stu_1_pub_24251363 | <p>isReportedIn pub_24251363</p> <p>hasDrugTherapyOI some (WarfarinTherapy and (hasDrugTherapyStrategy some (GenotypeGuidedDrugDosing and ((considersGeneticVariant exactly 1 CYP2C9star2) and (considersGeneticVariant exactly 1 CYP2C9star3) and (considersGeneticVariant exactly 1 VKORC1_G-1639A) and (considersGeneticVariant exactly 3 GeneticVariant))))))</p> <p>hasDrugTherapyRef some (WarfarinTherapy and (hasDrugTherapyStrategy some PharmacologicallyMonitoredDrugDosing and (hasDrugRegimen some WarfarinInitialDose5mg_day) and (monitorsPharmacodynamicsParameter some INR))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some (AtrialFibrillation or Thromboembolism)) and (hasIndicationByDrug some Warfarin))</p> <p>hasStudyType some (InterventionalStudy and (hasStudyDesign some (ParallelGroup and (hasAllocationScheme some Randomization))))</p> <p>hasROBA_Cochrane_RandomSequenceGeneration roba_low</p> <p>hasROBA_Cochrane_AllocationConcealment roba_low</p> <p>hasROBA_Cochrane_BlindingParticipantPersonnel roba_low</p> <p>hasROBA_Cochrane_BlindingOutcomeAssessment roba_low</p> <p>hasROBA_Cochrane_IncompleteOutcomeData roba_low</p> <p>hasROBA_Cochrane_SelectiveReporting roba_low</p> |
| stu_1_pub_Mega_2008 | <p>isReportedIn pub_Mega_2008</p> <p>hasDrugTherapyObserved some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and (hasDrugRegimen some ClopidogrelStandardDose))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some CoronaryArteryDisease) and (hasIndicationByDrug some Clopidogrel) and (hasProcedure some PCIWithDES))</p> <p>hasStudyType some (ObservationalStudy and (hasStudyDesign some (Cohort and (hasTimePerspective some Prospective))))</p> |
| stu_1_pub_Anderson_2009 | <p>isReportedIn pub_Anderson_2009</p> <p>hasDrugTherapyObserved some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and (hasDrugRegimen some ClopidogrelStandardDose))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some CoronaryArteryDisease) and (hasIndicationByDrug some Clopidogrel) and (hasProcedure some PCIWithDES))</p> <p>hasStudyType some (ObservationalStudy and (hasStudyDesign some (Cohort and (hasTimePerspective some Prospective))))</p> |
| stu_1_pub_Worrall_2009 | <p>isReportedIn pub_Worrall_2009</p> <p>hasDrugTherapyObserved some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and (hasDrugRegimen some ClopidogrelStandardDose))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some AcuteCoronarySyndrome) and (hasIndicationByDrug</p> |

| | |
|------------------------|--|
| | <p>some Clopidogrel) and (hasProcedureAll some PCI))</p> <p>hasStudyType some (ObservationalStudy and (hasStudyDesign some (Cohort and (hasTimePerspective some Prospective))))</p> |
| stu_1_pub_Komarov_2011 | <p>isReportedIn pub_Komarov_2011</p> <p>hasDrugTherapyObserved some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and (hasDrugRegimen some ClopidogrelMD75mg))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some (CoronaryArteryDisease and (hasDiseaseStatus some Stable))) and (hasIndicationByDrug some Clopidogrel) and (hasProcedure some (PCI and (hasProcedureDescriptor some Elective))))</p> <p>hasStudyType some (ObservationalStudy and (hasStudyDesign some (Cohort and (hasTimePerspective some Prospective))))</p> |
| stu_1_pub_Nisho_2011 | <p>isReportedIn pub_Nisho_2011</p> <p>hasDrugTherapyObserved some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and (hasDrugRegimen some ClopidogrelStandardDose))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some CoronaryArteryDisease) and (hasIndicationByDrug some Clopidogrel) and (hasProcedure some PCIWithDES))</p> <p>hasStudyType some (ObservationalStudy and (hasStudyDesign some (Cohort and (hasTimePerspective some Prospective))))</p> |
| stu_1_pub_Yuan_2011 | <p>isReportedIn pub_Yuan_2011</p> <p>hasDrugTherapyObserved some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and (hasDrugRegimen some ClopidogrelStandardDose))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some CoronaryArteryDisease) and (hasIndicationByDrug some Clopidogrel) and (hasProcedure some PCIWithStent))</p> <p>hasStudyType some (ObservationalStudy and (hasStudyDesign some (Cohort and (hasTimePerspective some Prospective))))</p> |
| stu_2_pub_19106084 | <p>isReportedIn pub_19106084</p> <p>hasDrugTherapyOI some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and ((hasDrugRegimen some ClopidogrelMD75mg) and (hasDrugRegimen some (ClopidogrelLD300mgOnce or ClopidogrelLD600mgOnce))))))</p> <p>not (hasDrugTherapyRef some DrugTherapy)</p> <p>hasStudyPopulation some HealthySubject</p> <p>hasStudyType some (InterventionalStudy and (hasStudyDesign some SingleGroup))</p> |
| stu_2_pub_19228618 | <p>isReportedIn pub_19228618</p> <p>hasDrugTherapyOI some (WarfarinTherapy and (hasDrugTherapyStrategy some (GenotypeGuidedDrugDosing and ((considersGeneticVariant exactly 1 CYP2C9star2) and (considersGeneticVariant exactly 1 CYP2C9star3) and (considersGeneticVariant exactly 1 VKORC1_G-1639A) and (considersGeneticVariant exactly 3 GeneticVariant))))))</p> <p>hasDrugTherapyRef some (WarfarinTherapy and (hasDrugTherapyStrategy some (PharmacologicallyMonitoredDrugDosing and (hasDrugRegimen some WarfarinInitialDose5mg_day) and (monitorsPharmacodynamicsParameter some INR))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some (AtrialFibrillation or DeepVeinThrombosis or DilatedCardiomyopathy or PulmonaryEmbolism or Stroke)) and (hasIndicationByDrug some Warfarin) and (hasProcedure some (HeartValveReplacement or OrthopedicSurgery)))</p> <p>hasStudyType some (SimulationStudy and (hasStudyDesign some SimulationVsSimulation))</p> |
| stu_2_pub_19414633 | <p>isReportedIn pub_19414633</p> <p>hasDrugTherapyOI some (PrasugrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and (hasDrugRegimen some PrasugrelLD60mgOnce))))</p> <p>not (hasDrugTherapyRef some DrugTherapy)</p> <p>hasStudyPopulation some HealthySubject</p> <p>hasStudyType some (InterventionalStudy and (hasStudyDesign some SingleGroup))</p> |
| stu_2_pub_20979470 | <p>isReportedIn pub_20979470</p> <p>hasDrugTherapyOI some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and (hasDrugRegimen some ClopidogrelMD75mg))))</p> <p>hasDrugTherapyRef some Placebo</p> <p>hasStudyPopulation some (Patient and (hasDisease some AtrialFibrillation) and (hasIndicationByDrug some Clopidogrel) and (hasRisk some Stroke))</p> <p>hasStudyType some (InterventionalStudy and (hasStudyDesign some (ParallelGroup and (hasAllocationScheme some Randomization))))</p> <p>hasROBA_Cochrane_RandomSequenceGeneration roba_low</p> <p>hasROBA_Cochrane_AllocationConcealment roba_low</p> <p>hasROBA_Cochrane_BlindingParticipantPersonnel roba_low</p> <p>hasROBA_Cochrane_BlindingOutcomeAssessment roba_low</p> <p>hasROBA_Cochrane_IncompleteOutcomeData roba_low</p> <p>hasROBA_Cochrane_SelectiveReporting roba_low</p> <p>hasROBA_QUADAS2_PatientSelection roba_low</p> <p>hasROBA_QUADAS2_OutcomeAssessment roba_unclear</p> <p>hasROBA_QUADAS2_GeneticTesting roba_unclear</p> <p>hasROBA_QUADAS2_FlowAndTiming roba_low</p> |

| | |
|--------------------|--|
| stu_2_pub_21170047 | <p>isReportedIn pub_21170047</p> <p>hasDrugTherapyObserved some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and ((hasDrugRegimen some ClopidogrelMD75mg) and (hasDrugRegimen some (ClopidogrelLD300mgOnce or ClopidogrelLD600mgOnce))))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some (AcuteCoronarySyndrome or StableAngina)) and (hasIndicationByDrug some Clopidogrel) and (hasProcedure some PCIWithStent))</p> <p>hasStudyType some (ObservationalStudy and (hasStudyDesign some CaseCohort))</p> |
| stu_2_pub_21272753 | <p>isReportedIn pub_21272753</p> <p>hasDrugTherapyOI some (WarfarinTherapy and (hasDrugTherapyStrategy some (GenotypeGuidedDrugDosing and ((considersGeneticVariant exactly 1 CYP2C9star2) and (considersGeneticVariant exactly 1 CYP2C9star3) and (considersGeneticVariant exactly 1 VKORC1_G-1639A) and (considersGeneticVariant exactly 3 GeneticVariant))))))</p> <p>hasDrugTherapyRef some (WarfarinTherapy and (hasDrugTherapyStrategy some ClinicallyGuidedDrugDosing))</p> <p>hasStudyPopulation some (Patient and (hasIndicationByDrug some Warfarin))</p> <p>hasStudyType some (SimulationStudy and (hasStudyDesign some SimulationVsSimulation))</p> |
| stu_2_pub_22088980 | <p>isReportedIn pub_22088980</p> <p>hasDrugTherapyOI some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and (hasDrugRegimen some ClopidogrelMD225mg))))</p> <p>hasDrugTherapyRef some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and (hasDrugRegimen some ClopidogrelMD75mg))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some (CardiovascularDisease and (hasDiseaseStatus some Stable))) and (hasIndicationByDrug some Clopidogrel) and (hasProcedure some PCI))</p> <p>hasStudyType some (InterventionalStudy and (hasStudyDesign some (CrossOver and (hasAllocationScheme some Randomization))))</p> <p>hasROBA_Cochrane_RandomSequenceGeneration roba_low</p> <p>hasROBA_Cochrane_AllocationConcealment roba_low</p> <p>hasROBA_Cochrane_BlindingParticipantPersonnel roba_low</p> <p>hasROBA_Cochrane_BlindingOutcomeAssessment roba_low</p> <p>hasROBA_Cochrane_IncompleteOutcomeData roba_low</p> <p>hasROBA_Cochrane_SelectiveReporting roba_low</p> <p>hasROBA_QUADAS2_PatientSelection roba_low</p> <p>hasROBA_QUADAS2_OutcomeAssessment roba_high</p> <p>hasROBA_QUADAS2_GeneticTesting roba_unclear</p> <p>hasROBA_QUADAS2_FlowAndTiming roba_low</p> |
| stu_2_pub_22431865 | <p>isReportedIn pub_22431865</p> <p>hasDrugTherapyOI some (WarfarinTherapy and (hasDrugTherapyStrategy some (GenotypeGuidedDrugDosing and ((considersGeneticVariant exactly 1 CYP2C9star2) and (considersGeneticVariant exactly 1 CYP2C9star3) and (considersGeneticVariant exactly 1 VKORC1_G-1639A) and (considersGeneticVariant exactly 3 GeneticVariant))))))</p> <p>hasDrugTherapyRef some (WarfarinTherapy and (hasDrugTherapyStrategy some (PharmacologicallyMonitoredDrugDosing and (hasDrugRegimen some WarfarinInitialDose5mg_day) and (monitorsPharmacodynamicsParameter some INR))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some (AtrialFibrillation or DVTandPE or DeepVeinThrombosis or PulmonaryEmbolism)) and (hasIndicationByDrug some Warfarin) and (hasProcedure some OrthopedicSurgery))</p> <p>hasStudyType some (InterventionalStudy and (hasStudyDesign some InterventionVsSimulation))</p> <p>hasROBA_Cochrane_RandomSequenceGeneration roba_high</p> <p>hasROBA_Cochrane_AllocationConcealment roba_high</p> <p>hasROBA_Cochrane_BlindingParticipantPersonnel roba_low</p> <p>hasROBA_Cochrane_BlindingOutcomeAssessment roba_low</p> <p>hasROBA_Cochrane_IncompleteOutcomeData roba_low</p> <p>hasROBA_Cochrane_SelectiveReporting roba_low</p> |
| stu_3_pub_22088980 | <p>isReportedIn pub_22088980</p> <p>hasDrugTherapyOI some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and (hasDrugRegimen some ClopidogrelMD300mg))))</p> <p>hasDrugTherapyRef some (ClopidogrelTherapy and (hasDrugTherapyStrategy some (FixedDrugDose and (hasDrugRegimen some ClopidogrelMD75mg))))</p> <p>hasStudyPopulation some (Patient and (hasDisease some (CardiovascularDisease and (hasDiseaseStatus some Stable))) and (hasIndicationByDrug some Clopidogrel) and (hasProcedure some PCI))</p> <p>hasStudyType some (InterventionalStudy and (hasStudyDesign some (CrossOver and (hasAllocationScheme some Randomization))))</p> <p>hasROBA_Cochrane_RandomSequenceGeneration roba_low</p> <p>hasROBA_Cochrane_AllocationConcealment roba_low</p> <p>hasROBA_Cochrane_BlindingParticipantPersonnel roba_low</p> <p>hasROBA_Cochrane_BlindingOutcomeAssessment roba_low</p> <p>hasROBA_Cochrane_IncompleteOutcomeData roba_low</p> <p>hasROBA_Cochrane_SelectiveReporting roba_low</p> |

| |
|---|
| hasROBA_QUADAS2_PatientSelection roba_low hasROBA_QUADAS2_OutcomeAssessment roba_high hasROBA_QUADAS2_GeneticTesting roba_unclear hasROBA_QUADAS2_FlowAndTiming roba_low |
|---|

APPENDIX 4: INSTANTIATION OF INDIVIDUAL EVIDENCE

| Name of individual | Assertion of individual |
|---------------------------|--|
| evi_01_pub_10509530_stu_1 | isAcquiredFrom stu_1_pub_10509530 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI |
| | hasGeneticContrast some (CarrierOf1VsNoncarrier and (hasSingleGeneticVariant some CYP2C9star3)) |
| | hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some BleedingOfAllType) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 90 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSize 1.6 |
| evi_01_pub_11127854_stu_1 | isAcquiredFrom stu_1_pub_11127854 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasTwoGeneticVariant some CYP2C9star2) and (hasTwoGeneticVariant some CYP2C9star3))) |
| | hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some BleedingOfAllType) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 547 |
| | hasEffectMetric some UnadjustedOddsRatio |
| | hasEffectSize 2.24 |
| evi_01_pub_11926893_stu_1 | isAcquiredFrom stu_1_pub_11926893 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasTwoGeneticVariant some CYP2C9star2) and (hasTwoGeneticVariant some CYP2C9star3))) |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INRInTherapeuticRange) and (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 818 |
| | hasEffectMetric some UnadjustedHazardRatio |
| | hasEffectSize 0.91 |
| evi_01_pub_15841315_stu_1 | isAcquiredFrom stu_1_pub_15841315 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasTwoGeneticVariant some CYP2C9star2) and (hasTwoGeneticVariant some CYP2C9star3))) |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some AchievingStableDose) and (isMeasuredAs some TimeRequiredToEvent)) |
| | hasTimeFrameInDays 42 |
| | hasEffectMetric some AbsoluteDifferenceGroupMedian |
| | hasEffectSize 1.0 |
| evi_01_pub_15888487_stu_1 | isAcquiredFrom stu_1_pub_15888487 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOf2VsCarrierOf1OrNoncarrier and (hasSingleGeneticVariant some VKORC1_G-1639A)) |
| | hasOutcomeMeasure some (DrugDoseRequirementMeasure and (hasSingleComponent some MeanMaintenanceDose) and (isMeasuredAs some PrimaryValue)) |
| | hasTimeFrame 0 |
| | hasEffectMetric some AbsoluteDifferenceGroupMean |
| | hasEffectSize -1.2 |
| evi_01_pub_16160068_stu_1 | isAcquiredFrom stu_1_pub_16160068 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INRInTherapeuticRange) and (isMeasuredAs some PercentageOfTimeWithEvent)) |
| | hasTimeFrameInDays 28 |
| | hasEffectMetric some AbsoluteDifferenceGroupMean |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 0.2 |
| evi_01_pub_17653141_stu_1 | isAcquiredFrom stu_1_pub_17653141 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasFiveGeneticVariant some |

| | |
|---------------------------|--|
| | <p>CYP2C9star11) and (hasFiveGeneticVariant some CYP2C9star2) and (hasFiveGeneticVariant some CYP2C9star3) and (hasFiveGeneticVariant some CYP2C9star5) and (hasFiveGeneticVariant some CYP2C9star6))</p> <p>hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MajorBleeding) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 730</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 10.9</p> <p>hasPValue 0.0024</p> |
| evi_01_pub_17851566_stu_1 | <p>isAcquiredFrom stu_1_pub_17851566</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INRInTherapeuticRange) and (isMeasuredAs some TimeRequiredToEvent))</p> <p>hasTimeFrameInDays 8</p> <p>hasEffectMetric some AbsoluteDifferenceGroupMean</p> <p>hasEffectSizeUnit day</p> <p>hasEffectSize -2.73</p> <p>hasLower95PercentCI -3.42</p> <p>hasUpper95PercentCI -2.05</p> <p>hasPValue 0.0010</p> |
| evi_01_pub_17982182_stu_1 | <p>isAcquiredFrom stu_1_pub_17982182</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or NonfatalMyocardialInfarction or NonfatalStroke)) and (isMeasuredAs some TimeToEvent))</p> <p>hasTimeFrameInDays 450</p> <p>hasEffectMetric some UnadjustedHazardRatio</p> <p>hasEffectSize 0.81</p> <p>hasLower95PercentCI 0.73</p> <p>hasUpper95PercentCI 0.9</p> |
| evi_01_pub_17989110_stu_1 | <p>isAcquiredFrom stu_1_pub_17989110</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INRBelow1.8OrOver3.2) and (isMeasuredAs some PercentageOfEncounterWithEvent))</p> <p>hasTimeFrameInDays 90</p> <p>hasEffectMetric some AbsoluteDifferenceGroupMean</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize -2.4</p> <p>hasPValue 0.47</p> |
| evi_01_pub_18305455_stu_1 | <p>isAcquiredFrom stu_1_pub_18305455</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (DrugDosingAccuracyMeasure and (hasSingleComponent some PercentageOfDoseVariationExplained) and (isMeasuredAs some AbsoluteDifferenceToFinalDose))</p> <p>hasTimeFrameInDays 30</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRSquare</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 37.0</p> <p>hasPValue 1.0E-4</p> |
| evi_01_pub_18482659_stu_1 | <p>isAcquiredFrom stu_1_pub_18482659</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasTwoComponent some (AllCauseDeath or NonfatalMyocardialInfarction)) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 365</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize -1.4</p> <p>hasPValue 0.371</p> |
| evi_01_pub_18577829_stu_1 | <p>isAcquiredFrom stu_1_pub_18577829</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasTwoComponent some (CVDeath or NonfatalMyocardialInfarction)) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 365</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> |

| | |
|---------------------------|---|
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize -1.2 |
| evi_01_pub_19106083_stu_1 | isAcquiredFrom stu_1_pub_19106083 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOf1VsNoncarrier and ((hasFourGeneticVariant some CYP2C19star2) and (hasFourGeneticVariant some CYP2C19star3) and (hasFourGeneticVariant some CYP2C19star4) and (hasFourGeneticVariant some CYP2C19star5))) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (AllCauseDeath or NonfatalMyocardialInfarction or Stroke)) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize -2.7 |
| evi_01_pub_19106084_stu_1 | isAcquiredFrom stu_1_pub_19106084 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyRef |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasFiveGeneticVariant some CYP2C19star2) and (hasFiveGeneticVariant some CYP2C19star3) and (hasFiveGeneticVariant some CYP2C19star4) and (hasFiveGeneticVariant some CYP2C19star5) and (hasFiveGeneticVariant some CYP2C19star8))) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or NonfatalMyocardialInfarction or NonfatalStroke)) and (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 450 |
| | hasEffectMetric some UnadjustedHazardRatio |
| | hasEffectSize 1.53 |
| | hasLower95PercentCI 1.07 |
| | hasUpper95PercentCI 2.19 |
| | hasPValue 0.01 |
| evi_01_pub_19108880_stu_1 | isAcquiredFrom stu_1_pub_19108880 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or NonfatalMyocardialInfarction or RevasUnspecified)) and (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 1825 |
| | hasEffectMetric some UnadjustedHazardRatio |
| | hasEffectSize 3.69 |
| | hasLower95PercentCI 1.69 |
| | hasUpper95PercentCI 8.05 |
| | hasPValue 5.0E-4 |
| evi_01_pub_19177029_stu_1 | isAcquiredFrom stu_1_pub_19177029 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some AchievingStableDose) and (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 50 |
| | hasEffectMetric some UnadjustedHazardRatio |
| | hasEffectSize 1.932 |
| | hasLower95PercentCI 1.257 |
| | hasUpper95PercentCI 2.969 |
| | hasPValue 0.0030 |
| evi_01_pub_19193675_stu_1 | isAcquiredFrom stu_1_pub_19193675 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some DefiniteStentThrombosis) and (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 30 |
| | hasEffectMetric some UnadjustedHazardRatio |
| | hasEffectSize 3.81 |
| | hasLower95PercentCI 1.45 |
| | hasUpper95PercentCI 10.02 |
| | hasPValue 0.0070 |
| evi_01_pub_19228618_stu_1 | isAcquiredFrom stu_1_pub_19228618 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (DrugDosingAccuracyMeasure and (hasSingleComponent some PercentageOfDoseVariationExplained) and (isMeasuredAs some AbsoluteDifferenceToFinalDose)) |

| | |
|---------------------------|---|
| | hasTimeFrame 0 |
| | hasEffectMetric some AbsoluteDifferenceGroupRSquare |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 17.0 |
| | hasPValue 0.0010 |
| evi_01_pub_19268736_stu_1 | isAcquiredFrom stu_1_pub_19268736 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (RiskVsWildTypeAllele and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some DefiniteOrProbableST) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 180 |
| | hasEffectMetric some UnadjustedOddsRatio |
| | hasEffectSize 2.59 |
| | hasLower95PercentCI 1.15 |
| | hasUpper95PercentCI 5.88 |
| | hasPValue 0.022 |
| evi_01_pub_19414633_stu_1 | isAcquiredFrom stu_1_pub_19414633 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasFiveGeneticVariant some CYP2C19star2) and (hasFiveGeneticVariant some CYP2C19star3) and (hasFiveGeneticVariant some CYP2C19star4) and (hasFiveGeneticVariant some CYP2C19star5) and (hasFiveGeneticVariant some CYP2C19star8))) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or NonfatalMyocardialInfarction or NonfatalStroke)) and (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 450 |
| | hasEffectMetric some UnadjustedHazardRatio |
| | hasEffectSize 0.89 |
| | hasLower95PercentCI 0.6 |
| | hasUpper95PercentCI 1.31 |
| | hasPValue 0.27 |
| evi_01_pub_19706858_stu_1 | isAcquiredFrom stu_1_pub_19706858 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSixComponent some (CVDeath or DefiniteStentThrombosis or HospitalizationDueToIschemia or IschemicStroke or MyocardialInfarction or NonTVROrTVR)) and (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some AdjustedHazardRatio |
| | hasEffectSize 2.42 |
| | hasLower95PercentCI 1.18 |
| | hasUpper95PercentCI 4.99 |
| | hasPValue 0.02 |
| evi_01_pub_19717846_stu_1 | isAcquiredFrom stu_1_pub_19717846 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or MyocardialInfarction or Stroke)) and (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some UnadjustedHazardRatio |
| | hasEffectSize 0.84 |
| | hasLower95PercentCI 0.77 |
| | hasUpper95PercentCI 0.92 |
| | hasPValue 0.0010 |
| evi_01_pub_20083681_stu_1 | isAcquiredFrom stu_1_pub_20083681 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOf1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star17)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some DefiniteOrProbableST) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 30 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 0.0 |
| evi_01_pub_20375999_stu_1 | isAcquiredFrom stu_1_pub_20375999 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (DrugDosingAccuracyMeasure and (hasSingleComponent some PercentageOfDoseVariationExplained) and (isMeasuredAs some AbsoluteDifferenceToFinalDose)) |
| | hasTimeFrame 0 |

| | |
|---------------------------|---|
| | hasEffectMetric some AbsoluteDifferenceGroupRSquare |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 15.0 |
| | hasPValue 0.0020 |
| evi_01_pub_20381283_stu_1 | isAcquiredFrom stu_1_pub_20381283 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some HospitalizationOfAllCause) and (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 180 |
| | hasEffectMetric some AdjustedHazardRatio |
| | hasEffectSize 0.69 |
| | hasLower95PercentCI 0.58 |
| | hasUpper95PercentCI 0.82 |
| | hasPValue 0.0010 |
| evi_01_pub_20492467_stu_1 | isAcquiredFrom stu_1_pub_20492467 |
| | hasComparison some ComparisonBetweenTreatmentWithinGenotype |
| | hasTwoGenotypeOI some (CarrierOfAtLeast1 and ((hasFiveGeneticVariant some CYP2C19star2) and (hasFiveGeneticVariant some CYP2C19star3) and (hasFiveGeneticVariant some CYP2C19star4) and (hasFiveGeneticVariant some CYP2C19star5) and (hasFiveGeneticVariant some CYP2C19star8))) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or NonfatalMyocardialInfarction or NonfatalStroke)) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 450 |
| | hasEffectMetric some UnadjustedRelativeRisk |
| | hasEffectSize 0.57 |
| | hasLower95PercentCI 0.39 |
| | hasUpper95PercentCI 0.83 |
| evi_01_pub_20708365_stu_1 | isAcquiredFrom stu_1_pub_20708365 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyRef |
| | hasGeneticContrast some (CarrierOfAtLeast1 VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some PRI) and (isMeasuredAs some PrimaryValue)) |
| | hasTimeFrameInHours 12 |
| | hasEffectMetric some AbsoluteDifferenceGroupMean |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 12.5 |
| | hasPValue 0.0010 |
| evi_01_pub_20801494_stu_1 | isAcquiredFrom stu_1_pub_20801494 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyRef |
| | hasGeneticContrast some (CarrierOf2VsCarrierOf1OrNoncarrier and (hasSingleGeneticVariant some ABCB1_C3435T)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or NonfatalMyocardialInfarction or NonfatalStroke)) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 450 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 5.1 |
| evi_01_pub_20801498_stu_1 | isAcquiredFrom stu_1_pub_20801498 |
| | hasComparison some ComparisonBetweenTreatmentWithinGenotype |
| | hasTwoGenotypeOI some (CarrierOfAtLeast1 and ((hasSixGeneticVariant some CYP2C19star2) and (hasSixGeneticVariant some CYP2C19star3) and (hasSixGeneticVariant some CYP2C19star4) and (hasSixGeneticVariant some CYP2C19star5) and (hasSixGeneticVariant some CYP2C19star6) and (hasSixGeneticVariant some CYP2C19star8))) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or MyocardialInfarction or Stroke)) and (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some AdjustedHazardRatio |
| | hasEffectSize 0.77 |
| | hasLower95PercentCI 0.6 |
| | hasUpper95PercentCI 0.99 |
| | hasPValue 0.038 |
| evi_01_pub_20826260_stu_1 | isAcquiredFrom stu_1_pub_20826260 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1 VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some TargetLesionRevas) and (isMeasuredAs some IncidenceOfEvent)) |

| | |
|---------------------------|---|
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 1.3 |
| | hasPValue 0.842 |
| evi_01_pub_20833683_stu_1 | isAcquiredFrom stu_1_pub_20833683 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some DefiniteStentThrombosis) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some UnadjustedOddsRatio |
| | hasEffectSize 1.6 |
| | hasLower95PercentCI 1.1 |
| | hasUpper95PercentCI 2.3 |
| | hasPValue 0.013 |
| evi_01_pub_20924183_stu_1 | isAcquiredFrom stu_1_pub_20924183 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some AllCauseDeath) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 1460 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 8.1 |
| | hasPValue 0.09 |
| evi_01_pub_20979470_stu_1 | isAcquiredFrom stu_1_pub_20979470 |
| | hasComparison some ComparisonBetweenTreatmentWithinGenotype |
| | hasTwoGenotypeOI some (CarrierOfAtLeast1 and ((hasTwoGeneticVariant some CYP2C19star2) and (hasTwoGeneticVariant some CYP2C19star3))) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or NonfatalMyocardialInfarction or Stroke)) and (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some AdjustedHazardRatio |
| | hasEffectSize 0.69 |
| | hasLower95PercentCI 0.49 |
| | hasUpper95PercentCI 0.98 |
| evi_01_pub_21099121_stu_1 | isAcquiredFrom stu_1_pub_21099121 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (AllCauseDeath or MyocardialInfarction or TargetVesselRevas)) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 243 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 12.0 |
| | hasPValue 0.25 |
| evi_01_pub_21168310_stu_1 | isAcquiredFrom stu_1_pub_21168310 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasTwoGeneticVariant some CYP2C19star2) and (hasTwoGeneticVariant some CYP2C19star3))) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or IschemicStroke or NonfatalMyocardialInfarction)) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 8.06 |
| evi_01_pub_21170047_stu_1 | isAcquiredFrom stu_1_pub_21170047 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some DefiniteOrProbableST) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 365 |

| | |
|---------------------------|---|
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 0.3 |
| evi_01_pub_21272753_stu_1 | isAcquiredFrom stu_1_pub_21272753 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (DrugDosingAccuracyMeasure and (hasSingleComponent some IdealDosePrediction) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrame 0 |
| | hasEffectMetric some UnadjustedOddsRatio |
| | hasEffectSize 2.18 |
| | hasLower95PercentCI 1.82 |
| | hasUpper95PercentCI 2.61 |
| evi_01_pub_21334530_stu_1 | isAcquiredFrom stu_1_pub_21334530 |
| | hasComparison some (ComparisonBetweenTreatmentWithinGenotype and (hasStratificationInComparison some ClopidogrelLDOver300mg)) |
| | hasTwoGenotypeOI some (CarrierOfAtLeast1 and ((hasSixGeneticVariant some CYP2C19star2) and (hasSixGeneticVariant some CYP2C19star3) and (hasSixGeneticVariant some CYP2C19star4) and (hasSixGeneticVariant some CYP2C19star5) and (hasSixGeneticVariant some CYP2C19star6) and (hasSixGeneticVariant some CYP2C19star8))) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or MyocardialInfarction or Stroke)) and (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some AdjustedHazardRatio |
| | hasEffectSize 0.56 |
| | hasLower95PercentCI 0.35 |
| | hasUpper95PercentCI 0.89 |
| evi_01_pub_21423021_stu_1 | isAcquiredFrom stu_1_pub_21423021 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (DrugDosingAccuracyMeasure and (hasSingleComponent some DosingError) and (isMeasuredAs some AbsoluteDifferenceToFinalDose)) |
| | hasTimeFrameInDays 60 |
| | hasEffectMetric some AbsoluteDifferenceGroupMedian |
| | hasEffectSizeUnit mg/day |
| | hasEffectSize -0.39 |
| | hasLower95PercentCI -0.57 |
| | hasUpper95PercentCI 0.26 |
| | hasPValue 1.0E-4 |
| evi_01_pub_21511218_stu_1 | isAcquiredFrom stu_1_pub_21511218 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyRef |
| | hasGeneticContrast some (CarrierOf1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some MPAOver64.5percent) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInHours 6 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 9.46 |
| evi_01_pub_21527445_stu_1 | isAcquiredFrom stu_1_pub_21527445 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some DefiniteStentThrombosis) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrame 0 |
| | hasEffectMetric some UnadjustedOddsRatio |
| | hasEffectSize 1.7 |
| evi_01_pub_21679849_stu_1 | isAcquiredFrom stu_1_pub_21679849 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (AllCauseDeath or MyocardialInfarction or Stroke)) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 7.3 |
| | hasPValue 0.03 |
| evi_01_pub_21700758_stu_1 | isAcquiredFrom stu_1_pub_21700758 |

| | |
|---------------------------|--|
| | <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or NonfatalMyocardialInfarction or TLROrTVR)) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 365</p> <p>hasEffectMetric some UnadjustedRelativeRisk</p> <p>hasEffectSize 1.24</p> <p>hasLower95PercentCI 0.93</p> <p>hasUpper95PercentCI 1.65</p> <p>hasPValue 0.143</p> |
| evi_01_pub_21778720_stu_1 | <p>isAcquiredFrom stu_1_pub_21778720</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOf2VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or NonfatalMyocardialInfarction or NonfatalStroke)) and (isMeasuredAs some TimeToEvent))</p> <p>hasTimeFrameInHours 0</p> <p>hasEffectMetric some UnadjustedHazardRatio</p> <p>hasEffectSize 4.86</p> <p>hasLower95PercentCI 1.62</p> <p>hasUpper95PercentCI 14.56</p> <p>hasPValue 0.0050</p> |
| evi_01_pub_21854540_stu_1 | <p>isAcquiredFrom stu_1_pub_21854540</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasFourComponent some (AllCauseDeath or IschemicStroke or NonfatalMyocardialInfarction or StentThrombosisUnspecified)) and (isMeasuredAs some TimeToEvent))</p> <p>hasTimeFrameInDays 365</p> <p>hasEffectMetric some UnadjustedHazardRatio</p> <p>hasEffectSize 1.4</p> <p>hasLower95PercentCI 0.82</p> <p>hasUpper95PercentCI 2.3</p> <p>hasPValue 0.23</p> |
| evi_01_pub_21862109_stu_1 | <p>isAcquiredFrom stu_1_pub_21862109</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasTwoGeneticVariant some CYP2C19star2) and (hasTwoGeneticVariant some CYP2C19star3)))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasFourComponent some (CVDeath or IschemicStroke or NonfatalMyocardialInfarction or UnstableAngina)) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 365</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 1.5</p> |
| evi_01_pub_22028352_stu_1 | <p>isAcquiredFrom stu_1_pub_22028352</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some DefiniteStentThrombosis) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrame 0</p> <p>hasEffectMetric some UnadjustedOddsRatio</p> <p>hasEffectSize 2.53</p> <p>hasLower95PercentCI 1.61</p> <p>hasUpper95PercentCI 3.97</p> |
| evi_01_pub_22045970_stu_1 | <p>isAcquiredFrom stu_1_pub_22045970</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOf1VsNoncarrier and ((hasTwoGeneticVariant some CYP2C19star2) and (hasTwoGeneticVariant some CYP2C19star3)))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or IschemicStroke or NonfatalMyocardialInfarction)) and (isMeasuredAs some TimeToEvent))</p> <p>hasTimeFrameInDays 912</p> <p>hasEffectMetric some UnadjustedHazardRatio</p> <p>hasEffectSize 3.1</p> <p>hasLower95PercentCI 0.8</p> |

| | |
|---------------------------|---|
| | hasUpper95PercentCI 11.6 |
| | hasPValue 0.089 |
| evi_01_pub_22088240_stu_1 | isAcquiredFrom stu_1_pub_22088240 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasFiveComponent some (AllCauseDeath or AnginaPectoris or MyocardialInfarction or RevasUnspecified or StentThrombosisUnspecified)) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 5.7 |
| | hasPValue 0.049 |
| evi_01_pub_22088980_stu_1 | isAcquiredFrom stu_1_pub_22088980 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyRef |
| | hasGeneticContrast some (CarrierOf1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some PRI) and (isMeasuredAs some PrimaryValue)) |
| | hasTimeFrameInDays 14 |
| | hasEffectMetric some AbsoluteDifferenceGroupMean |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 12.5 |
| | hasPValue 0.0010 |
| evi_01_pub_22116003_stu_1 | isAcquiredFrom stu_1_pub_22116003 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasTwoComponent some (AcuteCoronarySyndrome or CVDeath)) and (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 180 |
| | hasEffectMetric some UnadjustedHazardRatio |
| | hasEffectSize 0.99 |
| | hasLower95PercentCI 0.64 |
| | hasUpper95PercentCI 1.55 |
| | hasPValue 0.984 |
| evi_01_stu_1_pub_22190063 | isAcquiredFrom stu_1_pub_22190063 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasFourComponent some (AllCauseDeath or MyocardialInfarction or RevasUnspecified or Stroke)) and (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 730 |
| | hasEffectMetric some UnadjustedHazardRatio |
| | hasEffectSize 1.5 |
| | hasLower95PercentCI 1.13 |
| | hasUpper95PercentCI 2.0 |
| | hasPValue 0.0049 |
| evi_01_pub_22377481_stu_1 | isAcquiredFrom stu_1_pub_22377481 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or NonfatalMyocardialInfarction or UnstableAngina)) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 180 |
| | hasEffectMetric some UnadjustedOddsRatio |
| | hasEffectSize 5.25 |
| | hasLower95PercentCI 1.36 |
| | hasUpper95PercentCI 20.65 |
| evi_01_pub_22390861_stu_1 | isAcquiredFrom stu_1_pub_22390861 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasTwoComponent some (CVDeath or NonfatalMyocardialInfarction)) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |

| | |
|---------------------------|---|
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 4.7 |
| evi_01_pub_22431865_stu_1 | isAcquiredFrom stu_1_pub_22431865 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INRBelow1.8OrOver3.3) and (isMeasuredAs some PercentageOfEncounterWithEvent)) |
| | hasTimeFrameInDays 30 |
| | hasEffectMetric some AbsoluteDifferenceGroupMean |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize -10.3 |
| | hasPValue 0.0010 |
| evi_01_pub_22450429_stu_1 | isAcquiredFrom stu_1_pub_22450429 |
| | hasComparison some ComparisonBetweenTreatmentWithinGenotype |
| | hasTwoGenotypeOI some (CarrierOfAtLeast1 and ((hasTwoGeneticVariant some CYP2C19star2) and (hasTwoGeneticVariant some CYP2C19star3))) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or (FatalMyocardialInfarction or NonfatalMyocardialInfarction) or (FatalStroke or NonfatalStroke))) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 840 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 1.7 |
| evi_01_pub_22464343_stu_1 | isAcquiredFrom stu_1_pub_22464343 |
| | hasComparison some ComparisonBetweenTreatmentWithinGenotype |
| | hasTwoGenotypeOI some (CarrierOfAtLeast1 and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some PRUOver234) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 7 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize -30.0 |
| | hasPValue 0.0092 |
| evi_01_pub_22624833_stu_1 | isAcquiredFrom stu_1_pub_22624833 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI |
| | hasGeneticContrast some (CarrierOf1 VsNoncarrier and ((hasFiveGeneticVariant some CYP2C19star2) and (hasFiveGeneticVariant some CYP2C19star3) and (hasFiveGeneticVariant some CYP2C19star4) and (hasFiveGeneticVariant some CYP2C19star6) and (hasFiveGeneticVariant some CYP2C19star8))) |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some PRUOver230) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 30 |
| | hasEffectMetric some AdjustedOddsRatio |
| | hasEffectSize 1.63 |
| | hasLower95PercentCI 0.93 |
| | hasUpper95PercentCI 2.88 |
| evi_01_pub_22836303_stu_1 | isAcquiredFrom stu_1_pub_22836303 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INRInTherapeuticRange) and (isMeasuredAs some TimeRequiredToEvent)) |
| | hasTimeFrameInDays 84 |
| | hasEffectMetric some AbsoluteDifferenceGroupMean |
| | hasEffectSizeUnit day |
| | hasEffectSize -3.6 |
| | hasPValue 0.0152 |
| evi_01_pub_22927772_stu_1 | isAcquiredFrom stu_1_pub_22927772 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some AchievingStableDose) and (isMeasuredAs some TimeRequiredToEvent)) |
| | hasTimeFrameInDays 50 |
| | hasEffectMetric some AbsoluteDifferenceGroupMean |
| | hasEffectSizeUnit day |
| | hasEffectSize -7.2 |
| | hasPValue 0.0010 |
| evi_01_pub_22990067_stu_1 | isAcquiredFrom stu_1_pub_22990067 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOf1 VsNoncarrier and ((hasTwoGeneticVariant some CYP2C19star2) and (hasTwoGeneticVariant some CYP2C19star3))) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or |

| | |
|--------------------------------|--|
| | <p>IschemicStroke or NonfatalMyocardialInfarction)) and (isMeasuredAs some TimeToEvent))</p> <p>hasTimeFrameInDays 180</p> <p>hasEffectMetric some UnadjustedHazardRatio</p> <p>hasEffectSize 1.508</p> <p>hasLower95PercentCI 0.594</p> <p>hasUpper95PercentCI 3.83</p> <p>hasPValue 0.388</p> |
| evi_01_pub_23001453_stu_1 | <p>isAcquiredFrom stu_1_pub_23001453</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOfAtLeast1 VsNoncarrier and ((hasTwoGeneticVariant some CYP2C19star2) and (hasTwoGeneticVariant some CYP2C19star3)))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some DefiniteStentThrombosis) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 365</p> <p>hasEffectMetric some UnadjustedOddsRatio</p> <p>hasEffectSize 4.4</p> <p>hasLower95PercentCI 0.53</p> <p>hasUpper95PercentCI 36.75</p> |
| evi_01_pub_23850318_stu_1 | <p>isAcquiredFrom stu_1_pub_23850318</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasFourComponent some (AllCauseDeath or MyocardialInfarction or Stroke or TargetVesselRevas) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 180</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize -6.37</p> <p>hasPValue 0.0010</p> |
| evi_01_pub_24251360_stu_1 | <p>isAcquiredFrom stu_1_pub_24251360</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INRInTherapeuticRange) and (isMeasuredAs some PercentageOfTimeWithEvent))</p> <p>hasTimeFrameInDays 84</p> <p>hasEffectMetric some AbsoluteDifferenceGroupMean</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 1.4</p> <p>hasLower95PercentCI -2.8</p> <p>hasUpper95PercentCI 5.5</p> <p>hasPValue 0.52</p> |
| evi_01_pub_24251361_stu_1 | <p>isAcquiredFrom stu_1_pub_24251361</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INRInTherapeuticRange) and (isMeasuredAs some PercentageOfTimeWithEvent))</p> <p>hasTimeFrameInDays 28</p> <p>hasEffectMetric some AbsoluteDifferenceGroupMean</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize -0.2</p> <p>hasLower95PercentCI -3.4</p> <p>hasUpper95PercentCI 3.1</p> <p>hasPValue 0.91</p> |
| evi_01_pub_24251363_stu_1 | <p>isAcquiredFrom stu_1_pub_24251363</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INRInTherapeuticRange) and (isMeasuredAs some PercentageOfTimeWithEvent))</p> <p>hasTimeFrameInDays 90</p> <p>hasEffectMetric some AbsoluteDifferenceGroupMean</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 7.0</p> <p>hasLower95PercentCI 3.3</p> <p>hasUpper95PercentCI 10.6</p> <p>hasPValue 0.0010</p> |
| evi_01_pub_Anderson_2009_stu_1 | <p>isAcquiredFrom stu_1_pub_Anderson_2009</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOfAtLeast1 VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasTwoComponent some (AllCauseDeath or MyocardialInfarction)) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 365</p> |

| | |
|-------------------------------|---|
| | hasEffectMetric some UnadjustedOddsRatio |
| | hasEffectSize 1.43 |
| | hasLower95PercentCI 0.98 |
| | hasUpper95PercentCI 2.09 |
| | hasPValue 0.06 |
| evi_01_pub_Komarov_2011_stu_1 | isAcquiredFrom stu_1_pub_Komarov_2011 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasFourComponent some (AcuteCoronarySyndrome or CVDeath or RevasUnspecified or Stroke)) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 540 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 3.9 |
| evi_01_pub_Nisho_2011_stu_1 | isAcquiredFrom stu_1_pub_Nisho_2011 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some TargetLesionRevas) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrame 0 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 16.9 |
| | hasPValue 0.0249 |
| evi_01_pub_Worrall_2009_stu_1 | isAcquiredFrom stu_1_pub_Worrall_2009 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasFourComponent some (AllCauseDeath or MyocardialInfarction or RevasUnspecified or Stroke)) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrame 0 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectMetric percentagePoint |
| | hasEffectSize 9.2 |
| | hasPValue 0.17 |
| evi_01_pub_Yuan_2011_stu_1 | isAcquiredFrom stu_1_pub_Yuan_2011 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasFourComponent some (AllCauseDeath or MyocardialInfarction or RevasUnspecified or StentThrombosisUnspecified)) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 5.7 |
| evi_02_pub_10509530_stu_1 | isAcquiredFrom stu_1_pub_10509530 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI |
| | hasGeneticContrast some (CarrierOf2VsNoncarrier and (hasSingleGeneticVariant some CYP2C9star3)) |
| | hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some BleedingOfAllType) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 90 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 91.6 |
| evi_02_pub_11127854_stu_1 | isAcquiredFrom stu_1_pub_11127854 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C9star2)) |
| | hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some BleedingOfAllType) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 547 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |

| | |
|---------------------------|---|
| | hasEffectSize 13.0 |
| evi_02_pub_11926893_stu_1 | isAcquiredFrom stu_1_pub_11926893 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasTwoGeneticVariant some CYP2C9star2) and (hasTwoGeneticVariant some CYP2C9star3))) |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INROver4.0) and (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 818 |
| | hasEffectMetric some UnadjustedHazardRatio |
| | hasEffectSize 1.28 |
| | hasLower95PercentCI 0.94 |
| | hasUpper95PercentCI 1.74 |
| evi_02_pub_15841315_stu_1 | isAcquiredFrom stu_1_pub_15841315 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasTwoGeneticVariant some CYP2C9star2) and (hasTwoGeneticVariant some CYP2C9star3))) |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some AchievingStableDose) and (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 42 |
| | hasEffectMetric some UnadjustedHazardRatio |
| | hasEffectSize 0.74 |
| | hasLower95PercentCI 0.36 |
| | hasUpper95PercentCI 1.5 |
| evi_02_pub_16160068_stu_1 | isAcquiredFrom stu_1_pub_16160068 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INROver4.0) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 28 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 3.3 |
| evi_02_pub_17653141_stu_1 | isAcquiredFrom stu_1_pub_17653141 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasFiveGeneticVariant some CYP2C9star11) and (hasFiveGeneticVariant some CYP2C9star2) and (hasFiveGeneticVariant some CYP2C9star3) and (hasFiveGeneticVariant some CYP2C9star5) and (hasFiveGeneticVariant some CYP2C9star6))) |
| | hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MinorBleeding) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 730 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 7.5 |
| | hasPValue 0.15 |
| evi_02_pub_17851566_stu_1 | isAcquiredFrom stu_1_pub_17851566 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INRInTherapeuticRange) and (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 8 |
| | hasEffectMetric some UnadjustedHazardRatio |
| | hasEffectSize 2.89 |
| | hasLower95PercentCI 2.11 |
| | hasUpper95PercentCI 3.97 |
| | hasPValue 0.0010 |
| evi_02_pub_17989110_stu_1 | isAcquiredFrom stu_1_pub_17989110 |
| | hasComparison some ComparisonBetweenTreatmentWithinGenotype |
| | hasFourGenotypeOI some (((hasThreeGeneticVariant some CYP2C9star2) and (hasThreeGeneticVariant some CYP2C9star3) and (hasThreeGeneticVariant some VKORC1_C1173T)) and (CarrierOf2 or CarrierOf3 or CarrierOf4 or Noncarrier)) |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INRBelow1.8OrOver3.2) and (isMeasuredAs some PercentageOfEncounterWithEvent)) |
| | hasTimeFrameInDays 90 |
| | hasEffectMetric some AbsoluteDifferenceGroupMean |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize -9.8 |
| | hasPValue 0.03 |
| evi_02_pub_18305455_stu_1 | isAcquiredFrom stu_1_pub_18305455 |

| | |
|---------------------------|---|
| | <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (DrugDosingAccuracyMeasure and (hasSingleComponent some DosingError) and (isMeasuredAs some AbsoluteDifferenceToFinalDose))</p> <p>hasTimeFrameInDays 30</p> <p>hasEffectMetric some AbsoluteDifferenceGroupMedian</p> <p>hasEffectSizeUnit mg/day</p> <p>hasEffectSize -0.5</p> <p>hasPValue 0.0010</p> |
| evi_02_pub_18577829_stu_1 | <p>isAcquiredFrom stu_1_pub_18577829</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some NonfatalMyocardialInfarction) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 365</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 1.2</p> |
| evi_02_pub_19106083_stu_1 | <p>isAcquiredFrom stu_1_pub_19106083</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOf2VsNoncarrier and ((hasFourGeneticVariant some CYP2C19star2) and (hasFourGeneticVariant some CYP2C19star3) and (hasFourGeneticVariant some CYP2C19star4) and (hasFourGeneticVariant some CYP2C19star5)))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (AllCauseDeath or NonfatalMyocardialInfarction or Stroke)) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 365</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 6.9</p> |
| evi_02_pub_19106084_stu_1 | <p>isAcquiredFrom stu_1_pub_19106084</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyRef</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasFiveGeneticVariant some CYP2C19star2) and (hasFiveGeneticVariant some CYP2C19star3) and (hasFiveGeneticVariant some CYP2C19star4) and (hasFiveGeneticVariant some CYP2C19star5) and (hasFiveGeneticVariant some CYP2C19star8)))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some DefiniteOrProbableST) and (isMeasuredAs some TimeToEvent))</p> <p>hasTimeFrameInDays 450</p> <p>hasEffectMetric some UnadjustedHazardRatio</p> <p>hasEffectSize 3.09</p> <p>hasLower95PercentCI 1.19</p> <p>hasUpper95PercentCI 8.0</p> <p>hasPValue 0.02</p> |
| evi_02_pub_19108880_stu_1 | <p>isAcquiredFrom stu_1_pub_19108880</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some CVDeath) and (isMeasuredAs some TimeToEvent))</p> <p>hasTimeFrameInDays 1825</p> <p>hasEffectMetric some UnadjustedHazardRatio</p> <p>hasEffectSize 5.74</p> <p>hasLower95PercentCI 0.52</p> <p>hasUpper95PercentCI 63.48</p> <p>hasPValue 0.1</p> |
| evi_02_pub_19177029_stu_1 | <p>isAcquiredFrom stu_1_pub_19177029</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INRInTherapeuticRange) and (isMeasuredAs some DurationOfTimeWithEvent))</p> <p>hasTimeFrameInDays 50</p> <p>hasEffectMetric some AbsoluteDifferenceGroupMean</p> <p>hasEffectSizeUnit day</p> <p>hasEffectSize 6.2</p> <p>hasPValue 0.0010</p> |
| evi_02_pub_19193675_stu_1 | <p>isAcquiredFrom stu_1_pub_19193675</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some</p> |

| | |
|---------------------------|---|
| | <p>CYP2C19star2))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some AllCauseDeath) and (isMeasuredAs some TimeToEvent))</p> <p>hasTimeFrameInDays 30</p> <p>hasEffectMetric some UnadjustedHazardRatio</p> <p>hasEffectSize 0.83</p> <p>hasLower95PercentCI 0.3</p> <p>hasUpper95PercentCI 2.26</p> <p>hasPValue 0.71</p> |
| evi_02_pub_19228618_stu_1 | <p>isAcquiredFrom stu_1_pub_19228618</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (DrugDosingAccuracyMeasure and (hasSingleComponent some DosingError) and (isMeasuredAs some AbsoluteDifferenceToFinalDose))</p> <p>hasTimeFrame 0</p> <p>hasEffectMetric some AbsoluteDifferenceGroupMean</p> <p>hasEffectSizeUnit mg/week</p> <p>hasEffectSize -1.4</p> <p>hasPValue 0.0010</p> |
| evi_02_pub_19268736_stu_1 | <p>isAcquiredFrom stu_1_pub_19268736</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some CVDeath) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 180</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 2.5</p> <p>hasPValue 0.037</p> |
| evi_02_pub_19414633_stu_1 | <p>isAcquiredFrom stu_1_pub_19414633</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasFiveGeneticVariant some CYP2C19star2) and (hasFiveGeneticVariant some CYP2C19star3) and (hasFiveGeneticVariant some CYP2C19star4) and (hasFiveGeneticVariant some CYP2C19star5) and (hasFiveGeneticVariant some CYP2C19star8)))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some DefiniteOrProbableST) and (isMeasuredAs some TimeToEvent))</p> <p>hasTimeFrameInDays 450</p> <p>hasEffectMetric some UnadjustedHazardRatio</p> <p>hasEffectSize 0.58</p> <p>hasLower95PercentCI 0.13</p> <p>hasUpper95PercentCI 2.69</p> <p>hasPValue 0.48</p> |
| evi_02_pub_19706858_stu_1 | <p>isAcquiredFrom stu_1_pub_19706858</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSixComponent some (CVDeath or DefiniteStentThrombosis or HospitalizationDueToIschemia or IschemicStroke or MyocardialInfarction or NonTVROrTVR)) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 365</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 10.9</p> |
| evi_02_pub_20083681_stu_1 | <p>isAcquiredFrom stu_1_pub_20083681</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOf2VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star17))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some DefiniteOrProbableST) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 30</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 0.4</p> |
| evi_02_pub_20375999_stu_1 | <p>isAcquiredFrom stu_1_pub_20375999</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (DrugDosingAccuracyMeasure and (hasSingleComponent some DosingError) and (isMeasuredAs some AbsoluteDifferenceToFinalDose))</p> |

| | |
|---------------------------|---|
| | hasTimeFrame 0 |
| | hasEffectMetric some AbsoluteDifferenceGroupMedian |
| | hasEffectSizeUnit mg/week |
| | hasEffectSize -1.2 |
| | hasPValue 0.02 |
| evi_02_pub_20381283_stu_1 | isAcquiredFrom stu_1_pub_20381283 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (ClinicalEfficacySafetyMeasure and (hasTwoComponent some (BleedingOfAllType or Thromboembolism)) and (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 180 |
| | hasEffectMetric some AdjustedHazardRatio |
| | hasEffectSize 0.72 |
| | hasLower95PercentCI 0.53 |
| | hasUpper95PercentCI 0.97 |
| | hasPValue 0.029 |
| evi_02_pub_20492467_stu_1 | isAcquiredFrom stu_1_pub_20492467 |
| | hasComparison some ComparisonBetweenTreatmentWithinGenotype |
| | hasSingleGenotypeOI some (Noncarrier and ((hasFiveGeneticVariant some CYP2C19star2) and (hasFiveGeneticVariant some CYP2C19star3) and (hasFiveGeneticVariant some CYP2C19star4) and (hasFiveGeneticVariant some CYP2C19star5) and (hasFiveGeneticVariant some CYP2C19star8))) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or NonfatalMyocardialInfarction or NonfatalStroke)) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 450 |
| | hasEffectMetric some UnadjustedRelativeRisk |
| | hasEffectSize 0.98 |
| | hasLower95PercentCI 0.8 |
| | hasUpper95PercentCI 1.2 |
| evi_02_pub_20708365_stu_1 | isAcquiredFrom stu_1_pub_20708365 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyRef |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some PRIOver50percent) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInHours 12 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 21.4 |
| | hasPValue 1.0E-4 |
| evi_02_pub_20801494_stu_1 | isAcquiredFrom stu_1_pub_20801494 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyRef |
| | hasGeneticContrast some (CarrierOf2VsCarrierOf1OrNoncarrier and (hasSingleGeneticVariant some ABCB1_C3435T)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some DefiniteOrProbableST) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 450 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 0.0 |
| evi_02_pub_20801498_stu_1 | isAcquiredFrom stu_1_pub_20801498 |
| | hasComparison some ComparisonBetweenTreatmentWithinGenotype |
| | hasSingleGenotypeOI some (Noncarrier and ((hasSixGeneticVariant some CYP2C19star2) and (hasSixGeneticVariant some CYP2C19star3) and (hasSixGeneticVariant some CYP2C19star4) and (hasSixGeneticVariant some CYP2C19star5) and (hasSixGeneticVariant some CYP2C19star6) and (hasSixGeneticVariant some CYP2C19star8))) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or MyocardialInfarction or Stroke)) and (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some AdjustedHazardRatio |
| | hasEffectSize 0.86 |
| | hasLower95PercentCI 0.74 |
| | hasUpper95PercentCI 1.01 |
| | hasPValue 0.0608 |
| evi_02_pub_20826260_stu_1 | isAcquiredFrom stu_1_pub_20826260 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some AllCauseDeath)) |

| | |
|---------------------------|---|
| | <p>and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 365</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize -3.5</p> <p>hasPValue 0.08</p> |
| evi_02_pub_20979470_stu_1 | <p>isAcquiredFrom stu_1_pub_20979470</p> <p>hasComparison some ComparisonBetweenTreatmentWithinGenotype</p> <p>hasSingleGenotypeOI some (Noncarrier and ((hasTwoGeneticVariant some CYP2C19star2) and (hasTwoGeneticVariant some CYP2C19star3)))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or NonfatalMyocardialInfarction or Stroke)) and (isMeasuredAs some TimeToEvent))</p> <p>hasTimeFrameInDays 365</p> <p>hasEffectMetric some AdjustedHazardRatio</p> <p>hasEffectSize 0.72</p> <p>hasLower95PercentCI 0.59</p> <p>hasUpper95PercentCI 0.87</p> |
| evi_02_pub_21099121_stu_1 | <p>isAcquiredFrom stu_1_pub_21099121</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some AllCauseDeath) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 243</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 2.4</p> <p>hasPValue 0.87</p> |
| evi_02_pub_21168310_stu_1 | <p>isAcquiredFrom stu_1_pub_21168310</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasTwoGeneticVariant some CYP2C19star2) and (hasTwoGeneticVariant some CYP2C19star3)))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some CVDeath) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 365</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 1.6</p> |
| evi_02_pub_21170047_stu_1 | <p>isAcquiredFrom stu_1_pub_21170047</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOf1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some DefiniteOrProbableST) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 365</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 0.3</p> |
| evi_02_pub_21272753_stu_2 | <p>isAcquiredFrom stu_2_pub_21272753</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (DrugDosingAccuracyMeasure and (hasSingleComponent some IdealDosePrediction) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrame 0</p> <p>hasEffectMetric some UnadjustedOddsRatio</p> <p>hasEffectSize 2.17</p> <p>hasLower95PercentCI 1.79</p> <p>hasUpper95PercentCI 2.64</p> |
| evi_02_pub_21334530_stu_1 | <p>isAcquiredFrom stu_1_pub_21334530</p> <p>hasComparison some (ComparisonBetweenTreatmentWithinGenotype and (hasStratificationInComparison some ClopidogrelLDOver300mg))</p> <p>hasSingleGenotypeOI some (Noncarrier and ((hasSixGeneticVariant some CYP2C19star2) and (hasSixGeneticVariant some CYP2C19star3) and (hasSixGeneticVariant some CYP2C19star4) and (hasSixGeneticVariant some CYP2C19star5) and (hasSixGeneticVariant some CYP2C19star6) and (hasSixGeneticVariant some CYP2C19star8)))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or MyocardialInfarction or Stroke)) and (isMeasuredAs some TimeToEvent))</p> <p>hasTimeFrameInDays 365</p> <p>hasEffectMetric some AdjustedHazardRatio</p> |

| | |
|---------------------------|--|
| | hasEffectSize 0.67 |
| | hasLower95PercentCI 0.48 |
| | hasUpper95PercentCI 0.93 |
| evi_02_pub_21423021_stu_1 | isAcquiredFrom stu_1_pub_21423021 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INRInTherapeuticRange) and (isMeasuredAs some PercentageOfTimeWithEvent)) |
| | hasTimeFrameInDays 14 |
| | hasEffectMetric some AbsoluteDifferenceGroupMean |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize -1.7 |
| | hasPValue 0.564 |
| evi_02_pub_21511218_stu_1 | isAcquiredFrom stu_1_pub_21511218 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI |
| | hasGeneticContrast some (CarrierOf1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some MPAOver64.5percent) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInHours 6 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 1.43 |
| evi_02_pub_21527445_stu_1 | isAcquiredFrom stu_1_pub_21527445 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOf2VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some DefiniteStentThrombosis) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrame 0 |
| | hasEffectMetric some AdjustedOddsRatio |
| | hasEffectSize 2.27 |
| | hasLower95PercentCI 1.08 |
| | hasUpper95PercentCI 4.74 |
| evi_02_pub_21679849_stu_1 | isAcquiredFrom stu_1_pub_21679849 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some AllCauseDeath) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 0.7 |
| evi_02_pub_21700758_stu_1 | isAcquiredFrom stu_1_pub_21700758 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or DefiniteOrProbableST or NonfatalMyocardialInfarction)) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some UnadjustedRelativeRisk |
| | hasEffectSize 2.62 |
| | hasLower95PercentCI 1.24 |
| | hasUpper95PercentCI 5.53 |
| | hasPValue 0.0090 |
| evi_02_pub_21854540_stu_1 | isAcquiredFrom stu_1_pub_21854540 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOf1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasFourComponent some (AllCauseDeath or IschemicStroke or NonfatalMyocardialInfarction or StentThrombosisUnspecified)) and (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some UnadjustedHazardRatio |
| | hasEffectSize 1.3 |
| | hasLower95PercentCI 0.74 |
| | hasUpper95PercentCI 2.2 |
| evi_02_pub_22028352_stu_1 | isAcquiredFrom stu_1_pub_22028352 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOf2VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |

| | |
|---------------------------|---|
| | <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some DefiniteStentThrombosis) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrame 0</p> <p>hasEffectMetric some UnadjustedOddsRatio</p> <p>hasEffectSize 7.73</p> <p>hasLower95PercentCI 3.02</p> <p>hasUpper95PercentCI 19.82</p> |
| evi_02_pub_22045970_stu_1 | <p>isAcquiredFrom stu_1_pub_22045970</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOf2VsNoncarrier and ((hasTwoGeneticVariant some CYP2C19star2) and (hasTwoGeneticVariant some CYP2C19star3)))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or IschemicStroke or NonfatalMyocardialInfarction)) and (isMeasuredAs some TimeToEvent))</p> <p>hasTimeFrameInDays 912</p> <p>hasEffectMetric some UnadjustedHazardRatio</p> <p>hasEffectSize 10.1</p> <p>hasLower95PercentCI 1.8</p> <p>hasUpper95PercentCI 58.8</p> <p>hasPValue 0.0080</p> |
| evi_02_pub_22088980_stu_1 | <p>isAcquiredFrom stu_1_pub_22088980</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyRef</p> <p>hasGeneticContrast some (CarrierOf2VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some PRI) and (isMeasuredAs some PrimaryValue))</p> <p>hasTimeFrameInDays 14</p> <p>hasEffectMetric some AbsoluteDifferenceGroupMean</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 29.1</p> <p>hasPValue 0.0010</p> |
| evi_02_pub_22431865_stu_1 | <p>isAcquiredFrom stu_1_pub_22431865</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INRInTherapeuticRange) and (isMeasuredAs some PercentageOfTimeWithEvent))</p> <p>hasTimeFrameInDays 30</p> <p>hasEffectMetric some AbsoluteDifferenceGroupMean</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 10.5</p> <p>hasPValue 0.0010</p> |
| evi_02_pub_22450429_stu_1 | <p>isAcquiredFrom stu_1_pub_22450429</p> <p>hasComparison some ComparisonBetweenTreatmentWithinGenotype</p> <p>hasSingleGenotypeOI some (Noncarrier and ((hasTwoGeneticVariant some CYP2C19star2) and (hasTwoGeneticVariant some CYP2C19star3)))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or FatalMyocardialInfarction or NonfatalMyocardialInfarction) or (FatalStroke or NonfatalStroke))) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 840</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize -0.2</p> |
| evi_02_pub_22464343_stu_1 | <p>isAcquiredFrom stu_1_pub_22464343</p> <p>hasComparison some ComparisonBetweenTreatmentWithinGenotype</p> <p>hasTwoGenotypeOI some (CarrierOfAtLeast1 and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some PRUOver208) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 7</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize -44.0</p> <p>hasPValue 0.0017</p> |
| evi_02_pub_22624833_stu_1 | <p>isAcquiredFrom stu_1_pub_22624833</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyRef</p> <p>hasGeneticContrast some (CarrierOf1VsNoncarrier and ((hasFiveGeneticVariant some CYP2C19star2) and (hasFiveGeneticVariant some CYP2C19star3) and (hasFiveGeneticVariant some CYP2C19star4) and (hasFiveGeneticVariant some CYP2C19star6) and (hasFiveGeneticVariant some CYP2C19star8)))</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some PRUOver230) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 30</p> |

| | |
|---------------------------|---|
| | hasEffectMetric some AdjustedOddsRatio |
| | hasEffectSize 2.66 |
| | hasLower95PercentCI 1.47 |
| | hasUpper95PercentCI 4.82 |
| evi_02_pub_22836303_stu_1 | isAcquiredFrom stu_1_pub_22836303 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INRInTherapeuticRange) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 5 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 30.7 |
| | hasPValue 0.1156 |
| evi_02_pub_22927772_stu_1 | isAcquiredFrom stu_1_pub_22927772 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some AchievingStableDose) and (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 50 |
| | hasEffectMetric some AdjustedHazardRatio |
| | hasEffectSize 1.568 |
| | hasLower95PercentCI 1.103 |
| | hasUpper95PercentCI 3.284 |
| | hasPValue 0.026 |
| evi_02_pub_22990067_stu_1 | isAcquiredFrom stu_1_pub_22990067 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOf2VsNoncarrier and ((hasTwoGeneticVariant some CYP2C19star2) and (hasTwoGeneticVariant some CYP2C19star3))) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or IschemicStroke or NonfatalMyocardialInfarction)) and (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 180 |
| | hasEffectSize 3.644 |
| | hasEffectMetric some UnadjustedHazardRatio |
| | hasLower95PercentCI 1.357 |
| | hasUpper95PercentCI 9.787 |
| evi_02_pub_23001453_stu_1 | isAcquiredFrom stu_1_pub_23001453 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOf2VsNoncarrier and ((hasTwoGeneticVariant some CYP2C19star2) and (hasTwoGeneticVariant some CYP2C19star3))) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some DefiniteStentThrombosis) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some UnadjustedOddsRatio |
| | hasEffectSize 13.58 |
| | hasLower95PercentCI 1.49 |
| | hasUpper95PercentCI 123.31 |
| evi_02_pub_23850318_stu_1 | isAcquiredFrom stu_1_pub_23850318 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some AllCauseDeath) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 180 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize -2.68 |
| | hasPValue 0.011 |
| evi_02_pub_24251360_stu_1 | isAcquiredFrom stu_1_pub_24251360 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INRInTherapeuticRange) and (isMeasuredAs some PercentageOfTimeWithEvent)) |
| | hasTimeFrameInDays 28 |
| | hasEffectMetric some AbsoluteDifferenceGroupMean |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 5.3 |
| | hasPValue 0.02 |
| evi_02_pub_24251361_stu_1 | isAcquiredFrom stu_1_pub_24251361 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (CompositeOutcomeMeasure and (hasThreeComponent some (INROver4.0 or MajorBleeding or Thromboembolism)) and (isMeasuredAs some TimeToEvent)) |

| | |
|--------------------------------|---|
| | <p>hasTimeFrameInDays 28</p> <p>hasEffectMetric some AdjustedHazardRatio</p> <p>hasEffectSize 1.01</p> <p>hasLower95PercentCI 0.77</p> <p>hasUpper95PercentCI 1.33</p> <p>hasPValue 0.93</p> |
| evi_02_pub_24251363_stu_1 | <p>isAcquiredFrom stu_1_pub_24251363</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INROver4.0) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 90</p> <p>hasEffectMetric some AdjustedOddsRatio</p> <p>hasEffectSize 0.63</p> <p>hasLower95PercentCI 0.41</p> <p>hasUpper95PercentCI 0.97</p> <p>hasPValue 0.03</p> |
| evi_02_pub_Anderson_2009_stu_1 | <p>isAcquiredFrom stu_1_pub_Anderson_2009</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some MyocardialInfarction) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 365</p> <p>hasEffectMetric some UnadjustedOddsRatio</p> <p>hasEffectSize 1.5</p> <p>hasLower95PercentCI 1.0</p> <p>hasUpper95PercentCI 2.24</p> <p>hasPValue 0.048</p> |
| evi_03_pub_10509530_stu_1 | <p>isAcquiredFrom stu_1_pub_10509530</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C9star3))</p> <p>hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some BleedingOfAllType) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 90</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 7.2</p> |
| evi_03_pub_11127854_stu_1 | <p>isAcquiredFrom stu_1_pub_11127854</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C9star3))</p> <p>hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some BleedingOfAllType) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 547</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 13.1</p> |
| evi_03_pub_11926893_stu_1 | <p>isAcquiredFrom stu_1_pub_11926893</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasTwoGeneticVariant some CYP2C9star2) and (hasTwoGeneticVariant some CYP2C9star3)))</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some AchievingStableDose) and (isMeasuredAs some TimeToEvent))</p> <p>hasTimeFrameInDays 818</p> <p>hasEffectMetric some UnadjustedHazardRatio</p> <p>hasEffectSize 0.6</p> <p>hasLower95PercentCI 0.42</p> <p>hasUpper95PercentCI 0.85</p> |
| evi_03_pub_15841315_stu_1 | <p>isAcquiredFrom stu_1_pub_15841315</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasTwoGeneticVariant some CYP2C9star2) and (hasTwoGeneticVariant some CYP2C9star3)))</p> <p>hasOutcomeMeasure some (CompositeOutcomeMeasure and (hasThreeComponent some (INROver4.0 or MajorBleeding or Thromboembolism)) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 42</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> |

| | |
|---------------------------|---|
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 41.0 |
| | hasPValue 0.03 |
| evi_03_pub_16160068_stu_1 | isAcquiredFrom stu_1_pub_16160068 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (DrugDosingAccuracyMeasure and (hasSingleComponent some DosingError) and (isMeasuredAs some AbsoluteDifferenceToFinalDose)) |
| | hasTimeFrameInDays 28 |
| | hasEffectMetric some AbsoluteDifferenceGroupMean |
| | hasEffectSizeUnit mg/week |
| | hasEffectSize -0.6 |
| evi_03_pub_17653141_stu_1 | isAcquiredFrom stu_1_pub_17653141 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some VKORC1_C1173T)) |
| | hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MajorBleeding) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 730 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 0.4 |
| | hasPValue 0.75 |
| evi_03_pub_17851566_stu_1 | isAcquiredFrom stu_1_pub_17851566 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some AllINRTTest) and (isMeasuredAs some CountOfEvent)) |
| | hasTimeFrameInDays 60 |
| | hasEffectMetric some AbsoluteDifferenceGroupMean |
| | hasEffectSizeUnit countNumbers |
| | hasEffectSize -5.8 |
| | hasPValue 0.0010 |
| evi_03_pub_17989110_stu_1 | isAcquiredFrom stu_1_pub_17989110 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INROver3.2) and (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 90 |
| | hasEffectMetric some UnadjustedHazardRatio |
| | hasEffectSize 0.88 |
| | hasLower95PercentCI 0.6 |
| | hasUpper95PercentCI 1.3 |
| | hasPValue 0.53 |
| evi_03_pub_18577829_stu_1 | isAcquiredFrom stu_1_pub_18577829 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some CVDeath) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize -2.4 |
| evi_03_pub_19106083_stu_1 | isAcquiredFrom stu_1_pub_19106083 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasFourGeneticVariant some CYP2C19star2) and (hasFourGeneticVariant some CYP2C19star3) and (hasFourGeneticVariant some CYP2C19star4) and (hasFourGeneticVariant some CYP2C19star5))) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (AllCauseDeath or NonfatalMyocardialInfarction or Stroke)) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize -1.8 |
| evi_03_pub_19106084_stu_1 | isAcquiredFrom stu_1_pub_19106084 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyRef |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasFiveGeneticVariant some CYP2C19star2) and (hasFiveGeneticVariant some CYP2C19star3) and (hasFiveGeneticVariant some CYP2C19star4) and (hasFiveGeneticVariant some CYP2C19star5) and (hasFiveGeneticVariant some |

| | |
|---------------------------|--|
| | <p>CYP2C19star8)))</p> <p>hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MajorOrMinorBleeding) and (isMeasuredAs some TimeToEvent))</p> <p>hasTimeFrameInDays 450</p> <p>hasEffectMetric some UnadjustedHazardRatio</p> <p>hasEffectSize 1.01</p> <p>hasLower95PercentCI 0.51</p> <p>hasUpper95PercentCI 2.01</p> <p>hasPValue 0.98</p> |
| evi_03_pub_19108880_stu_1 | <p>isAcquiredFrom stu_1_pub_19108880</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOfAtLeast1 VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some NonfatalMyocardialInfarction) and (isMeasuredAs some TimeToEvent))</p> <p>hasTimeFrameInDays 1825</p> <p>hasEffectMetric some UnadjustedHazardRatio</p> <p>hasEffectSize 4.54</p> <p>hasLower95PercentCI 1.64</p> <p>hasUpper95PercentCI 12.53</p> <p>hasPValue 0.0010</p> |
| evi_03_pub_19177029_stu_1 | <p>isAcquiredFrom stu_1_pub_19177029</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some DoseAdjustment) and (isMeasuredAs some DurationOfTimeWithEvent))</p> <p>hasTimeFrameInDays 50</p> <p>hasEffectMetric some AbsoluteDifferenceGroupMean</p> <p>hasEffectSizeUnit day</p> <p>hasEffectSize -1.1</p> <p>hasPValue 0.3</p> |
| evi_03_pub_19193675_stu_1 | <p>isAcquiredFrom stu_1_pub_19193675</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOfAtLeast1 VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some MyocardialInfarction) and (isMeasuredAs some TimeToEvent))</p> <p>hasTimeFrameInDays 30</p> <p>hasEffectMetric some UnadjustedHazardRatio</p> <p>hasEffectSize 1.15</p> <p>hasLower95PercentCI 0.82</p> <p>hasUpper95PercentCI 1.61</p> <p>hasPValue 0.42</p> |
| evi_03_pub_19228618_stu_2 | <p>isAcquiredFrom stu_2_pub_19228618</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (DrugDosingAccuracyMeasure and (hasSingleComponent some PercentageOfDoseVariationExplained) and (isMeasuredAs some AbsoluteDifferenceToFinalDose))</p> <p>hasTimeFrame 0</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRSquare</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 43.0</p> <p>hasPValue 0.0010</p> |
| evi_03_pub_19268736_stu_1 | <p>isAcquiredFrom stu_1_pub_19268736</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOfAtLeast1 VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasTwoComponent some (CVDeath or DefiniteOrProbableST)) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 180</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 4.3</p> <p>hasPValue 0.02</p> |
| evi_03_pub_19414633_stu_1 | <p>isAcquiredFrom stu_1_pub_19414633</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI</p> <p>hasGeneticContrast some (CarrierOfAtLeast1 VsNoncarrier and ((hasFiveGeneticVariant some CYP2C19star2) and (hasFiveGeneticVariant some CYP2C19star3) and (hasFiveGeneticVariant some CYP2C19star4) and (hasFiveGeneticVariant some CYP2C19star5) and (hasFiveGeneticVariant some</p> |

| | |
|---------------------------|--|
| | <p>CYP2C19star8))</p> <p>hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MajorOrMinorBleeding) and (isMeasuredAs some TimeToEvent))</p> <p>hasTimeFrameInDays 450</p> <p>hasEffectMetric some UnadjustedHazardRatio</p> <p>hasEffectSize 1.17</p> <p>hasLower95PercentCI 0.66</p> <p>hasUpper95PercentCI 2.07</p> <p>hasPValue 0.6</p> |
| evi_03_pub_19706858_stu_1 | <p>isAcquiredFrom stu_1_pub_19706858</p> <p>hasComparison some (ComparisonBetweenGenotypeWithinDrugTherapyObserved and (hasStratificationInComparison some OngoingDrugTherapy))</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSixComponent some (CVDeath or DefiniteStentThrombosis or HospitalizationDueToIschemia or IschemicStroke or MyocardialInfarction or NonTVROrTVR)) and (isMeasuredAs some TimeToEvent))</p> <p>hasTimeFrameInDays 365</p> <p>hasEffectMetric some AdjustedHazardRatio</p> <p>hasEffectSize 3.4</p> <p>hasLower95PercentCI 1.36</p> <p>hasUpper95PercentCI 8.46</p> <p>hasPValue 0.0040</p> |
| evi_03_pub_20083681_stu_1 | <p>isAcquiredFrom stu_1_pub_20083681</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star17))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some DefiniteOrProbableST) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 30</p> <p>hasEffectMetric some UnadjustedOddsRatio</p> <p>hasEffectSize 1.09</p> <p>hasLower95PercentCI 0.39</p> <p>hasUpper95PercentCI 3.02</p> |
| evi_03_pub_20381283_stu_1 | <p>isAcquiredFrom stu_1_pub_20381283</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some HospitalizationOfAllCause) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 180</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize -7.07</p> <p>hasPValue 0.0010</p> |
| evi_03_pub_20492467_stu_1 | <p>isAcquiredFrom stu_1_pub_20492467</p> <p>hasComparison some ComparisonBetweenTreatmentWithinGenotype</p> <p>hasTwoGenotypeOI some (CarrierOfAtLeast1 and ((hasFiveGeneticVariant some CYP2C19star2) and (hasFiveGeneticVariant some CYP2C19star3) and (hasFiveGeneticVariant some CYP2C19star4) and (hasFiveGeneticVariant some CYP2C19star5) and (hasFiveGeneticVariant some CYP2C19star8)))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some CVDeath) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 450</p> <p>hasEffectMetric some UnadjustedRelativeRisk</p> <p>hasEffectSize 0.36</p> <p>hasLower95PercentCI 0.13</p> <p>hasUpper95PercentCI 0.96</p> |
| evi_03_pub_20708365_stu_1 | <p>isAcquiredFrom stu_1_pub_20708365</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some PRIOver50percent) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInHours 12</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 1.0</p> |
| evi_03_pub_20801494_stu_1 | <p>isAcquiredFrom stu_1_pub_20801494</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyRef</p> |

| | |
|---------------------------|---|
| | <p>hasGeneticContrast some (CarrierOf2VsCarrierOf1OrNoncarrier and (hasSingleGeneticVariant some ABCB1_C3435T))</p> <p>hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MajorOrMinorBleeding) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 450</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 1.1</p> |
| evi_03_pub_20801498_stu_1 | <p>isAcquiredFrom stu_1_pub_20801498</p> <p>hasComparison some ComparisonBetweenTreatmentWithinGenotype</p> <p>hasTwoGenotypeOI some (CarrierOfAtLeast1 and ((hasSixGeneticVariant some CYP2C19star2) and (hasSixGeneticVariant some CYP2C19star3) and (hasSixGeneticVariant some CYP2C19star4) and (hasSixGeneticVariant some CYP2C19star5) and (hasSixGeneticVariant some CYP2C19star6) and (hasSixGeneticVariant some CYP2C19star8)))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some DefiniteStentThrombosis) and (isMeasuredAs some TimeToEvent))</p> <p>hasTimeFrameInDays 365</p> <p>hasEffectMetric some AdjustedHazardRatio</p> <p>hasEffectSize 0.71</p> <p>hasLower95PercentCI 0.36</p> <p>hasUpper95PercentCI 1.37</p> <p>hasPValue 0.3</p> |
| evi_03_pub_20826260_stu_1 | <p>isAcquiredFrom stu_1_pub_20826260</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some NonfatalMyocardialInfarction) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 365</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize -0.5</p> <p>hasPValue 0.666</p> |
| evi_03_pub_20979470_stu_1 | <p>isAcquiredFrom stu_1_pub_20979470</p> <p>hasComparison some ComparisonBetweenTreatmentWithinGenotype</p> <p>hasTwoGenotypeOI some (CarrierOfAtLeast1 and ((hasTwoGeneticVariant some CYP2C19star2) and (hasTwoGeneticVariant some CYP2C19star3)))</p> <p>hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MajorBleeding) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 365</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 1.0</p> |
| evi_03_pub_21099121_stu_1 | <p>isAcquiredFrom stu_1_pub_21099121</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some MyocardialInfarction) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 243</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize -1.0</p> <p>hasPValue 0.76</p> |
| evi_03_pub_21168310_stu_1 | <p>isAcquiredFrom stu_1_pub_21168310</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasTwoGeneticVariant some CYP2C19star2) and (hasTwoGeneticVariant some CYP2C19star3)))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some NonfatalMyocardialInfarction) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 365</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 3.2</p> |
| evi_03_pub_21170047_stu_1 | <p>isAcquiredFrom stu_1_pub_21170047</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOf2VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2))</p> |

| | |
|---------------------------|--|
| | <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some DefiniteOrProbableST) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 365</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 0.8</p> |
| evi_03_pub_21334530_stu_1 | <p>isAcquiredFrom stu_1_pub_21334530</p> <p>hasComparison some (ComparisonBetweenTreatmentWithinGenotype and (hasStratificationInComparison some ClopidogrelLDBelow300mg))</p> <p>hasTwoGenotypeOI some (CarrierOfAtLeast1 and ((hasSixGeneticVariant some CYP2C19star2) and (hasSixGeneticVariant some CYP2C19star3) and (hasSixGeneticVariant some CYP2C19star4) and (hasSixGeneticVariant some CYP2C19star5) and (hasSixGeneticVariant some CYP2C19star6) and (hasSixGeneticVariant some CYP2C19star8)))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or MyocardialInfarction or Stroke)) and (isMeasuredAs some TimeToEvent))</p> <p>hasTimeFrameInDays 365</p> <p>hasEffectMetric some AdjustedHazardRatio</p> <p>hasEffectSize 0.89</p> <p>hasLower95PercentCI 0.65</p> <p>hasUpper95PercentCI 1.22</p> |
| evi_03_pub_21423021_stu_1 | <p>isAcquiredFrom stu_1_pub_21423021</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some AchievingStableDose) and (isMeasuredAs some TimeRequiredToEvent))</p> <p>hasTimeFrameInDays 60</p> <p>hasEffectMetric some AbsoluteDifferenceGroupMedian</p> <p>hasEffectSizeUnit day</p> <p>hasEffectSize -2.0</p> <p>hasPValue 0.9</p> |
| evi_03_pub_21511218_stu_1 | <p>isAcquiredFrom stu_1_pub_21511218</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyRef</p> <p>hasGeneticContrast some (CarrierOf2VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some MPAOver64.5percent) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInHours 6</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 51.97</p> |
| evi_03_pub_21527445_stu_1 | <p>isAcquiredFrom stu_1_pub_21527445</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (RiskVsWildTypeAllele and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some DefiniteStentThrombosis) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrame 0</p> <p>hasEffectMetric some AdjustedOddsRatio</p> <p>hasEffectSize 1.51</p> <p>hasLower95PercentCI 1.04</p> <p>hasUpper95PercentCI 2.18</p> |
| evi_03_pub_21679849_stu_1 | <p>isAcquiredFrom stu_1_pub_21679849</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some DefiniteOrProbableST) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 365</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize -0.2</p> |
| evi_03_pub_21700758_stu_1 | <p>isAcquiredFrom stu_1_pub_21700758</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some DefiniteOrProbableST) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 365</p> <p>hasEffectMetric some UnadjustedRelativeRisk</p> <p>hasEffectSize 8.53</p> |

| | |
|---------------------------|---|
| | hasLower95PercentCI 1.95 |
| | hasUpper95PercentCI 37.4 |
| | hasPValue 0.0010 |
| evi_03_pub_21854540_stu_1 | isAcquiredFrom stu_1_pub_21854540 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOf2VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasFourComponent some (AllCauseDeath or IschemicStroke or NonfatalMyocardialInfarction or StentThrombosisUnspecified)) and (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some UnadjustedHazardRatio |
| | hasEffectSize 2.3 |
| | hasLower95PercentCI 0.81 |
| | hasUpper95PercentCI 6.3 |
| evi_03_pub_22028352_stu_1 | isAcquiredFrom stu_1_pub_22028352 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOf1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some DefiniteStentThrombosis) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrame 0 |
| | hasEffectMetric some UnadjustedOddsRatio |
| | hasEffectSize 1.45 |
| evi_03_pub_22045970_stu_1 | isAcquiredFrom stu_1_pub_22045970 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasTwoGeneticVariant some CYP2C19star2) and (hasTwoGeneticVariant some CYP2C19star3))) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or IschemicStroke or NonfatalMyocardialInfarction)) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 912 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 4.9 |
| evi_03_pub_22088980_stu_1 | isAcquiredFrom stu_1_pub_22088980 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyRef |
| | hasGeneticContrast some (CarrierOf1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some PRU) and (isMeasuredAs some PrimaryValue)) |
| | hasTimeFrameInDays 14 |
| | hasEffectMetric some AbsoluteDifferenceGroupMean |
| | hasEffectSize 62.0 |
| | hasPValue 0.0010 |
| evi_03_pub_22431865_stu_1 | isAcquiredFrom stu_1_pub_22431865 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INRBelow1.8OrOver3.3) and (isMeasuredAs some PercentageOfEncounterWithEvent)) |
| | hasTimeFrameInDays 90 |
| | hasEffectMetric some AbsoluteDifferenceGroupMean |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize -12.0 |
| | hasPValue 0.0010 |
| evi_03_pub_22450429_stu_1 | isAcquiredFrom stu_1_pub_22450429 |
| | hasComparison some ComparisonBetweenTreatmentWithinGenotype |
| | hasTwoGenotypeOI some (CarrierOfAtLeast1 and ((hasTwoGeneticVariant some CYP2C19star2) and (hasTwoGeneticVariant some CYP2C19star3))) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSixComponent some (CVDeath or RevasUnspecified or TransientIschemicAttack or UnstableAngina or (FatalMyocardialInfarction or NonfatalMyocardialInfarction) or (FatalStroke or NonfatalStroke))) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 840 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 0.3 |
| evi_03_pub_22464343_stu_1 | isAcquiredFrom stu_1_pub_22464343 |
| | hasComparison some ComparisonBetweenTreatmentWithinGenotype |
| | hasTwoGenotypeOI some (CarrierOfAtLeast1 and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some PRU) and (isMeasuredAs some PrimaryValue)) |

| | |
|---------------------------|--|
| | hasTimeFrameInDays 7 |
| | hasEffectMetric some AbsoluteDifferenceGroupMean |
| | hasEffectSize -131.7 |
| | hasPValue 1.0E-4 |
| evi_03_pub_22624833_stu_1 | isAcquiredFrom stu_1_pub_22624833 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI |
| | hasGeneticContrast some (CarrierOf2VsNoncarrier and ((hasFiveGeneticVariant some CYP2C19star2) and (hasFiveGeneticVariant some CYP2C19star3) and (hasFiveGeneticVariant some CYP2C19star4) and (hasFiveGeneticVariant some CYP2C19star6) and (hasFiveGeneticVariant some CYP2C19star8))) |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some PRUOver230) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 30 |
| | hasEffectMetric some AdjustedOddsRatio |
| | hasEffectSize 11.53 |
| | hasLower95PercentCI 2.08 |
| | hasUpper95PercentCI 64.07 |
| evi_03_pub_22836303_stu_1 | isAcquiredFrom stu_1_pub_22836303 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INRInTherapeuticRange) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 8 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 38.5 |
| | hasPValue 0.0128 |
| evi_03_pub_22927772_stu_1 | isAcquiredFrom stu_1_pub_22927772 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some AchievingStableDose) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 50 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 25.2 |
| | hasPValue 0.0078 |
| evi_03_pub_23001453_stu_1 | isAcquiredFrom stu_1_pub_23001453 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOf1VsNoncarrier and ((hasTwoGeneticVariant some CYP2C19star2) and (hasTwoGeneticVariant some CYP2C19star3))) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some DefiniteStentThrombosis) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectMetric percentagePoint |
| | hasEffectSize 0.33 |
| evi_03_pub_23850318_stu_1 | isAcquiredFrom stu_1_pub_23850318 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some MyocardialInfarction) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 180 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize -2.01 |
| | hasPValue 0.038 |
| evi_03_pub_24251360_stu_1 | isAcquiredFrom stu_1_pub_24251360 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INROver4.0) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 84 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize -2.1 |
| | hasPValue 0.62 |
| evi_03_pub_24251361_stu_1 | isAcquiredFrom stu_1_pub_24251361 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INRInTherapeuticRange) and (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 28 |

| | |
|--------------------------------|--|
| | hasEffectMetric some AdjustedHazardRatio |
| | hasEffectSize 0.94 |
| | hasLower95PercentCI 0.82 |
| | hasUpper95PercentCI 1.1 |
| | hasPValue 0.36 |
| evi_03_pub_24251363_stu_1 | isAcquiredFrom stu_1_pub_24251363 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MajorOrMinorBleeding) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 90 |
| | hasEffectMetric some AdjustedOddsRatio |
| | hasEffectSize 0.96 |
| | hasLower95PercentCI 0.62 |
| | hasUpper95PercentCI 1.49 |
| | hasPValue 0.87 |
| evi_03_pub_Anderson_2009_stu_1 | isAcquiredFrom stu_1_pub_Anderson_2009 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some AllCauseDeath) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 0.1 |
| | hasPValue 0.86 |
| evi_04_pub_10509530_stu_1 | isAcquiredFrom stu_1_pub_10509530 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI |
| | hasGeneticContrast some (CarrierOf1VsNoncarrier and (hasSingleGeneticVariant some CYP2C9star3)) |
| | hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some BleedingOfAllType) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 1825 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 5.0 |
| evi_04_pub_11926893_stu_1 | isAcquiredFrom stu_1_pub_11926893 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasTwoGeneticVariant some CYP2C9star2) and (hasTwoGeneticVariant some CYP2C9star3))) |
| | hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MajorBleeding) and (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 90 |
| | hasEffectMetric some UnadjustedHazardRatio |
| | hasEffectSize 3.94 |
| | hasLower95PercentCI 1.29 |
| | hasUpper95PercentCI 12.06 |
| evi_04_pub_15841315_stu_1 | isAcquiredFrom stu_1_pub_15841315 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasTwoGeneticVariant some CYP2C9star2) and (hasTwoGeneticVariant some CYP2C9star3))) |
| | hasOutcomeMeasure some (CompositeOutcomeMeasure and (hasThreeComponent some (INROver4.0 or MajorBleeding or Thromboembolism)) and (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 42 |
| | hasEffectMetric some UnadjustedHazardRatio |
| | hasEffectSize 3.6 |
| | hasLower95PercentCI 1.4 |
| | hasUpper95PercentCI 9.5 |
| | hasPValue 0.01 |
| evi_04_pub_16160068_stu_1 | isAcquiredFrom stu_1_pub_16160068 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (ClinicalEfficacySafetyMeasure and (hasTwoComponent some (MajorOrMinorBleeding or Thromboembolism)) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 28 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize -13.9 |

| | |
|---------------------------|---|
| evi_04_pub_17653141_stu_1 | isAcquiredFrom stu_1_pub_17653141 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some VKORC1_C1173T)) |
| | hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MinorBleeding) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 730 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 2.0 |
| hasPValue 0.38 | |
| evi_04_pub_17851566_stu_1 | isAcquiredFrom stu_1_pub_17851566 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INRInTherapeuticRange) and (isMeasuredAs some PercentageOfTimeWithEvent)) |
| | hasTimeFrameInDays 8 |
| | hasEffectMetric some AbsoluteDifferenceGroupMean |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 20.9 |
| hasPValue 0.0010 | |
| evi_04_pub_17989110_stu_1 | isAcquiredFrom stu_1_pub_17989110 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INRInTherapeuticRange) and (isMeasuredAs some PercentageOfTimeWithEvent)) |
| | hasTimeFrameInDays 90 |
| | hasEffectMetric some AbsoluteDifferenceGroupMean |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 1.1 |
| hasPValue 0.74 | |
| evi_04_pub_18577829_stu_1 | isAcquiredFrom stu_1_pub_18577829 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some StentThrombosisUnspecified) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| hasEffectSize 4.8 | |
| evi_04_pub_19106083_stu_1 | isAcquiredFrom stu_1_pub_19106083 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (AllCauseDeath or NonfatalMyocardialInfarction or Stroke)) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| hasEffectSize -1.7 | |
| evi_04_pub_19106084_stu_1 | isAcquiredFrom stu_1_pub_19106084 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyRef |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasFiveGeneticVariant some CYP2C19star2) and (hasFiveGeneticVariant some CYP2C19star3) and (hasFiveGeneticVariant some CYP2C19star4) and (hasFiveGeneticVariant some CYP2C19star5) and (hasFiveGeneticVariant some CYP2C19star8))) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some CVDeath) and (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 450 |
| | hasEffectMetric some UnadjustedHazardRatio |
| | hasEffectSize 4.79 |
| hasLower95PercentCI 1.4 | |
| hasUpper95PercentCI 16.37 | |
| evi_04_pub_19108880_stu_1 | isAcquiredFrom stu_1_pub_19108880 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some RevasUnspecified) |

| | |
|---------------------------|--|
| | <p>and (isMeasuredAs some TimeToEvent))</p> <p>hasTimeFrameInDays 1825</p> <p>hasEffectMetric some UnadjustedHazardRatio</p> <p>hasEffectSize 1.94</p> <p>hasLower95PercentCI 0.43</p> <p>hasUpper95PercentCI 8.73</p> <p>hasPValue 0.38</p> |
| evi_04_pub_19177029_stu_1 | <p>isAcquiredFrom stu_1_pub_19177029</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some AchievingStableDose) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 50</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 20.3</p> <p>hasPValue 0.013</p> |
| evi_04_pub_19193675_stu_1 | <p>isAcquiredFrom stu_1_pub_19193675</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some STE_MI) and (isMeasuredAs some TimeToEvent))</p> <p>hasTimeFrameInDays 30</p> <p>hasEffectMetric some UnadjustedHazardRatio</p> <p>hasEffectSize 2.96</p> <p>hasLower95PercentCI 1.2</p> <p>hasUpper95PercentCI 7.28</p> <p>hasPValue 0.02</p> |
| evi_04_pub_19228618_stu_2 | <p>isAcquiredFrom stu_2_pub_19228618</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (DrugDosingAccuracyMeasure and (hasSingleComponent some DosingError) and (isMeasuredAs some AbsoluteDifferenceToFinalDose))</p> <p>hasTimeFrame 0</p> <p>hasEffectMetric some AbsoluteDifferenceGroupMean</p> <p>hasEffectSizeUnit mg/week</p> <p>hasEffectSize -4.5</p> <p>hasPValue 0.0010</p> |
| evi_04_pub_19268736_stu_1 | <p>isAcquiredFrom stu_1_pub_19268736</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some DefiniteStentThrombosis) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 180</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 1.5</p> <p>hasPValue 0.1</p> |
| evi_04_pub_19414633_stu_1 | <p>isAcquiredFrom stu_1_pub_19414633</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasFiveGeneticVariant some CYP2C19star2) and (hasFiveGeneticVariant some CYP2C19star3) and (hasFiveGeneticVariant some CYP2C19star4) and (hasFiveGeneticVariant some CYP2C19star5) and (hasFiveGeneticVariant some CYP2C19star8)))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some CVDeath) and (isMeasuredAs some TimeToEvent))</p> <p>hasTimeFrameInDays 450</p> <p>hasEffectMetric some UnadjustedHazardRatio</p> <p>hasEffectSize 0.8</p> <p>hasLower95PercentCI 0.26</p> <p>hasUpper95PercentCI 2.47</p> <p>hasPValue 0.7</p> |
| evi_04_pub_20083681_stu_1 | <p>isAcquiredFrom stu_1_pub_20083681</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOf1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star17))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some AllCauseDeath) and (isMeasuredAs some IncidenceOfEvent))</p> |

| | |
|---------------------------|---|
| | hasTimeFrameInDays 30 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize -0.2 |
| evi_04_pub_20381283_stu_1 | isAcquiredFrom stu_1_pub_20381283 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (ClinicalEfficacySafetyMeasure and (hasTwoComponent some (BleedingOfAllType or Thromboembolism)) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 180 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize -2.16 |
| | hasPValue 0.039 |
| evi_04_pub_20492467_stu_1 | isAcquiredFrom stu_1_pub_20492467 |
| | hasComparison some ComparisonBetweenTreatmentWithinGenotype |
| | hasSingleGenotypeOI some (Noncarrier and ((hasFiveGeneticVariant some CYP2C19star2) and (hasFiveGeneticVariant some CYP2C19star3) and (hasFiveGeneticVariant some CYP2C19star4) and (hasFiveGeneticVariant some CYP2C19star5) and (hasFiveGeneticVariant some CYP2C19star8))) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some CVDeath) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 450 |
| | hasEffectMetric some UnadjustedRelativeRisk |
| | hasEffectSize 2.07 |
| | hasLower95PercentCI 0.96 |
| | hasUpper95PercentCI 5.66 |
| evi_04_pub_20801498_stu_1 | isAcquiredFrom stu_1_pub_20801498 |
| | hasComparison some ComparisonBetweenTreatmentWithinGenotype |
| | hasSingleGenotypeOI some (Noncarrier and ((hasSixGeneticVariant some CYP2C19star2) and (hasSixGeneticVariant some CYP2C19star3) and (hasSixGeneticVariant some CYP2C19star4) and (hasSixGeneticVariant some CYP2C19star5) and (hasSixGeneticVariant some CYP2C19star6) and (hasSixGeneticVariant some CYP2C19star8))) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some DefiniteStentThrombosis) and (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some AdjustedHazardRatio |
| | hasEffectSize 0.62 |
| | hasLower95PercentCI 0.36 |
| | hasUpper95PercentCI 1.05 |
| | hasPValue 0.0772 |
| evi_04_pub_20826260_stu_1 | isAcquiredFrom stu_1_pub_20826260 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasTwoComponent some (AllCauseDeath or NonfatalMyocardialInfarction)) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize -3.5 |
| | hasPValue 0.086 |
| evi_04_pub_20979470_stu_1 | isAcquiredFrom stu_1_pub_20979470 |
| | hasComparison some ComparisonBetweenTreatmentWithinGenotype |
| | hasSingleGenotypeOI some (Noncarrier and ((hasTwoGeneticVariant some CYP2C19star2) and (hasTwoGeneticVariant some CYP2C19star3))) |
| | hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MajorBleeding) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 1.0 |
| evi_04_pub_21099121_stu_1 | isAcquiredFrom stu_1_pub_21099121 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some TargetVesselRevas) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 243 |

| | |
|---------------------------|---|
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 15.5 |
| | hasPValue 0.11 |
| evi_04_pub_21168310_stu_1 | isAcquiredFrom stu_1_pub_21168310 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1 VsNoncarrier and ((hasTwoGeneticVariant some CYP2C19star2) and (hasTwoGeneticVariant some CYP2C19star3))) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some IschemicStroke) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 3.2 |
| evi_04_pub_21170047_stu_1 | isAcquiredFrom stu_1_pub_21170047 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1 VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star17)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some DefiniteOrProbableST) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize -0.2 |
| evi_04_pub_21334530_stu_1 | isAcquiredFrom stu_1_pub_21334530 |
| | hasComparison some (ComparisonBetweenTreatmentWithinGenotype and (hasStratificationInComparison some ClopidogrelLDBelow300mg)) |
| | hasSingleGenotypeOI some (Noncarrier and ((hasSixGeneticVariant some CYP2C19star2) and (hasSixGeneticVariant some CYP2C19star3) and (hasSixGeneticVariant some CYP2C19star4) and (hasSixGeneticVariant some CYP2C19star5) and (hasSixGeneticVariant some CYP2C19star6) and (hasSixGeneticVariant some CYP2C19star8))) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or MyocardialInfarction or Stroke)) and (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some AdjustedHazardRatio |
| | hasEffectSize 0.88 |
| | hasLower95PercentCI 0.73 |
| | hasUpper95PercentCI 1.07 |
| evi_04_pub_21423021_stu_1 | isAcquiredFrom stu_1_pub_21423021 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INROver4.0) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 60 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 3.0 |
| | hasPValue 0.94 |
| evi_04_pub_21511218_stu_1 | isAcquiredFrom stu_1_pub_21511218 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI |
| | hasGeneticContrast some (CarrierOf2VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some MPAOver64.5percent) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInHours 6 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 53.69 |
| evi_04_pub_21679849_stu_1 | isAcquiredFrom stu_1_pub_21679849 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1 VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MajorOrMinorBleeding) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize -3.6 |
| | hasPValue 0.4 |

| | |
|---------------------------|--|
| evi_04_pub_21700758_stu_1 | isAcquiredFrom stu_1_pub_21700758 hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some CVDeath) and (isMeasuredAs some IncidenceOfEvent)) hasTimeFrameInDays 365 hasEffectMetric some UnadjustedRelativeRisk hasEffectSize 2.26 hasLower95PercentCI 0.77 hasUpper95PercentCI 6.63 hasPValue 0.128 |
| evi_04_pub_22088980_stu_1 | isAcquiredFrom stu_1_pub_22088980 hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyRef hasGeneticContrast some (CarrierOf2VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some PRU) and (isMeasuredAs some PrimaryValue)) hasTimeFrameInDays 14 hasEffectMetric some AbsoluteDifferenceGroupMean hasEffectSize 165.2 hasPValue 0.0010 |
| evi_04_pub_22431865_stu_1 | isAcquiredFrom stu_1_pub_22431865 hasComparison some ComparisonBetweenTreatmentWithoutGenotype hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INRInTherapeuticRange) and (isMeasuredAs some PercentageOfTimeWithEvent)) hasTimeFrameInDays 90 hasEffectMetric some AbsoluteDifferenceGroupMean hasEffectSizeUnit percentagePoint hasEffectSize 12.6 hasPValue 0.0010 |
| evi_04_pub_22450429_stu_1 | isAcquiredFrom stu_1_pub_22450429 hasComparison some ComparisonBetweenTreatmentWithinGenotype hasSingleGenotypeOI some (Noncarrier and ((hasTwoGeneticVariant some CYP2C19star2) and (hasTwoGeneticVariant some CYP2C19star3))) hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSixComponent some (CVDeath or RevasUnspecified or TransientIschemicAttack or UnstableAngina or (FatalMyocardialInfarction or NonfatalMyocardialInfarction) or (FatalStroke or NonfatalStroke))) and (isMeasuredAs some IncidenceOfEvent)) hasTimeFrameInDays 840 hasEffectMetric some AbsoluteDifferenceGroupRate hasEffectSizeUnit percentagePoint hasEffectSize -0.5 |
| evi_04_pub_22464343_stu_1 | isAcquiredFrom stu_1_pub_22464343 hasComparison some ComparisonBetweenTreatmentWithinGenotype hasTwoGenotypeOI some (CarrierOfAtLeast1 and (hasSingleGeneticVariant some CYP2C19star2)) hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some PRU) and (isMeasuredAs some RelativeReductionFromBaseline)) hasTimeFrameInDays 7 hasEffectMetric some AbsoluteDifferenceGroupMean hasEffectSizeUnit percentagePoint hasEffectSize 46.3 hasPValue 1.0E-4 |
| evi_04_pub_22624833_stu_1 | isAcquiredFrom stu_1_pub_22624833 hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyRef hasGeneticContrast some (CarrierOf2VsNoncarrier and ((hasFiveGeneticVariant some CYP2C19star2) and (hasFiveGeneticVariant some CYP2C19star3) and (hasFiveGeneticVariant some CYP2C19star4) and (hasFiveGeneticVariant some CYP2C19star6) and (hasFiveGeneticVariant some CYP2C19star8))) hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some PRUOver230) and (isMeasuredAs some IncidenceOfEvent)) hasTimeFrameInDays 30 hasEffectMetric some AdjustedOddsRatio hasEffectSize 10.57 hasLower95PercentCI 1.19 hasUpper95PercentCI 93.88 |
| evi_04_pub_22836303_stu_1 | isAcquiredFrom stu_1_pub_22836303 hasComparison some ComparisonBetweenTreatmentWithoutGenotype hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some |

| | |
|---------------------------|---|
| | <p>INRInTherapeuticRange) and (isMeasuredAs some PercentageOfTimeWithEvent))</p> <p>hasTimeFrameInDays 25</p> <p>hasEffectMetric some AbsoluteDifferenceGroupMean</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 8.1</p> <p>hasPValue 0.181</p> |
| evi_04_pub_22927772_stu_1 | <p>isAcquiredFrom stu_1_pub_22927772</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (CompositeOutcomeMeasure and (hasTwoComponent some (BleedingOfAllType or INROver3.5)) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 50</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize -5.7</p> <p>hasPValue 0.55</p> |
| evi_04_pub_23850318_stu_1 | <p>isAcquiredFrom stu_1_pub_23850318</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some DefiniteOrProbableOrPossibleST) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 180</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize -2.35</p> <p>hasPValue 0.037</p> |
| evi_04_pub_24251360_stu_1 | <p>isAcquiredFrom stu_1_pub_24251360</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INROver4.0) and (isMeasuredAs some PercentageOfTimeWithEvent))</p> <p>hasTimeFrameInDays 84</p> <p>hasEffectMetric some AbsoluteDifferenceGroupMean</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize -0.5</p> <p>hasPValue 0.44</p> |
| evi_04_pub_24251361_stu_1 | <p>isAcquiredFrom stu_1_pub_24251361</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some AchievingStableDose) and (isMeasuredAs some TimeToEvent))</p> <p>hasTimeFrameInDays 180</p> <p>hasEffectMetric some AdjustedHazardRatio</p> <p>hasEffectSize 1.1</p> <p>hasLower95PercentCI 0.91</p> <p>hasUpper95PercentCI 1.2</p> <p>hasPValue 0.45</p> |
| evi_04_pub_24251363_stu_1 | <p>isAcquiredFrom stu_1_pub_24251363</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INRInTherapeuticRange) and (isMeasuredAs some TimeToEvent))</p> <p>hasTimeFrameInDays 90</p> <p>hasEffectMetric some AdjustedHazardRatio</p> <p>hasEffectSize 1.43</p> <p>hasLower95PercentCI 1.17</p> <p>hasUpper95PercentCI 1.76</p> <p>hasPValue 0.0010</p> |
| evi_05_pub_10509530_stu_1 | <p>isAcquiredFrom stu_1_pub_10509530</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI</p> <p>hasGeneticContrast some (CarrierOf2VsNoncarrier and (hasSingleGeneticVariant some CYP2C9star3))</p> <p>hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some BleedingOfAllType) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 1825</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 61.7</p> |
| evi_05_pub_11926893_stu_1 | <p>isAcquiredFrom stu_1_pub_11926893</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasTwoGeneticVariant some CYP2C9star2) and (hasTwoGeneticVariant some CYP2C9star3)))</p> <p>hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MajorBleeding) and</p> |

| | |
|---------------------------|--|
| | (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 818 |
| | hasEffectMetric some UnadjustedHazardRatio |
| | hasEffectSize 2.39 |
| | hasLower95PercentCI 1.18 |
| | hasUpper95PercentCI 4.86 |
| evi_05_pub_15841315_stu_1 | isAcquiredFrom stu_1_pub_15841315 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasTwoGeneticVariant some CYP2C9star2) and (hasTwoGeneticVariant some CYP2C9star3))) |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INROver4.0) and (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 42 |
| | hasEffectMetric some UnadjustedHazardRatio |
| | hasEffectSize 4.6 |
| | hasPValue 0.01 |
| evi_05_pub_16160068_stu_1 | isAcquiredFrom stu_1_pub_16160068 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MajorBleeding) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 28 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 6.0 |
| evi_05_pub_17653141_stu_1 | isAcquiredFrom stu_1_pub_17653141 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasFiveGeneticVariant some CYP2C9star1) and (hasFiveGeneticVariant some CYP2C9star2) and (hasFiveGeneticVariant some CYP2C9star3) and (hasFiveGeneticVariant some CYP2C9star5) and (hasFiveGeneticVariant some CYP2C9star6))) |
| | hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MajorBleeding) and (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 730 |
| | hasEffectMetric some AdjustedHazardRatio |
| | hasEffectSize 3.0 |
| | hasLower95PercentCI 1.1 |
| | hasUpper95PercentCI 8.3 |
| evi_05_pub_17851566_stu_1 | isAcquiredFrom stu_1_pub_17851566 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some AchievingStableDose) and (isMeasuredAs some TimeRequiredToEvent)) |
| | hasTimeFrameInDays 60 |
| | hasEffectMetric some AbsoluteDifferenceGroupMean |
| | hasEffectSizeUnit day |
| | hasEffectSize -18.1 |
| | hasLower95PercentCI -22.7 |
| | hasUpper95PercentCI -13.6 |
| | hasPValue 0.0010 |
| evi_05_pub_17989110_stu_1 | isAcquiredFrom stu_1_pub_17989110 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INRInTherapeuticRange) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 8 |
| | hasEffectMetric some UnadjustedOddsRatio |
| | hasEffectSize 1.29 |
| | hasLower95PercentCI 0.71 |
| | hasUpper95PercentCI 2.36 |
| | hasPValue 0.41 |
| evi_05_pub_19106083_stu_1 | isAcquiredFrom stu_1_pub_19106083 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star17)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (AllCauseDeath or NonfatalMyocardialInfarction or Stroke)) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |

| | |
|---------------------------|--|
| | hasEffectSize -2.9 |
| evi_05_pub_19106084_stu_1 | isAcquiredFrom stu_1_pub_19106084 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyRef |
| | hasGeneticContrast some (CarrierOfAtLeast1 VsNoncarrier and ((hasFiveGeneticVariant some CYP2C19star2) and (hasFiveGeneticVariant some CYP2C19star3) and (hasFiveGeneticVariant some CYP2C19star4) and (hasFiveGeneticVariant some CYP2C19star5) and (hasFiveGeneticVariant some CYP2C19star8))) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some NonfatalMyocardialInfarction) and (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 450 |
| | hasEffectMetric some UnadjustedHazardRatio |
| | hasEffectSize 1.38 |
| | hasLower95PercentCI 0.94 |
| | hasUpper95PercentCI 2.02 |
| evi_05_pub_19108880_stu_1 | isAcquiredFrom stu_1_pub_19108880 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1 VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some DefiniteStentThrombosis) and (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 1825 |
| | hasEffectMetric some UnadjustedHazardRatio |
| | hasEffectSize 6.02 |
| | hasLower95PercentCI 1.81 |
| | hasUpper95PercentCI 20.04 |
| | hasPValue 9.0E-4 |
| evi_05_pub_19177029_stu_1 | isAcquiredFrom stu_1_pub_19177029 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (CompositeOutcomeMeasure and (hasTwoComponent some (INROver3.5 or MinorBleeding)) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 50 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize -1.8 |
| | hasPValue 0.757 |
| evi_05_pub_19193675_stu_1 | isAcquiredFrom stu_1_pub_19193675 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1 VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some NSTEMI) and (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 30 |
| | hasEffectMetric some UnadjustedHazardRatio |
| | hasEffectSize 0.99 |
| | hasLower95PercentCI 0.68 |
| | hasUpper95PercentCI 1.44 |
| | hasPValue 0.96 |
| evi_05_pub_19228618_stu_1 | isAcquiredFrom stu_1_pub_19228618 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (DrugDosingAccuracyMeasure and (hasSingleComponent some CorrectPredictionOfLowDoseRequirement) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrame 0 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 16.1 |
| | hasPValue 0.0010 |
| evi_05_pub_19268736_stu_1 | isAcquiredFrom stu_1_pub_19268736 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOf1 VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasTwoComponent some (CVDeath or DefiniteOrProbableST)) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 180 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 3.2 |
| evi_05_pub_19414633_stu_1 | isAcquiredFrom stu_1_pub_19414633 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI |

| | |
|---------------------------|---|
| | <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasFiveGeneticVariant some CYP2C19star2) and (hasFiveGeneticVariant some CYP2C19star3) and (hasFiveGeneticVariant some CYP2C19star4) and (hasFiveGeneticVariant some CYP2C19star5) and (hasFiveGeneticVariant some CYP2C19star8)))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some NonfatalMyocardialInfarction) and (isMeasuredAs some TimeToEvent))</p> <p>hasTimeFrameInDays 450</p> <p>hasEffectMetric some UnadjustedHazardRatio</p> <p>hasEffectSize 0.82</p> <p>hasLower95PercentCI 0.53</p> <p>hasUpper95PercentCI 1.27</p> <p>hasPValue 0.37</p> |
| evi_05_pub_20083681_stu_1 | <p>isAcquiredFrom stu_1_pub_20083681</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOf2VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star17))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some AllCauseDeath) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 30</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 0.7</p> |
| evi_05_pub_20492467_stu_1 | <p>isAcquiredFrom stu_1_pub_20492467</p> <p>hasComparison some ComparisonBetweenTreatmentWithinGenotype</p> <p>hasTwoGenotypeOI some (CarrierOfAtLeast1 and ((hasFiveGeneticVariant some CYP2C19star2) and (hasFiveGeneticVariant some CYP2C19star3) and (hasFiveGeneticVariant some CYP2C19star4) and (hasFiveGeneticVariant some CYP2C19star5) and (hasFiveGeneticVariant some CYP2C19star8)))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some NonfatalMyocardialInfarction) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 450</p> <p>hasEffectMetric some UnadjustedRelativeRisk</p> <p>hasEffectSize 0.53</p> <p>hasLower95PercentCI 0.34</p> <p>hasUpper95PercentCI 0.81</p> |
| evi_05_pub_20801498_stu_1 | <p>isAcquiredFrom stu_1_pub_20801498</p> <p>hasComparison some ComparisonBetweenTreatmentWithinGenotype</p> <p>hasTwoGenotypeOI some (CarrierOfAtLeast1 and ((hasSixGeneticVariant some CYP2C19star2) and (hasSixGeneticVariant some CYP2C19star3) and (hasSixGeneticVariant some CYP2C19star4) and (hasSixGeneticVariant some CYP2C19star5) and (hasSixGeneticVariant some CYP2C19star6) and (hasSixGeneticVariant some CYP2C19star8)))</p> <p>hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MajorBleeding) and (isMeasuredAs some TimeToEvent))</p> <p>hasTimeFrameInDays 365</p> <p>hasEffectMetric some AdjustedHazardRatio</p> <p>hasEffectSize 1.04</p> <p>hasLower95PercentCI 0.82</p> <p>hasUpper95PercentCI 1.3</p> <p>hasPValue 0.77</p> |
| evi_05_pub_20826260_stu_1 | <p>isAcquiredFrom stu_1_pub_20826260</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some DefiniteOrProbableST) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 365</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 0.2</p> <p>hasPValue 0.822</p> |
| evi_05_pub_20979470_stu_1 | <p>isAcquiredFrom stu_1_pub_20979470</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasTwoGeneticVariant some CYP2C19star2) and (hasTwoGeneticVariant some CYP2C19star3)))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or NonfatalMyocardialInfarction or Stroke)) and (isMeasuredAs some TimeToEvent))</p> <p>hasTimeFrameInDays 365</p> <p>hasEffectMetric some AdjustedHazardRatio</p> <p>hasEffectSize 0.86</p> |

| | |
|---------------------------|---|
| | hasLower95PercentCI 0.63 |
| | hasUpper95PercentCI 1.17 |
| evi_05_pub_21099121_stu_1 | isAcquiredFrom stu_1_pub_21099121 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some TargetLesionRevas) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 243 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 15.8 |
| | hasPValue 0.06 |
| evi_05_pub_21170047_stu_1 | isAcquiredFrom stu_1_pub_21170047 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOf1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star17)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some DefiniteOrProbableST) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 0.0 |
| evi_05_pub_21334530_stu_1 | isAcquiredFrom stu_1_pub_21334530 |
| | hasComparison some (ComparisonBetweenTreatmentWithinGenotype and (hasStratificationInComparison some Invasive)) |
| | hasTwoGenotypeOI some (CarrierOfAtLeast1 and ((hasSixGeneticVariant some CYP2C19star2) and (hasSixGeneticVariant some CYP2C19star3) and (hasSixGeneticVariant some CYP2C19star4) and (hasSixGeneticVariant some CYP2C19star5) and (hasSixGeneticVariant some CYP2C19star6) and (hasSixGeneticVariant some CYP2C19star8))) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or MyocardialInfarction or Stroke)) and (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some AdjustedHazardRatio |
| | hasEffectSize 0.71 |
| | hasLower95PercentCI 0.53 |
| | hasUpper95PercentCI 0.96 |
| evi_05_pub_21423021_stu_1 | isAcquiredFrom stu_1_pub_21423021 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (ClinicalEfficacySafetyMeasure and (hasThreeComponent some (AllCauseDeath or MajorBleeding or Thromboembolism)) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 60 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 0.0 |
| evi_05_pub_21700758_stu_1 | isAcquiredFrom stu_1_pub_21700758 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some NonfatalMyocardialInfarction) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some UnadjustedRelativeRisk |
| | hasEffectSize 2.71 |
| | hasLower95PercentCI 0.95 |
| | hasUpper95PercentCI 7.73 |
| | hasPValue 0.052 |
| evi_05_pub_22088980_stu_1 | isAcquiredFrom stu_1_pub_22088980 |
| | hasComparison some ComparisonBetweenTreatmentWithinGenotype |
| | hasSingleGenotypeOI some (CarrierOf1 and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some PRI) and (isMeasuredAs some PrimaryValue)) |
| | hasTimeFrameInDays 14 |
| | hasEffectMetric some AbsoluteDifferenceGroupMean |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize -8.6 |
| | hasPValue 0.0010 |
| evi_05_pub_22431865_stu_2 | isAcquiredFrom stu_2_pub_22431865 |

| | |
|---------------------------|---|
| | <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (DrugDosingAccuracyMeasure and (hasSingleComponent some IdealDosePrediction) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 90</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 25.6</p> <p>hasPValue 0.0010</p> |
| evi_05_pub_22450429_stu_1 | <p>isAcquiredFrom stu_1_pub_22450429</p> <p>hasComparison some ComparisonBetweenTreatmentWithinGenotype</p> <p>hasTwoGenotypeOI some (CarrierOfAtLeast1 and ((hasTwoGeneticVariant some CYP2C19star2) and (hasTwoGeneticVariant some CYP2C19star3)))</p> <p>hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MajorBleeding) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 840</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 2.8</p> |
| evi_05_pub_22464343_stu_1 | <p>isAcquiredFrom stu_1_pub_22464343</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some PRUOver234) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 7</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize -7.0</p> <p>hasPValue 0.1735</p> |
| evi_05_pub_22624833_stu_1 | <p>isAcquiredFrom stu_1_pub_22624833</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI</p> <p>hasGeneticContrast some (CarrierOf1VsNoncarrier and ((hasFiveGeneticVariant some CYP2C19star2) and (hasFiveGeneticVariant some CYP2C19star3) and (hasFiveGeneticVariant some CYP2C19star4) and (hasFiveGeneticVariant some CYP2C19star6) and (hasFiveGeneticVariant some CYP2C19star8)))</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some PRUOver230) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 180</p> <p>hasEffectMetric some AdjustedOddsRatio</p> <p>hasEffectSize 1.77</p> <p>hasLower95PercentCI 0.96</p> <p>hasUpper95PercentCI 3.25</p> |
| evi_05_pub_22836303_stu_1 | <p>isAcquiredFrom stu_1_pub_22836303</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INRInTherapeuticRange) and (isMeasuredAs some PercentageOfTimeWithEvent))</p> <p>hasTimeFrameInDays 60</p> <p>hasEffectMetric some AbsoluteDifferenceGroupMean</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 7.4</p> <p>hasPValue 0.441</p> |
| evi_05_pub_22927772_stu_1 | <p>isAcquiredFrom stu_1_pub_22927772</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (CompositeOutcomeMeasure and (hasTwoComponent some (BleedingOfAllType or INROver3.5)) and (isMeasuredAs some TimeRequiredToEvent))</p> <p>hasTimeFrameInDays 50</p> <p>hasEffectMetric some AbsoluteDifferenceGroupMean</p> <p>hasEffectSizeUnit day</p> <p>hasEffectSize 2.5</p> <p>hasPValue 0.15</p> |
| evi_05_pub_23850318_stu_1 | <p>isAcquiredFrom stu_1_pub_23850318</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some TargetVesselRevas) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 180</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize -1.35</p> <p>hasPValue 0.089</p> |
| evi_05_pub_24251360_stu_1 | <p>isAcquiredFrom stu_1_pub_24251360</p> |

| | |
|---------------------------|---|
| | <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INRBelow2.0) and (isMeasuredAs some PercentageOfTimeWithEvent))</p> <p>hasTimeFrameInDays 84</p> <p>hasEffectMetric some AbsoluteDifferenceGroupMean</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 1.2</p> <p>hasPValue 0.49</p> |
| evi_05_pub_24251361_stu_1 | <p>isAcquiredFrom stu_1_pub_24251361</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INROver4.0) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 28</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectMetric percentagePoint</p> <p>hasEffectSize 1.0</p> |
| evi_05_pub_24251363_stu_1 | <p>isAcquiredFrom stu_1_pub_24251363</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some AchievingStableDose) and (isMeasuredAs some TimeToEvent))</p> <p>hasTimeFrameInDays 90</p> <p>hasEffectMetric some AdjustedHazardRatio</p> <p>hasEffectSize 1.4</p> <p>hasLower95PercentCI 1.12</p> <p>hasUpper95PercentCI 1.74</p> <p>hasPValue 0.0030</p> |
| evi_06_pub_10509530_stu_1 | <p>isAcquiredFrom stu_1_pub_10509530</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C9star3))</p> <p>hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some BleedingOfAllType) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 1825</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 8.6</p> |
| evi_06_pub_15841315_stu_1 | <p>isAcquiredFrom stu_1_pub_15841315</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasTwoGeneticVariant some CYP2C9star2) and (hasTwoGeneticVariant some CYP2C9star3)))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some Thromboembolism) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 42</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 4.0</p> <p>hasPValue 0.55</p> |
| evi_06_pub_16160068_stu_1 | <p>isAcquiredFrom stu_1_pub_16160068</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MinorBleeding) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 28</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize -15.0</p> |
| evi_06_pub_17653141_stu_1 | <p>isAcquiredFrom stu_1_pub_17653141</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasFiveGeneticVariant some CYP2C9star1) and (hasFiveGeneticVariant some CYP2C9star2) and (hasFiveGeneticVariant some CYP2C9star3) and (hasFiveGeneticVariant some CYP2C9star5) and (hasFiveGeneticVariant some CYP2C9star6)))</p> <p>hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MinorBleeding) and (isMeasuredAs some TimeToEvent))</p> <p>hasTimeFrameInDays 730</p> <p>hasEffectMetric some AdjustedHazardRatio</p> <p>hasEffectSize 1.3</p> <p>hasLower95PercentCI 0.8</p> |

| | |
|---------------------------|---|
| | hasUpper95PercentCI 2.1 |
| evi_06_pub_17851566_stu_1 | isAcquiredFrom stu_1_pub_17851566 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some AchievingStableDose) and (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 60 |
| | hasEffectMetric some UnadjustedHazardRatio |
| | hasEffectSize 4.23 |
| | hasLower95PercentCI 2.95 |
| | hasUpper95PercentCI 6.07 |
| | hasPValue 0.0010 |
| evi_06_pub_17989110_stu_1 | isAcquiredFrom stu_1_pub_17989110 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some AllINRTTest) and (isMeasuredAs some CountOfEvent)) |
| | hasTimeFrameInDays 90 |
| | hasEffectMetric some AbsoluteDifferenceGroupMean |
| | hasEffectSizeUnit countNumbers |
| | hasEffectSize -0.84 |
| | hasLower95PercentCI -1.73 |
| | hasUpper95PercentCI 0.04 |
| | hasPValue 0.06 |
| evi_06_pub_19106083_stu_1 | isAcquiredFrom stu_1_pub_19106083 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOf2VsCarrierOf1OrNoncarrier and (hasSingleGeneticVariant some ABCB1_C3435T)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (AllCauseDeath or NonfatalMyocardialInfarction or Stroke)) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 2.1 |
| evi_06_pub_19106084_stu_1 | isAcquiredFrom stu_1_pub_19106084 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyRef |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasFiveGeneticVariant some CYP2C19star2) and (hasFiveGeneticVariant some CYP2C19star3) and (hasFiveGeneticVariant some CYP2C19star4) and (hasFiveGeneticVariant some CYP2C19star5) and (hasFiveGeneticVariant some CYP2C19star8))) |
| | hasOutcomeMeasure some ClinicalEfficacyMeasure and (hasSingleComponent some NonfatalStroke) and (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 450 |
| | hasEffectMetric some UnadjustedHazardRatio |
| | hasEffectSize 3.93 |
| | hasLower95PercentCI 0.66 |
| | hasUpper95PercentCI 23.51 |
| evi_06_pub_19108880_stu_1 | isAcquiredFrom stu_1_pub_19108880 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or NonfatalMyocardialInfarction or RevasUnspecified)) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 1825 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 14.6 |
| evi_06_pub_19177029_stu_1 | isAcquiredFrom stu_1_pub_19177029 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MinorBleeding) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 50 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize -1.7 |
| evi_06_pub_19193675_stu_1 | isAcquiredFrom stu_1_pub_19193675 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |

| | |
|---------------------------|--|
| | <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some IschemicStroke) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 30</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 0.6</p> <p>hasPValue 0.0010</p> |
| evi_06_pub_19228618_stu_1 | <p>isAcquiredFrom stu_1_pub_19228618</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (DrugDosingAccuracyMeasure and (hasSingleComponent some CorrectPredictionOfHighDoseRequirement) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrame 0</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 17.6</p> <p>hasPValue 0.0010</p> |
| evi_06_pub_19268736_stu_1 | <p>isAcquiredFrom stu_1_pub_19268736</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOf2VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasTwoComponent some (CVDeath or DefiniteOrProbableST)) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 180</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 5.0</p> |
| evi_06_pub_19414633_stu_1 | <p>isAcquiredFrom stu_1_pub_19414633</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasFiveGeneticVariant some CYP2C19star2) and (hasFiveGeneticVariant some CYP2C19star3) and (hasFiveGeneticVariant some CYP2C19star4) and (hasFiveGeneticVariant some CYP2C19star5) and (hasFiveGeneticVariant some CYP2C19star8)))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some NonfatalStroke) and (isMeasuredAs some TimeToEvent))</p> <p>hasTimeFrameInDays 450</p> <p>hasEffectMetric some UnadjustedHazardRatio</p> <p>hasEffectSize 1.3</p> <p>hasLower95PercentCI 0.39</p> <p>hasUpper95PercentCI 4.31</p> <p>hasPValue 0.67</p> |
| evi_06_pub_20083681_stu_1 | <p>isAcquiredFrom stu_1_pub_20083681</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star17))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some AllCauseDeath) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 30</p> <p>hasEffectMetric some UnadjustedOddsRatio</p> <p>hasEffectSize 0.87</p> <p>hasLower95PercentCI 0.23</p> <p>hasUpper95PercentCI 3.31</p> |
| evi_06_pub_20492467_stu_1 | <p>isAcquiredFrom stu_1_pub_20492467</p> <p>hasComparison some ComparisonBetweenTreatmentWithinGenotype</p> <p>hasSingleGenotypeOI some (Noncarrier and ((hasFiveGeneticVariant some CYP2C19star2) and (hasFiveGeneticVariant some CYP2C19star3) and (hasFiveGeneticVariant some CYP2C19star4) and (hasFiveGeneticVariant some CYP2C19star5) and (hasFiveGeneticVariant some CYP2C19star8)))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some NonfatalMyocardialInfarction) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 450</p> <p>hasEffectMetric some UnadjustedRelativeRisk</p> <p>hasEffectSize 0.89</p> <p>hasLower95PercentCI 0.72</p> <p>hasUpper95PercentCI 1.11</p> |
| evi_06_pub_20801498_stu_1 | <p>isAcquiredFrom stu_1_pub_20801498</p> <p>hasComparison some ComparisonBetweenTreatmentWithinGenotype</p> <p>hasSingleGenotypeOI some (Noncarrier and ((hasSixGeneticVariant some CYP2C19star2) and (hasSixGeneticVariant some CYP2C19star3) and (hasSixGeneticVariant some CYP2C19star4) and (hasSixGeneticVariant some CYP2C19star5) and (hasSixGeneticVariant some CYP2C19star6) and</p> |

| | |
|---------------------------|---|
| | <p>(hasSixGeneticVariant some CYP2C19star8)))</p> <p>hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MajorBleeding) and (isMeasuredAs some TimeToEvent))</p> <p>hasTimeFrameInDays 365</p> <p>hasEffectMetric some AdjustedHazardRatio</p> <p>hasEffectSize 0.96</p> <p>hasLower95PercentCI 0.83</p> <p>hasUpper95PercentCI 1.12</p> <p>hasPValue 0.61</p> |
| evi_06_pub_20826260_stu_1 | <p>isAcquiredFrom stu_1_pub_20826260</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOfAtLeast1 VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (AllCauseDeath or NonfatalMyocardialInfarction or TargetLesionRevas)) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 365</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize -2.1</p> <p>hasPValue 0.525</p> |
| evi_06_pub_20979470_stu_1 | <p>isAcquiredFrom stu_1_pub_20979470</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI</p> <p>hasGeneticContrast some (CarrierOfAtLeast1 VsNoncarrier and ((hasTwoGeneticVariant some CYP2C19star2) and (hasTwoGeneticVariant some CYP2C19star3)))</p> <p>hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MajorBleeding) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 365</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize -1.1</p> <p>hasPValue 0.21</p> |
| evi_06_pub_21099121_stu_1 | <p>isAcquiredFrom stu_1_pub_21099121</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOfAtLeast1 VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some DefiniteStentThrombosis) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 243</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 2.4</p> <p>hasPValue 0.87</p> |
| evi_06_pub_21170047_stu_1 | <p>isAcquiredFrom stu_1_pub_21170047</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOf2 VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star17))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some DefiniteOrProbableST) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 365</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize -1.1</p> |
| evi_06_pub_21334530_stu_1 | <p>isAcquiredFrom stu_1_pub_21334530</p> <p>hasComparison some (ComparisonBetweenTreatmentWithinGenotype and (hasStratificationInComparison some Invasive))</p> <p>hasSingleGenotypeOI some (Noncarrier and ((hasSixGeneticVariant some CYP2C19star2) and (hasSixGeneticVariant some CYP2C19star3) and (hasSixGeneticVariant some CYP2C19star4) and (hasSixGeneticVariant some CYP2C19star5) and (hasSixGeneticVariant some CYP2C19star6) and (hasSixGeneticVariant some CYP2C19star8)))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or MyocardialInfarction or Stroke)) and (isMeasuredAs some TimeToEvent))</p> <p>hasTimeFrameInDays 365</p> <p>hasEffectMetric some AdjustedHazardRatio</p> <p>hasEffectSize 0.9</p> <p>hasLower95PercentCI 0.73</p> <p>hasUpper95PercentCI 1.1</p> |
| evi_06_pub_21423021_stu_1 | <p>isAcquiredFrom stu_1_pub_21423021</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> |

| | |
|---------------------------|---|
| | <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some AllCauseDeath) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 60</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize -0.9</p> |
| evi_06_pub_21700758_stu_1 | <p>isAcquiredFrom stu_1_pub_21700758</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOfAtLeast1 VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some RevasUnspecified) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 365</p> <p>hasEffectMetric some UnadjustedRelativeRisk</p> <p>hasEffectSize 1.2</p> <p>hasLower95PercentCI 0.89</p> <p>hasUpper95PercentCI 1.62</p> <p>hasPValue 0.222</p> |
| evi_06_pub_22088980_stu_2 | <p>isAcquiredFrom stu_2_pub_22088980</p> <p>hasComparison some ComparisonBetweenTreatmentWithinGenotype</p> <p>hasSingleGenotypeOI some (CarrierOf1 and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some PRI) and (isMeasuredAs some PrimaryValue))</p> <p>hasTimeFrameInDays 14</p> <p>hasEffectMetric some AbsoluteDifferenceGroupMean</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize -17.3</p> <p>hasPValue 0.0010</p> |
| evi_06_pub_22431865_stu_2 | <p>isAcquiredFrom stu_2_pub_22431865</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (DrugDosingAccuracyMeasure and (hasSingleComponent some DosingError) and (isMeasuredAs some AbsoluteDifferenceToFinalDose))</p> <p>hasTimeFrameInDays 90</p> <p>hasEffectMetric some AbsoluteDifferenceGroupMean</p> <p>hasEffectSizeUnit mg/week</p> <p>hasEffectSize -4.28</p> <p>hasPValue 0.0010</p> |
| evi_06_pub_22450429_stu_1 | <p>isAcquiredFrom stu_1_pub_22450429</p> <p>hasComparison some ComparisonBetweenTreatmentWithinGenotype</p> <p>hasSingleGenotypeOI some (Noncarrier and ((hasTwoGeneticVariant some CYP2C19star2) and (hasTwoGeneticVariant some CYP2C19star3)))</p> <p>hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MajorBleeding) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 840</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 0.8</p> |
| evi_06_pub_22464343_stu_1 | <p>isAcquiredFrom stu_1_pub_22464343</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some PRUOver208) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 7</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize -16.0</p> <p>hasPValue 0.0106</p> |
| evi_06_pub_22624833_stu_1 | <p>isAcquiredFrom stu_1_pub_22624833</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyRef</p> <p>hasGeneticContrast some (CarrierOf1 VsNoncarrier and ((hasFiveGeneticVariant some CYP2C19star2) and (hasFiveGeneticVariant some CYP2C19star3) and (hasFiveGeneticVariant some CYP2C19star4) and (hasFiveGeneticVariant some CYP2C19star6) and (hasFiveGeneticVariant some CYP2C19star8)))</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some PRUOver230) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 180</p> <p>hasEffectMetric some AdjustedOddsRatio</p> <p>hasEffectSize 2.48</p> <p>hasLower95PercentCI 1.38</p> |

| | |
|---------------------------|--|
| | hasUpper95PercentCI 4.45 |
| evi_06_pub_22836303_stu_1 | isAcquiredFrom stu_1_pub_22836303 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some DoseAdjustment) and (isMeasuredAs some CountOfEvent)) |
| | hasTimeFrameInDays 60 |
| | hasEffectMetric some AbsoluteDifferenceGroupMean |
| | hasEffectSizeUnit countNumbers |
| | hasEffectSize -2.8 |
| | hasPValue 0.0070 |
| evi_06_pub_23850318_stu_1 | isAcquiredFrom stu_1_pub_23850318 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some BleedingOfAllType) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 180 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize -2.35 |
| | hasPValue 0.073 |
| evi_06_pub_24251360_stu_1 | isAcquiredFrom stu_1_pub_24251360 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INRInTherapeuticRange) and (isMeasuredAs some TimeRequiredToEvent)) |
| | hasTimeFrameInDays 84 |
| | hasEffectMetric some AbsoluteDifferenceGroupMedian |
| | hasEffectSizeUnit day |
| | hasEffectSize 0.0 |
| | hasPValue 0.53 |
| evi_06_pub_24251361_stu_1 | isAcquiredFrom stu_1_pub_24251361 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MajorBleeding) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 28 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize -1.2 |
| evi_06_pub_24251363_stu_1 | isAcquiredFrom stu_1_pub_24251363 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INROver4.0) and (isMeasuredAs some PercentageOfTimeWithEvent)) |
| | hasTimeFrameInDays 90 |
| | hasEffectMetric some AbsoluteDifferenceGroupMean |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize -2.9 |
| | hasLower95PercentCI -4.5 |
| | hasUpper95PercentCI -1.4 |
| | hasPValue 0.0010 |
| evi_07_pub_15841315_stu_1 | isAcquiredFrom stu_1_pub_15841315 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI |
| | hasGeneticContrast some (CarrierOfAtLeast1 VsNoncarrier and ((hasTwoGeneticVariant some CYP2C9star2) and (hasTwoGeneticVariant some CYP2C9star3))) |
| | hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MajorBleeding) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 42 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 0.0 |
| evi_07_pub_16160068_stu_1 | isAcquiredFrom stu_1_pub_16160068 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some Thromboembolism) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 28 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize -10.0 |
| evi_07_pub_17653141_stu_1 | isAcquiredFrom stu_1_pub_17653141 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |

| | |
|---------------------------|--|
| | <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some VKORC1_C1173T))</p> <p>hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MajorBleeding) and (isMeasuredAs some TimeToEvent))</p> <p>hasTimeFrameInDays 730</p> <p>hasEffectMetric some AdjustedHazardRatio</p> <p>hasEffectSize 1.7</p> <p>hasLower95PercentCI 0.7</p> <p>hasUpper95PercentCI 4.4</p> |
| evi_07_pub_17851566_stu_1 | <p>isAcquiredFrom stu_1_pub_17851566</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INRInTherapeuticRange) and (isMeasuredAs some PercentageOfTimeWithEvent))</p> <p>hasTimeFrameInDays 60</p> <p>hasEffectMetric some AbsoluteDifferenceGroupMean</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 17.0</p> <p>hasPValue 0.0010</p> |
| evi_07_pub_17989110_stu_1 | <p>isAcquiredFrom stu_1_pub_17989110</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some DoseAdjustment) and (isMeasuredAs some CountOfEvent))</p> <p>hasTimeFrameInDays 90</p> <p>hasEffectMetric some AbsoluteDifferenceGroupMean</p> <p>hasEffectSizeUnit countNumbers</p> <p>hasEffectSize -0.62</p> <p>hasLower95PercentCI -1.19</p> <p>hasUpper95PercentCI -0.04</p> <p>hasPValue 0.035</p> |
| evi_07_pub_19106084_stu_1 | <p>isAcquiredFrom stu_1_pub_19106084</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyRef</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or NonfatalMyocardialInfarction or NonfatalStroke)) and (isMeasuredAs some TimeToEvent))</p> <p>hasTimeFrameInDays 450</p> <p>hasEffectMetric some UnadjustedHazardRatio</p> <p>hasEffectSize 1.42</p> <p>hasLower95PercentCI 0.98</p> <p>hasUpper95PercentCI 2.05</p> <p>hasPValue 0.04</p> |
| evi_07_pub_19108880_stu_1 | <p>isAcquiredFrom stu_1_pub_19108880</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some CVDeath) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 1825</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 2.2</p> |
| evi_07_pub_19177029_stu_1 | <p>isAcquiredFrom stu_1_pub_19177029</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INROver3.5) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 50</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize -0.1</p> |
| evi_07_pub_19193675_stu_1 | <p>isAcquiredFrom stu_1_pub_19193675</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasTwoComponent some (AllCauseDeath or MyocardialInfarction)) and (isMeasuredAs some TimeToEvent))</p> <p>hasTimeFrameInDays 30</p> <p>hasEffectMetric some UnadjustedHazardRatio</p> |

| | |
|---------------------------|---|
| | hasEffectSize 1.14 |
| | hasLower95PercentCI 0.83 |
| | hasUpper95PercentCI 1.58 |
| | hasPValue 0.42 |
| evi_07_pub_19268736_stu_1 | isAcquiredFrom stu_1_pub_19268736 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1 VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some DefiniteOrProbableST) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 180 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 3.2 |
| | hasPValue 0.025 |
| evi_07_pub_19414633_stu_1 | isAcquiredFrom stu_1_pub_19414633 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI |
| | hasGeneticContrast some (CarrierOfAtLeast1 VsNoncarrier and ((hasFiveGeneticVariant some CYP2C9star11) and (hasFiveGeneticVariant some CYP2C9star12) and (hasFiveGeneticVariant some CYP2C9star2) and (hasFiveGeneticVariant some CYP2C9star3) and (hasFiveGeneticVariant some CYP2C9star6))) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or NonfatalMyocardialInfarction or NonfatalStroke)) and (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 450 |
| | hasEffectMetric some UnadjustedHazardRatio |
| | hasEffectSize 1.2 |
| | hasLower95PercentCI 0.78 |
| | hasUpper95PercentCI 1.85 |
| | hasPValue 0.58 |
| evi_07_pub_20083681_stu_1 | isAcquiredFrom stu_1_pub_20083681 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOf1 VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star17)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some MyocardialInfarction) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 30 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize -0.1 |
| evi_07_pub_20492467_stu_1 | isAcquiredFrom stu_1_pub_20492467 |
| | hasComparison some ComparisonBetweenTreatmentWithinGenotype |
| | hasTwoGenotypeOI some (CarrierOfAtLeast1 and ((hasFiveGeneticVariant some CYP2C19star2) and (hasFiveGeneticVariant some CYP2C19star3) and (hasFiveGeneticVariant some CYP2C19star4) and (hasFiveGeneticVariant some CYP2C19star5) and (hasFiveGeneticVariant some CYP2C19star8))) |
| | hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MajorOrMinorBleeding) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 450 |
| | hasEffectMetric some UnadjustedRelativeRisk |
| | hasEffectSize 1.6 |
| | hasLower95PercentCI 0.8 |
| | hasUpper95PercentCI 3.1 |
| evi_07_pub_20801498_stu_1 | isAcquiredFrom stu_1_pub_20801498 |
| | hasComparison some ComparisonBetweenTreatmentWithinGenotype |
| | hasSingleGenotypeOI some (CarrierOf2 and (hasSingleGeneticVariant some ABCB1_C3435T)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or MyocardialInfarction or Stroke)) and (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some AdjustedHazardRatio |
| | hasEffectSize 0.9 |
| | hasLower95PercentCI 0.7 |
| | hasUpper95PercentCI 1.15 |
| | hasPValue 0.4 |
| evi_07_pub_20826260_stu_1 | isAcquiredFrom stu_1_pub_20826260 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1 VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some Stroke) and (isMeasuredAs some IncidenceOfEvent)) |

| | |
|---------------------------|---|
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize -1.2 |
| | hasPValue 0.085 |
| evi_07_pub_20979470_stu_2 | isAcquiredFrom stu_2_pub_20979470 |
| | hasComparison some ComparisonBetweenTreatmentWithinGenotype |
| | hasTwoGenotypeOI some (CarrierOfAtLeast1 and ((hasTwoGeneticVariant some CYP2C19star2) and (hasTwoGeneticVariant some CYP2C19star3))) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasFourComponent some (CVDeath or NonfatalMyocardialInfarction or Stroke or Thromboembolism)) and (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 1314 |
| | hasEffectMetric some AdjustedHazardRatio |
| | hasEffectSize 0.78 |
| | hasLower95PercentCI 0.48 |
| | hasUpper95PercentCI 1.28 |
| evi_07_pub_21099121_stu_1 | isAcquiredFrom stu_1_pub_21099121 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1 VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasTwoComponent some (AllCauseDeath or MyocardialInfarction)) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 243 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 1.4 |
| evi_07_pub_21170047_stu_2 | isAcquiredFrom stu_2_pub_21170047 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1 VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some DefiniteStentThrombosis) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 540 |
| | hasEffectMetric some UnadjustedOddsRatio |
| | hasEffectSize 1.3 |
| | hasPValue 0.53 |
| evi_07_pub_21334530_stu_1 | isAcquiredFrom stu_1_pub_21334530 |
| | hasComparison some (ComparisonBetweenTreatmentWithinGenotype and (hasStratificationInComparison some Noninvasive)) |
| | hasTwoGenotypeOI some (CarrierOfAtLeast1 and ((hasSixGeneticVariant some CYP2C19star2) and (hasSixGeneticVariant some CYP2C19star3) and (hasSixGeneticVariant some CYP2C19star4) and (hasSixGeneticVariant some CYP2C19star5) and (hasSixGeneticVariant some CYP2C19star6) and (hasSixGeneticVariant some CYP2C19star8))) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or MyocardialInfarction or Stroke)) and (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some AdjustedHazardRatio |
| | hasEffectSize 0.86 |
| | hasLower95PercentCI 0.57 |
| | hasUpper95PercentCI 1.31 |
| evi_07_pub_21423021_stu_1 | isAcquiredFrom stu_1_pub_21423021 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MajorBleeding) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 60 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize -0.9 |
| evi_07_pub_22088980_stu_3 | isAcquiredFrom stu_3_pub_22088980 |
| | hasComparison some ComparisonBetweenTreatmentWithinGenotype |
| | hasSingleGenotypeOI some (CarrierOf1 and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some PRI) and (isMeasuredAs some PrimaryValue)) |
| | hasTimeFrameInDays 14 |
| | hasEffectMetric some AbsoluteDifferenceGroupMean |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize -21.1 |

| | |
|---------------------------|--|
| | hasPValue 0.0010 |
| evi_07_pub_22431865_stu_2 | isAcquiredFrom stu_2_pub_22431865 |
| | hasComparison some ComparisonBetweenTreatmentWithinGenotype |
| | hasSingleGenotypeOI some (Noncarrier and ((hasThreeGeneticVariant some CYP2C9star2) and (hasThreeGeneticVariant some CYP2C9star3) and (hasThreeGeneticVariant some VKORC1_G-1639A))) |
| | hasOutcomeMeasure some (DrugDosingAccuracyMeasure and (hasSingleComponent some DosingError) and (isMeasuredAs some AbsoluteDifferenceToFinalDose)) |
| | hasTimeFrameInDays 90 |
| | hasEffectMetric some AbsoluteDifferenceGroupMean |
| | hasEffectSizeUnit mg/week |
| | hasEffectSize -4.5 |
| | hasPValue 0.0010 |
| evi_07_pub_22450429_stu_1 | isAcquiredFrom stu_1_pub_22450429 |
| | hasComparison some ComparisonBetweenTreatmentWithinGenotype |
| | hasTwoGenotypeOI some (CarrierOfAtLeast1 and ((hasTwoGeneticVariant some CYP2C19star2) and (hasTwoGeneticVariant some CYP2C19star3))) |
| | hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some BleedingOfAllType) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 840 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 12.7 |
| evi_07_pub_22464343_stu_1 | isAcquiredFrom stu_1_pub_22464343 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some PRU) and (isMeasuredAs some PrimaryValue)) |
| | hasTimeFrameInDays 7 |
| | hasEffectMetric some AbsoluteDifferenceGroupMean |
| | hasEffectSize -38.6 |
| | hasPValue 7.0E-4 |
| evi_07_pub_22624833_stu_1 | isAcquiredFrom stu_1_pub_22624833 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI |
| | hasGeneticContrast some (CarrierOf2VsNoncarrier and ((hasFiveGeneticVariant some CYP2C19star2) and (hasFiveGeneticVariant some CYP2C19star3) and (hasFiveGeneticVariant some CYP2C19star4) and (hasFiveGeneticVariant some CYP2C19star6) and (hasFiveGeneticVariant some CYP2C19star8))) |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some PRUOver230) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 180 |
| | hasEffectMetric some AdjustedOddsRatio |
| | hasEffectSize 11.45 |
| | hasLower95PercentCI 2.29 |
| | hasUpper95PercentCI 57.23 |
| evi_07_pub_22836303_stu_1 | isAcquiredFrom stu_1_pub_22836303 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some DoseAdjustment) and (isMeasuredAs some PercentageOfEncounterWithEvent)) |
| | hasTimeFrameInDays 60 |
| | hasEffectMetric some AbsoluteDifferenceGroupMean |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize -18.8 |
| | hasPValue 0.0070 |
| evi_07_pub_23850318_stu_1 | isAcquiredFrom stu_1_pub_23850318 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some Stroke) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 180 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize -0.33 |
| | hasPValue 0.624 |
| evi_07_pub_24251360_stu_1 | isAcquiredFrom stu_1_pub_24251360 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some AchievingStableDose) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 84 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |

| | |
|---------------------------|--|
| | hasEffectSize -3.3 |
| | hasPValue 0.47 |
| evi_07_pub_24251361_stu_1 | isAcquiredFrom stu_1_pub_24251361 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some Thromboembolism) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 28 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 0.2 |
| evi_07_pub_24251363_stu_1 | isAcquiredFrom stu_1_pub_24251363 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INRBelow2.0) and (isMeasuredAs some PercentageOfTimeWithEvent)) |
| | hasTimeFrameInDays 90 |
| | hasEffectMetric some AbsoluteDifferenceGroupMean |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize -2.0 |
| | hasLower95PercentCI -4.9 |
| | hasUpper95PercentCI 1.0 |
| | hasPValue 0.2 |
| evi_08_pub_17653141_stu_1 | isAcquiredFrom stu_1_pub_17653141 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some VKORC1_C1173T)) |
| | hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MinorBleeding) and (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 730 |
| | hasEffectMetric some AdjustedHazardRatio |
| | hasEffectSize 0.8 |
| | hasLower95PercentCI 0.5 |
| | hasUpper95PercentCI 1.3 |
| evi_08_pub_17851566_stu_1 | isAcquiredFrom stu_1_pub_17851566 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MajorOrMinorBleeding) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 60 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize -9.3 |
| | hasPValue 0.02 |
| evi_08_pub_17989110_stu_1 | isAcquiredFrom stu_1_pub_17989110 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (CompositeOutcomeMeasure and (hasSevenComponent some (AllCauseDeath or INROver4.0 or MajorBleeding or MyocardialInfarction or Stroke or Thromboembolism or UseOfVitaminK) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 90 |
| | hasEffectMetric some UnadjustedOddsRatio |
| | hasEffectSize 0.72 |
| | hasLower95PercentCI 0.41 |
| | hasUpper95PercentCI 1.28 |
| | hasPValue 0.26 |
| evi_08_pub_19106084_stu_1 | isAcquiredFrom stu_1_pub_19106084 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyRef |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some DefiniteOrProbableST) and (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 450 |
| | hasEffectMetric some UnadjustedHazardRatio |
| | hasEffectSize 3.33 |
| | hasLower95PercentCI 1.28 |
| | hasUpper95PercentCI 8.62 |
| | hasPValue 0.0040 |
| evi_08_pub_19108880_stu_1 | isAcquiredFrom stu_1_pub_19108880 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some |

| | |
|---------------------------|--|
| | <p>CYP2C19star2))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some NonfatalMyocardialInfarction) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 1825</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 10.5</p> |
| evi_08_pub_19193675_stu_1 | <p>isAcquiredFrom stu_1_pub_19193675</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasTwoComponent some (AllCauseDeath or MyocardialInfarction)) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 30</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 0.9</p> |
| evi_08_pub_19414633_stu_1 | <p>isAcquiredFrom stu_1_pub_19414633</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasFiveGeneticVariant some CYP2C9star11) and (hasFiveGeneticVariant some CYP2C9star12) and (hasFiveGeneticVariant some CYP2C9star2) and (hasFiveGeneticVariant some CYP2C9star3) and (hasFiveGeneticVariant some CYP2C9star6)))</p> <p>hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MajorOrMinorBleeding) and (isMeasuredAs some TimeToEvent))</p> <p>hasTimeFrameInDays 450</p> <p>hasEffectMetric some UnadjustedHazardRatio</p> <p>hasEffectSize 1.48</p> <p>hasLower95PercentCI 0.78</p> <p>hasUpper95PercentCI 2.82</p> <p>hasPValue 0.23</p> |
| evi_08_pub_20083681_stu_1 | <p>isAcquiredFrom stu_1_pub_20083681</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOf2VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star17))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some MyocardialInfarction) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 30</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 2.1</p> |
| evi_08_pub_20492467_stu_1 | <p>isAcquiredFrom stu_1_pub_20492467</p> <p>hasComparison some ComparisonBetweenTreatmentWithinGenotype</p> <p>hasSingleGenotypeOI some (Noncarrier and ((hasFiveGeneticVariant some CYP2C19star2) and (hasFiveGeneticVariant some CYP2C19star3) and (hasFiveGeneticVariant some CYP2C19star4) and (hasFiveGeneticVariant some CYP2C19star5) and (hasFiveGeneticVariant some CYP2C19star8)))</p> <p>hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MajorOrMinorBleeding) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 450</p> <p>hasEffectMetric some UnadjustedRelativeRisk</p> <p>hasEffectSize 1.38</p> <p>hasLower95PercentCI 1.0</p> <p>hasUpper95PercentCI 1.93</p> |
| evi_08_pub_20801498_stu_1 | <p>isAcquiredFrom stu_1_pub_20801498</p> <p>hasComparison some ComparisonBetweenTreatmentWithinGenotype</p> <p>hasSingleGenotypeOI some (CarrierOf1 and (hasSingleGeneticVariant some ABCB1_C3435T))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or MyocardialInfarction or Stroke)) and (isMeasuredAs some TimeToEvent))</p> <p>hasTimeFrameInDays 365</p> <p>hasEffectMetric some AdjustedHazardRatio</p> <p>hasEffectSize 0.86</p> <p>hasLower95PercentCI 0.71</p> <p>hasUpper95PercentCI 1.03</p> <p>hasPValue 0.11</p> |
| evi_08_pub_20826260_stu_1 | <p>isAcquiredFrom stu_1_pub_20826260</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2))</p> |

| | |
|---------------------------|--|
| | <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasFourComponent some (AllCauseDeath or NonfatalMyocardialInfarction or Stroke or TargetLesionRevas)) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 365</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize -2.9</p> <p>hasPValue 0.378</p> |
| evi_08_pub_20979470_stu_2 | <p>isAcquiredFrom stu_2_pub_20979470</p> <p>hasComparison some ComparisonBetweenTreatmentWithinGenotype</p> <p>hasSingleGenotypeOI some (Noncarrier and ((hasTwoGeneticVariant some CYP2C19star2) and (hasTwoGeneticVariant some CYP2C19star3)))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasFourComponent some (CVDeath or NonfatalMyocardialInfarction or Stroke or Thromboembolism)) and (isMeasuredAs some TimeToEvent))</p> <p>hasTimeFrameInDays 1314</p> <p>hasEffectMetric some AdjustedHazardRatio</p> <p>hasEffectSize 0.72</p> <p>hasLower95PercentCI 0.54</p> <p>hasUpper95PercentCI 0.95</p> |
| evi_08_pub_21334530_stu_1 | <p>isAcquiredFrom stu_1_pub_21334530</p> <p>hasComparison some (ComparisonBetweenTreatmentWithinGenotype and (hasStratificationInComparison some Noninvasive))</p> <p>hasSingleGenotypeOI some (Noncarrier and ((hasSixGeneticVariant some CYP2C19star2) and (hasSixGeneticVariant some CYP2C19star3) and (hasSixGeneticVariant some CYP2C19star4) and (hasSixGeneticVariant some CYP2C19star5) and (hasSixGeneticVariant some CYP2C19star6) and (hasSixGeneticVariant some CYP2C19star8)))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or MyocardialInfarction or Stroke)) and (isMeasuredAs some TimeToEvent))</p> <p>hasTimeFrameInDays 365</p> <p>hasEffectMetric some AdjustedHazardRatio</p> <p>hasEffectSize 0.87</p> <p>hasLower95PercentCI 0.69</p> <p>hasUpper95PercentCI 1.11</p> |
| evi_08_pub_21423021_stu_1 | <p>isAcquiredFrom stu_1_pub_21423021</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some Thromboembolism) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 60</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 1.8</p> |
| evi_08_pub_22088980_stu_1 | <p>isAcquiredFrom stu_1_pub_22088980</p> <p>hasComparison some ComparisonBetweenTreatmentWithinGenotype</p> <p>hasSingleGenotypeOI some (CarrierOf1 and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some PRUOver230) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 14</p> <p>hasEffectMetric some UnadjustedRelativeRisk</p> <p>hasEffectSize 0.51</p> <p>hasLower95PercentCI 0.37</p> <p>hasUpper95PercentCI 0.69</p> <p>hasPValue 0.0010</p> |
| evi_08_pub_22431865_stu_2 | <p>isAcquiredFrom stu_2_pub_22431865</p> <p>hasComparison some ComparisonBetweenTreatmentWithinGenotype</p> <p>hasSingleGenotypeOI some (CarrierOf1 and ((hasThreeGeneticVariant some CYP2C9star2) and (hasThreeGeneticVariant some CYP2C9star3) and (hasThreeGeneticVariant some VKORC1_G-1639A)))</p> <p>hasOutcomeMeasure some (DrugDosingAccuracyMeasure and (hasSingleComponent some DosingError) and (isMeasuredAs some AbsoluteDifferenceToFinalDose))</p> <p>hasTimeFrameInDays 90</p> <p>hasEffectMetric some AbsoluteDifferenceGroupMean</p> <p>hasEffectSizeUnit mg/week</p> <p>hasEffectSize -2.3</p> <p>hasPValue 0.03</p> |
| evi_08_pub__stu_1 | <p>isAcquiredFrom stu_1_pub_22450429</p> <p>hasComparison some ComparisonBetweenTreatmentWithinGenotype</p> <p>hasSingleGenotypeOI some (Noncarrier and ((hasTwoGeneticVariant some CYP2C19star2) and (hasTwoGeneticVariant some CYP2C19star3)))</p> |

| | |
|---------------------------|---|
| | <p>hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some BleedingOfAllType) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 840</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 20.1</p> |
| evi_08_pub_22464343_stu_1 | <p>isAcquiredFrom stu_1_pub_22464343</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some PRU) and (isMeasuredAs some RelativeReductionFromBaseline))</p> <p>hasTimeFrameInDays 7</p> <p>hasEffectMetric some AbsoluteDifferenceGroupMean</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 12.6</p> <p>hasPValue 3.0E-4</p> |
| evi_08_pub_22624833_stu_1 | <p>isAcquiredFrom stu_1_pub_22624833</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyRef</p> <p>hasGeneticContrast some (CarrierOf2VsNoncarrier and ((hasFiveGeneticVariant some CYP2C19star2) and (hasFiveGeneticVariant some CYP2C19star3) and (hasFiveGeneticVariant some CYP2C19star4) and (hasFiveGeneticVariant some CYP2C19star6) and (hasFiveGeneticVariant some CYP2C19star8)))</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some PRUOver230) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 180</p> <p>hasEffectMetric some AdjustedOddsRatio</p> <p>hasEffectSize 12.54</p> <p>hasLower95PercentCI 1.48</p> <p>hasUpper95PercentCI 107.19</p> |
| evi_08_pub_22836303_stu_1 | <p>isAcquiredFrom stu_1_pub_22836303</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INROver4.0) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 84</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 0.0</p> |
| evi_08_pub_23850318_stu_1 | <p>isAcquiredFrom stu_1_pub_23850318</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (AllCauseDeath or MyocardialInfarction or Stroke)) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 180</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize -5.02</p> <p>hasPValue 0.0010</p> |
| evi_08_pub_24251360_stu_1 | <p>isAcquiredFrom stu_1_pub_24251360</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some AllINRTTest) and (isMeasuredAs some CountOfEvent))</p> <p>hasTimeFrameInDays 84</p> <p>hasEffectMetric some AbsoluteDifferenceGroupMean</p> <p>hasEffectSizeUnit countNumbers</p> <p>hasEffectSize -0.1</p> <p>hasPValue 0.68</p> |
| evi_08_pub_24251361_stu_1 | <p>isAcquiredFrom stu_1_pub_24251361</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MinorBleeding) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 28</p> <p>hasEffectMetric some AdjustedOddsRatio</p> <p>hasEffectSize 0.62</p> <p>hasLower95PercentCI 0.3</p> <p>hasUpper95PercentCI 1.27</p> <p>hasPValue 0.18</p> |
| evi_08_pub_24251363_stu_1 | <p>isAcquiredFrom stu_1_pub_24251363</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some DoseAdjustment) and (isMeasuredAs some CountOfEvent))</p> |

| | |
|---------------------------|--|
| | <p>hasTimeFrameInDays 90</p> <p>hasEffectMetric some AbsoluteDifferenceGroupMean</p> <p>hasEffectSizeUnit countNumbers</p> <p>hasEffectSize -0.5</p> <p>hasLower95PercentCI -1.03</p> <p>hasUpper95PercentCI 0.03</p> |
| evi_09_pub_17851566_stu_1 | <p>isAcquiredFrom stu_1_pub_17851566</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MajorBleeding) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 60</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize -1.0</p> |
| evi_09_pub_17989110_stu_1 | <p>isAcquiredFrom stu_1_pub_17989110</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (ClinicalEfficacySafetyMeasure and (hasSixComponent some (AllCauseDeath or MajorBleeding or MyocardialInfarction or Stroke or Thromboembolism or UseOfVitaminK)) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 90</p> <p>hasEffectMetric some UnadjustedOddsRatio</p> <p>hasEffectSize 0.78</p> <p>hasLower95PercentCI 0.2</p> <p>hasUpper95PercentCI 2.98</p> <p>hasPValue 0.71</p> |
| evi_09_pub_19106084_stu_1 | <p>isAcquiredFrom stu_1_pub_19106084</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyRef</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasFiveGeneticVariant some CYP2C9star1) and (hasFiveGeneticVariant some CYP2C9star2) and (hasFiveGeneticVariant some CYP2C9star3) and (hasFiveGeneticVariant some CYP2C9star6)))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or NonfatalMyocardialInfarction or NonfatalStroke)) and (isMeasuredAs some TimeToEvent))</p> <p>hasTimeFrameInDays 450</p> <p>hasEffectMetric some UnadjustedHazardRatio</p> <p>hasEffectSize 1.09</p> <p>hasLower95PercentCI 0.69</p> <p>hasUpper95PercentCI 1.73</p> <p>hasPValue 0.41</p> |
| evi_09_pub_19108880_stu_1 | <p>isAcquiredFrom stu_1_pub_19108880</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some DefiniteStentThrombosis) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 1825</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 8.8</p> |
| evi_09_pub_19193675_stu_1 | <p>isAcquiredFrom stu_1_pub_19193675</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some DefiniteStentThrombosis) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 30</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 1.1</p> <p>hasPValue 0.0070</p> |
| evi_09_pub_19414633_stu_2 | <p>isAcquiredFrom stu_2_pub_19414633</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasFiveGeneticVariant some CYP2C19star2) and (hasFiveGeneticVariant some CYP2C19star3) and (hasFiveGeneticVariant some CYP2C19star4) and (hasFiveGeneticVariant some CYP2C19star5) and (hasFiveGeneticVariant some CYP2C19star8)))</p> <p>hasOutcomeMeasure some (PharmacokineticsMeasure and (hasSingleComponent some</p> |

| | |
|---------------------------|---|
| | AreaUnderCurve_0-t) and (isMeasuredAs some PrimaryValue)) |
| | hasTimeFrame 0 |
| | hasEffectMetric some RelativeDifferenceGroupMean |
| | hasEffectSizeUnit percent |
| | hasEffectSize -6.1 |
| | hasPValue 0.06 |
| evi_09_pub_20083681_stu_1 | isAcquiredFrom stu_1_pub_20083681 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1 VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star17)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some MyocardialInfarction) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 30 |
| | hasEffectMetric some UnadjustedOddsRatio |
| | hasEffectSize 1.05 |
| | hasLower95PercentCI 0.59 |
| | hasUpper95PercentCI 1.85 |
| evi_09_pub_20801498_stu_1 | isAcquiredFrom stu_1_pub_20801498 |
| | hasComparison some ComparisonBetweenTreatmentWithinGenotype |
| | hasSingleGenotypeOI some (Noncarrier and (hasSingleGeneticVariant some ABCB1_C3435T)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or MyocardialInfarction or Stroke)) and (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some AdjustedHazardRatio |
| | hasEffectSize 0.71 |
| | hasLower95PercentCI 0.55 |
| | hasUpper95PercentCI 0.92 |
| | hasPValue 0.0104 |
| evi_09_pub_20826260_stu_1 | isAcquiredFrom stu_1_pub_20826260 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1 VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star17)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasTwoComponent some (AllCauseDeath or NonfatalMyocardialInfarction)) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 2.2 |
| | hasPValue 0.255 |
| evi_09_pub_20979470_stu_2 | isAcquiredFrom stu_2_pub_20979470 |
| | hasComparison some ComparisonBetweenTreatmentWithinGenotype |
| | hasTwoGenotypeOI some (CarrierOfAtLeast1 and ((hasTwoGeneticVariant some CYP2C19star2) and (hasTwoGeneticVariant some CYP2C19star3))) |
| | hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MajorBleeding) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 1314 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 5.8 |
| evi_09_pub_22088980_stu_2 | isAcquiredFrom stu_2_pub_22088980 |
| | hasComparison some ComparisonBetweenTreatmentWithinGenotype |
| | hasSingleGenotypeOI some (CarrierOf1 and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some PRUOver230) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 14 |
| | hasEffectMetric some UnadjustedRelativeRisk |
| | hasEffectSize 0.21 |
| | hasLower95PercentCI 0.11 |
| | hasUpper95PercentCI 0.39 |
| | hasPValue 0.0010 |
| evi_09_pub_22431865_stu_2 | isAcquiredFrom stu_2_pub_22431865 |
| | hasComparison some ComparisonBetweenTreatmentWithinGenotype |
| | hasThreeGenotypeOI some (((hasThreeGeneticVariant some CYP2C9star2) and (hasThreeGeneticVariant some CYP2C9star3) and (hasThreeGeneticVariant some VKORC1_G-1639A)) and (CarrierOf2 or CarrierOf3 or CarrierOf4)) |
| | hasOutcomeMeasure some (DrugDosingAccuracyMeasure and (hasSingleComponent some DosingError) and (isMeasuredAs some AbsoluteDifferenceToFinalDose)) |

| | |
|---------------------------|--|
| | hasTimeFrameInDays 90 |
| | hasEffectMetric some AbsoluteDifferenceGroupMean |
| | hasEffectSizeUnit mg/week |
| | hasEffectSize -7.2 |
| | hasPValue 0.0010 |
| evi_09_pub_22450429_stu_1 | isAcquiredFrom stu_1_pub_22450429 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasTwoGeneticVariant some CYP2C19star2) and (hasTwoGeneticVariant some CYP2C19star3))) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or (FatalMyocardialInfarction or NonfatalMyocardialInfarction) or (FatalStroke or NonfatalStroke))) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 840 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 1.5 |
| | hasPValue 0.17 |
| evi_09_pub_22464343_stu_1 | isAcquiredFrom stu_1_pub_22464343 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MajorBleeding) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 30 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 1.2 |
| | hasPValue 0.6134 |
| evi_09_pub_22836303_stu_1 | isAcquiredFrom stu_1_pub_22836303 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INROver3.3) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 84 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize -7.7 |
| evi_09_pub_24251360_stu_1 | isAcquiredFrom stu_1_pub_24251360 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (DrugDosingAccuracyMeasure and (hasSingleComponent some DosingError) and (isMeasuredAs some RelativeDifferenceToFinalDose)) |
| | hasTimeFrameInDays 84 |
| | hasEffectMetric some AbsoluteDifferenceGroupMean |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize -9.0 |
| | hasPValue 0.04 |
| evi_09_pub_24251361_stu_1 | isAcquiredFrom stu_1_pub_24251361 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some AllCauseDeath) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 28 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 0.2 |
| evi_09_pub_24251363_stu_1 | isAcquiredFrom stu_1_pub_24251363 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some AdditionalINRTTest) and (isMeasuredAs some CountOfEvent)) |
| | hasTimeFrameInDays 90 |
| | hasEffectMetric some AbsoluteDifferenceGroupMedian |
| | hasEffectSizeUnit countNumbers |
| | hasEffectSize 0.0 |
| evi_10_pub_17851566_stu_1 | isAcquiredFrom stu_1_pub_17851566 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MinorBleeding) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 60 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize -8.3 |

| | |
|---------------------------|---|
| evi_10_pub_17989110_stu_1 | isAcquiredFrom stu_1_pub_17989110 hasComparison some ComparisonBetweenTreatmentWithoutGenotype hasOutcomeMeasure some (DrugDosingAccuracyMeasure and (hasSingleComponent some DosingError) and (isMeasuredAs some AbsoluteDifferenceToFinalDose)) hasTimeFrameInDays 90 hasEffectMetric some AbsoluteDifferenceGroupMean hasEffectSizeUnit mg/week hasEffectSize -4.4 hasPValue 0.0020 |
| evi_10_pub_19106084_stu_1 | isAcquiredFrom stu_1_pub_19106084 hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyRef hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasFiveGeneticVariant some CYP2C9star11) and (hasFiveGeneticVariant some CYP2C9star12) and (hasFiveGeneticVariant some CYP2C9star2) and (hasFiveGeneticVariant some CYP2C9star3) and (hasFiveGeneticVariant some CYP2C9star6))) hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MajorOrMinorBleeding) and (isMeasuredAs some TimeToEvent)) hasTimeFrameInDays 450 hasEffectMetric some UnadjustedHazardRatio hasEffectSize 1.07 hasLower95PercentCI 0.47 hasUpper95PercentCI 2.4 hasPValue 0.88 |
| evi_10_pub_19108880_stu_1 | isAcquiredFrom stu_1_pub_19108880 hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasTwoComponent some (CVDeath or NonfatalMyocardialInfarction)) and (isMeasuredAs some IncidenceOfEvent)) hasTimeFrameInDays 1825 hasEffectMetric some AbsoluteDifferenceGroupRate hasEffectSizeUnit percentagePoint hasEffectSize 12.6 |
| evi_10_pub_19193675_stu_1 | isAcquiredFrom stu_1_pub_19193675 hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some AllCauseDeath) and (isMeasuredAs some IncidenceOfEvent)) hasTimeFrameInDays 30 hasEffectMetric some AbsoluteDifferenceGroupRate hasEffectSizeUnit percentagePoint hasEffectSize -0.2 hasPValue 0.71 |
| evi_10_pub_19414633_stu_2 | isAcquiredFrom stu_2_pub_19414633 hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasFiveGeneticVariant some CYP2C19star2) and (hasFiveGeneticVariant some CYP2C19star3) and (hasFiveGeneticVariant some CYP2C19star4) and (hasFiveGeneticVariant some CYP2C19star5) and (hasFiveGeneticVariant some CYP2C19star8))) hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some MPA) and (isMeasuredAs some AbsoluteReductionFromBaseline)) hasTimeFrame 0 hasEffectMetric some AbsoluteDifferenceGroupMean hasEffectSizeUnit percentagePoint hasEffectSize -1.3 hasPValue 0.63 |
| evi_10_pub_stu_1 | isAcquiredFrom stu_1_pub_20083681 hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved hasGeneticContrast some (CarrierOf1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star17)) hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (AllCauseDeath or MyocardialInfarction or TargetVesselRevas)) and (isMeasuredAs some IncidenceOfEvent)) hasTimeFrameInDays 30 hasEffectMetric some AbsoluteDifferenceGroupRate hasEffectSizeUnit percentagePoint hasEffectSize -0.5 |
| evi_10_pub_20801498_stu_1 | isAcquiredFrom stu_1_pub_20801498 |

| | |
|---------------------------|--|
| | <p>hasComparison some ComparisonBetweenTreatmentWithinGenotype</p> <p>hasTwoGenotypeOI some (CarrierOfAtLeast1 and ((hasSixGeneticVariant some CYP2C19star2) and (hasSixGeneticVariant some CYP2C19star3) and (hasSixGeneticVariant some CYP2C19star4) and (hasSixGeneticVariant some CYP2C19star5) and (hasSixGeneticVariant some CYP2C19star6) and (hasSixGeneticVariant some CYP2C19star8)))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasTwoComponent some (CVDeath or MyocardialInfarction)) and (isMeasuredAs some TimeToEvent))</p> <p>hasTimeFrameInDays 365</p> <p>hasEffectMetric some AdjustedHazardRatio</p> <p>hasEffectSize 0.73</p> <p>hasLower95PercentCI 0.57</p> <p>hasUpper95PercentCI 0.95</p> <p>hasPValue 0.0184</p> |
| evi_10_pub_20826260_stu_1 | <p>isAcquiredFrom stu_1_pub_20826260</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOfAtLeast1 VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star17))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some DefiniteOrProbableST) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 365</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 0.0</p> <p>hasPValue 0.964</p> |
| evi_10_pub_20979470_stu_2 | <p>isAcquiredFrom stu_2_pub_20979470</p> <p>hasComparison some ComparisonBetweenTreatmentWithinGenotype</p> <p>hasSingleGenotypeOI some (Noncarrier and ((hasTwoGeneticVariant some CYP2C19star2) and (hasTwoGeneticVariant some CYP2C19star3)))</p> <p>hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MajorBleeding) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 1314</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 0.4</p> |
| evi_10_pub_22088980_stu_3 | <p>isAcquiredFrom stu_3_pub_22088980</p> <p>hasComparison some ComparisonBetweenTreatmentWithinGenotype</p> <p>hasSingleGenotypeOI some (CarrierOf1 and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some PRUOver230) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 14</p> <p>hasEffectMetric some UnadjustedRelativeRisk</p> <p>hasEffectSize 0.2</p> <p>hasLower95PercentCI 0.11</p> <p>hasUpper95PercentCI 0.38</p> <p>hasPValue 0.0010</p> |
| evi_10_pub_22431865_stu_1 | <p>isAcquiredFrom stu_1_pub_22431865</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INRBelow1.5OrOver4.0) and (isMeasuredAs some PercentageOfEncounterWithEvent))</p> <p>hasTimeFrameInDays 90</p> <p>hasEffectMetric some AbsoluteDifferenceGroupMean</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize -12.1</p> <p>hasPValue 0.0010</p> |
| evi_10_pub_22450429_stu_1 | <p>isAcquiredFrom stu_1_pub_22450429</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI</p> <p>hasGeneticContrast some (CarrierOfAtLeast1 VsNoncarrier and ((hasTwoGeneticVariant some CYP2C19star2) and (hasTwoGeneticVariant some CYP2C19star3)))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSixComponent some (CVDeath or RevasUnspecified or TransientIschemicAttack or UnstableAngina or (FatalMyocardialInfarction or NonfatalMyocardialInfarction) or (FatalStroke or NonfatalStroke))) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 840</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 0.79</p> <p>hasPValue 0.593</p> |

| | |
|---------------------------|---|
| evi_10_pub_22464343_stu_1 | isAcquiredFrom stu_1_pub_22464343 hasComparison some ComparisonBetweenTreatmentWithoutGenotype hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MinorBleeding) and (isMeasuredAs some IncidenceOfEvent)) hasTimeFrameInDays 30 hasEffectMetric some AbsoluteDifferenceGroupRate hasEffectSizeUnit percentagePoint hasEffectSize 4.0 hasPValue 0.2693 |
| evi_10_pub_24251360_stu_1 | isAcquiredFrom stu_1_pub_24251360 hasComparison some ComparisonBetweenTreatmentWithoutGenotype hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MinorBleeding) and (isMeasuredAs some IncidenceOfEvent)) hasTimeFrameInDays 84 hasEffectMetric some AbsoluteDifferenceGroupRate hasEffectSizeUnit percentagePoint hasEffectSize -2.0 |
| evi_10_pub_24251361_stu_1 | isAcquiredFrom stu_1_pub_24251361 hasComparison some ComparisonBetweenTreatmentWithoutGenotype hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INROver4.0) and (isMeasuredAs some TimeToEvent)) hasTimeFrameInDays 28 hasEffectMetric some AdjustedHazardRatio hasEffectSize 1.08 hasLower95PercentCI 0.81 hasUpper95PercentCI 1.44 hasPValue 0.59 |
| evi_10_pub_24251363_stu_1 | isAcquiredFrom stu_1_pub_24251363 hasComparison some ComparisonBetweenTreatmentWithoutGenotype hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MajorBleeding) and (isMeasuredAs some IncidenceOfEvent)) hasTimeFrameInDays 90 hasEffectMetric some AbsoluteDifferenceGroupRate hasEffectSizeUnit percentagePoint hasEffectSize 0.0 |
| evi_11_pub_17851566_stu_1 | isAcquiredFrom stu_1_pub_17851566 hasComparison some ComparisonBetweenTreatmentWithoutGenotype hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some Thromboembolism) and (isMeasuredAs some IncidenceOfEvent)) hasTimeFrameInDays 60 hasEffectMetric some AbsoluteDifferenceGroupRate hasEffectSizeUnit percentagePoint hasEffectSize 0.0 |
| evi_11_pub_17989110_stu_1 | isAcquiredFrom stu_1_pub_17989110 hasComparison some ComparisonBetweenTreatmentWithinGenotype hasSingleGenotypeOI some (Noncarrier and ((hasThreeGeneticVariant some CYP2C9star2) and (hasThreeGeneticVariant some CYP2C9star3) and (hasThreeGeneticVariant some VKORC1_C1173T))) hasOutcomeMeasure some (DrugDosingAccuracyMeasure and (hasSingleComponent some DosingError) and (isMeasuredAs some AbsoluteDifferenceToFinalDose)) hasTimeFrameInDays 90 hasEffectMetric some AbsoluteDifferenceGroupMean hasEffectSizeUnit mg/week hasEffectSize -7.0 hasPValue 0.035 |
| evi_11_pub_19106084_stu_2 | isAcquiredFrom stu_2_pub_19106084 hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasFiveGeneticVariant some CYP2C19star2) and (hasFiveGeneticVariant some CYP2C19star3) and (hasFiveGeneticVariant some CYP2C19star4) and (hasFiveGeneticVariant some CYP2C19star5) and (hasFiveGeneticVariant some CYP2C19star8))) hasOutcomeMeasure some (PharmacokineticsMeasure and (hasSingleComponent some AreaUnderCurve_0-t) and (isMeasuredAs some PrimaryValue)) hasTimeFrame 0 hasEffectMetric some RelativeDifferenceGroupMean hasEffectSizeUnit percent hasEffectSize -32.4 hasPValue 0.0010 |

| | |
|---------------------------|--|
| evi_11_pub_19108880_stu_1 | isAcquiredFrom stu_1_pub_19108880 hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved hasGeneticContrast some (CarrierOf1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or NonfatalMyocardialInfarction or RevasUnspecified)) and (isMeasuredAs some IncidenceOfEvent)) hasTimeFrameInDays 1825 hasEffectMetric some AbsoluteDifferenceGroupRate hasEffectSizeUnit percentagePoint hasEffectSize 14.4 |
| evi_11_pub_19193675_stu_1 | isAcquiredFrom stu_1_pub_19193675 hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (AllCauseDeath or IschemicStroke or MyocardialInfarction)) and (isMeasuredAs some IncidenceOfEvent)) hasTimeFrameInDays 30 hasEffectMetric some AbsoluteDifferenceGroupRate hasEffectSizeUnit percentagePoint hasEffectSize 1.5 |
| evi_11_pub_20083681_stu_1 | isAcquiredFrom stu_1_pub_20083681 hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved hasGeneticContrast some (CarrierOf2VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star17)) hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (AllCauseDeath or MyocardialInfarction or TargetVesselRevas)) and (isMeasuredAs some IncidenceOfEvent)) hasTimeFrameInDays 30 hasEffectMetric some AbsoluteDifferenceGroupRate hasEffectSizeUnit percentagePoint hasEffectSize 1.5 |
| evi_11_pub_20801498_stu_1 | isAcquiredFrom stu_1_pub_20801498 hasComparison some ComparisonBetweenTreatmentWithinGenotype hasSingleGenotypeOI some (Noncarrier and ((hasSixGeneticVariant some CYP2C19star2) and (hasSixGeneticVariant some CYP2C19star3) and (hasSixGeneticVariant some CYP2C19star4) and (hasSixGeneticVariant some CYP2C19star5) and (hasSixGeneticVariant some CYP2C19star6) and (hasSixGeneticVariant some CYP2C19star8))) hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasTwoComponent some (CVDeath or MyocardialInfarction)) and (isMeasuredAs some TimeToEvent)) hasTimeFrameInDays 365 hasEffectMetric some AdjustedHazardRatio hasEffectSize 0.86 hasLower95PercentCI 0.73 hasUpper95PercentCI 1.01 hasPValue 0.0734 |
| evi_11_pub_20826260_stu_1 | isAcquiredFrom stu_1_pub_20826260 hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star17)) hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasFourComponent some (AllCauseDeath or NonfatalMyocardialInfarction or Stroke or TargetLesionRevas)) and (isMeasuredAs some IncidenceOfEvent)) hasTimeFrameInDays 365 hasEffectMetric some AbsoluteDifferenceGroupRate hasEffectSizeUnit percentagePoint hasEffectSize -6.1 hasPValue 0.042 |
| evi_11_pub_20979470_stu_2 | isAcquiredFrom stu_2_pub_20979470 hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasTwoGeneticVariant some CYP2C19star2) and (hasTwoGeneticVariant some CYP2C19star3))) hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasFourComponent some (CVDeath or NonfatalMyocardialInfarction or Stroke or Thromboembolism)) and (isMeasuredAs some TimeToEvent)) hasTimeFrameInDays 1314 hasEffectMetric some AdjustedHazardRatio hasEffectSize 1.07 hasLower95PercentCI 0.7 hasUpper95PercentCI 1.63 |
| evi_11_pub_22088980_stu_1 | isAcquiredFrom stu_1_pub_22088980 hasComparison some ComparisonBetweenTreatmentAndBetweenGenotype |

| | |
|---------------------------|--|
| | <p>hasGeneticContrast some (CarrierOf1 VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some PRI) and (isMeasuredAs some PrimaryValue))</p> <p>hasTimeFrameInDays 14</p> <p>hasEffectMetric some AbsoluteDifferenceGroupMean</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 3.9</p> <p>hasPValue 0.12</p> |
| evi_11_pub_22431865_stu_1 | <p>isAcquiredFrom stu_1_pub_22431865</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INROver4.0) and (isMeasuredAs some PercentageOfEncounterWithEvent))</p> <p>hasTimeFrameInDays 90</p> <p>hasEffectMetric some AbsoluteDifferenceGroupMean</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 0.02</p> <p>hasPValue 0.97</p> |
| evi_11_pub_22450429_stu_1 | <p>isAcquiredFrom stu_1_pub_22450429</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI</p> <p>hasGeneticContrast some (CarrierOfAtLeast1 VsNoncarrier and ((hasTwoGeneticVariant some CYP2C19star2) and (hasTwoGeneticVariant some CYP2C19star3)))</p> <p>hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MajorBleeding) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 840</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 0.5</p> <p>hasPValue 0.59</p> |
| evi_11_pub_22464343_stu_1 | <p>isAcquiredFrom stu_1_pub_22464343</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasFourComponent some (CVDDeath or DefiniteOrProbableST or HospitalizationOfAllCause or NonfatalMyocardialInfarction)) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 30</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 0.0</p> |
| evi_11_pub_24251360_stu_1 | <p>isAcquiredFrom stu_1_pub_24251360</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MajorBleeding) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 84</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize -0.4</p> |
| evi_11_pub_24251363_stu_1 | <p>isAcquiredFrom stu_1_pub_24251363</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some Thromboembolism) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 90</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize -0.5</p> |
| evi_12_pub_17851566_stu_1 | <p>isAcquiredFrom stu_1_pub_17851566</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INROver3.0) and (isMeasuredAs some DurationOfTimeWithEvent))</p> <p>hasTimeFrameInDays 8</p> <p>hasEffectMetric some AbsoluteDifferenceGroupMean</p> <p>hasEffectSizeUnit day</p> <p>hasEffectSize -0.03</p> <p>hasPValue 0.55</p> |
| evi_12_pub_17989110_stu_1 | <p>isAcquiredFrom stu_1_pub_17989110</p> <p>hasComparison some ComparisonBetweenTreatmentWithinGenotype</p> <p>hasSingleGenotypeOI some (CarrierOf1 and ((hasThreeGeneticVariant some CYP2C9star2) and (hasThreeGeneticVariant some CYP2C9star3) and (hasThreeGeneticVariant some VKORC1_C1173T)))</p> <p>hasOutcomeMeasure some (DrugDosingAccuracyMeasure and (hasSingleComponent some DosingError))</p> |

| | |
|---------------------------|---|
| | and (isMeasuredAs some AbsoluteDifferenceToFinalDose)) |
| | hasTimeFrameInDays 90 |
| | hasEffectMetric some AbsoluteDifferenceGroupMean |
| | hasEffectSizeUnit mg/week |
| | hasEffectSize -2.9 |
| | hasPValue 0.17 |
| evi_12_pub_19106084_stu_2 | isAcquiredFrom stu_2_pub_19106084 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasFiveGeneticVariant some CYP2C19star2) and (hasFiveGeneticVariant some CYP2C19star3) and (hasFiveGeneticVariant some CYP2C19star4) and (hasFiveGeneticVariant some CYP2C19star5) and (hasFiveGeneticVariant some CYP2C19star8))) |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some MPA) and (isMeasuredAs some AbsoluteReductionFromBaseline)) |
| | hasTimeFrame 0 |
| | hasEffectMetric some AbsoluteDifferenceGroupMean |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize -9.0 |
| | hasPValue 0.0010 |
| evi_12_pub_19108880_stu_1 | isAcquiredFrom stu_1_pub_19108880 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOf2VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or NonfatalMyocardialInfarction or RevasUnspecified)) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 1825 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 16.3 |
| evi_12_pub_19193675_stu_1 | isAcquiredFrom stu_1_pub_19193675 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some MyocardialInfarction) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 30 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 1.0 |
| | hasPValue 0.42 |
| evi_12_pub_20083681_stu_1 | isAcquiredFrom stu_1_pub_20083681 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star17)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (AllCauseDeath or MyocardialInfarction or TargetVesselRevas)) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 30 |
| | hasEffectMetric some UnadjustedOddsRatio |
| | hasEffectSize 0.94 |
| | hasLower95PercentCI 0.55 |
| | hasUpper95PercentCI 1.61 |
| evi_12_pub_20801498_stu_1 | isAcquiredFrom stu_1_pub_20801498 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyRef |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasSixGeneticVariant some CYP2C19star2) and (hasSixGeneticVariant some CYP2C19star3) and (hasSixGeneticVariant some CYP2C19star4) and (hasSixGeneticVariant some CYP2C19star5) and (hasSixGeneticVariant some CYP2C19star6) and (hasSixGeneticVariant some CYP2C19star8))) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or MyocardialInfarction or Stroke)) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 1.3 |
| | hasPValue 0.25 |
| evi_12_pub_20979470_stu_2 | isAcquiredFrom stu_2_pub_20979470 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasTwoGeneticVariant some CYP2C19star2) and (hasTwoGeneticVariant some CYP2C19star3))) |

| | |
|---------------------------|--|
| | <p>hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MajorBleeding) and (isMeasuredAs some TimeToEvent))</p> <p>hasTimeFrameInDays 1314</p> <p>hasEffectMetric some AdjustedHazardRatio</p> <p>hasEffectSize 2.47</p> <p>hasLower95PercentCI 1.23</p> <p>hasUpper95PercentCI 4.97</p> |
| evi_12_pub_22088980_stu_2 | <p>isAcquiredFrom stu_2_pub_22088980</p> <p>hasComparison some ComparisonBetweenTreatmentAndBetweenGenotype</p> <p>hasGeneticContrast some (CarrierOf1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some PRI) and (isMeasuredAs some PrimaryValue))</p> <p>hasTimeFrameInDays 14</p> <p>hasEffectMetric some AbsoluteDifferenceGroupMean</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize -4.8</p> <p>hasPValue 0.07</p> |
| evi_12_pub_22431865_stu_1 | <p>isAcquiredFrom stu_1_pub_22431865</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INRBelow1.5) and (isMeasuredAs some PercentageOfEncounterWithEvent))</p> <p>hasTimeFrameInDays 90</p> <p>hasEffectMetric some AbsoluteDifferenceGroupMean</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize -12.1</p> <p>hasPValue 0.0010</p> |
| evi_12_pub_22450429_stu_1 | <p>isAcquiredFrom stu_1_pub_22450429</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasTwoGeneticVariant some CYP2C19star2) and (hasTwoGeneticVariant some CYP2C19star3)))</p> <p>hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some BleedingOfAllType) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 840</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize -6.4</p> |
| evi_12_pub_24251360_stu_1 | <p>isAcquiredFrom stu_1_pub_24251360</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some Thromboembolism) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 84</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 0.3</p> |
| evi_12_pub_24251363_stu_1 | <p>isAcquiredFrom stu_1_pub_24251363</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some AchievingStableDose) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 90</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 11.6</p> |
| evi_13_pub_17851566_stu_1 | <p>isAcquiredFrom stu_1_pub_17851566</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INRBelow2.0) and (isMeasuredAs some DurationOfTimeWithEvent))</p> <p>hasTimeFrameInDays 8</p> <p>hasEffectMetric some AbsoluteDifferenceGroupMean</p> <p>hasEffectSizeUnit day</p> <p>hasEffectSize -1.65</p> <p>hasPValue 0.0010</p> |
| evi_13_pub_17989110_stu_1 | <p>isAcquiredFrom stu_1_pub_17989110</p> <p>hasComparison some ComparisonBetweenTreatmentWithinGenotype</p> <p>hasThreeGenotypeOI some (((hasThreeGeneticVariant some CYP2C9star2) and (hasThreeGeneticVariant some CYP2C9star3) and (hasThreeGeneticVariant some VKORC1_C1173T)) and (CarrierOf2 or CarrierOf3 or CarrierOf4))</p> <p>hasOutcomeMeasure some (DrugDosingAccuracyMeasure and (hasSingleComponent some DosingError))</p> |

| | |
|---------------------------|--|
| | <p>and (isMeasuredAs some AbsoluteDifferenceToFinalDose))</p> <p>hasTimeFrameInDays 90</p> <p>hasEffectMetric some AbsoluteDifferenceGroupMean</p> <p>hasEffectSizeUnit mg/week</p> <p>hasEffectSize -7.4</p> <p>hasPValue 0.0010</p> |
| evi_13_pub_19106084_stu_1 | <p>isAcquiredFrom stu_1_pub_19106084</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyRef</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasFiveGeneticVariant some CYP2C19star2) and (hasFiveGeneticVariant some CYP2C19star3) and (hasFiveGeneticVariant some CYP2C19star4) and (hasFiveGeneticVariant some CYP2C19star5) and (hasFiveGeneticVariant some CYP2C19star8)))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or NonfatalMyocardialInfarction or NonfatalStroke)) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 450</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 4.1</p> |
| evi_13_pub_20083681_stu_1 | <p>isAcquiredFrom stu_1_pub_20083681</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star17))</p> <p>hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MajorOrMinorBleeding) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 30</p> <p>hasEffectMetric some UnadjustedOddsRatio</p> <p>hasEffectSize 1.8</p> <p>hasLower95PercentCI 1.03</p> <p>hasUpper95PercentCI 3.14</p> |
| evi_13_pub_20801498_stu_1 | <p>isAcquiredFrom stu_1_pub_20801498</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyRef</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasSixGeneticVariant some CYP2C19star2) and (hasSixGeneticVariant some CYP2C19star3) and (hasSixGeneticVariant some CYP2C19star4) and (hasSixGeneticVariant some CYP2C19star5) and (hasSixGeneticVariant some CYP2C19star6) and (hasSixGeneticVariant some CYP2C19star8)))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or MyocardialInfarction or Stroke)) and (isMeasuredAs some TimeToEvent))</p> <p>hasTimeFrameInDays 30</p> <p>hasEffectMetric some AdjustedHazardRatio</p> <p>hasEffectSize 1.37</p> <p>hasLower95PercentCI 1.04</p> <p>hasUpper95PercentCI 1.82</p> <p>hasPValue 0.028</p> |
| evi_13_pub_20979470_stu_1 | <p>isAcquiredFrom stu_1_pub_20979470</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasTwoGeneticVariant some CYP2C19star2) and (hasTwoGeneticVariant some CYP2C19star3)))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or NonfatalMyocardialInfarction or Stroke)) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 365</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize -1.5</p> |
| evi_13_pub_22088980_stu_3 | <p>isAcquiredFrom stu_3_pub_22088980</p> <p>hasComparison some ComparisonBetweenTreatmentAndBetweenGenotype</p> <p>hasGeneticContrast some (CarrierOf1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some PRI) and (isMeasuredAs some PrimaryValue))</p> <p>hasTimeFrameInDays 14</p> <p>hasEffectMetric some AbsoluteDifferenceGroupMean</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize -8.6</p> <p>hasPValue 0.0010</p> |
| evi_13_pub_22431865_stu_1 | <p>isAcquiredFrom stu_1_pub_22431865</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (ClinicalEfficacySafetyMeasure and (hasFiveComponent some (AllCauseDeath or MajorBleeding or MyocardialInfarction or Stroke or Thromboembolism)) and</p> |

| | |
|---------------------------|---|
| | <p>(isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 90</p> <p>hasEffectMetric some UnadjustedRelativeRisk</p> <p>hasEffectSize 0.46</p> <p>hasLower95PercentCI 0.29</p> <p>hasUpper95PercentCI 0.72</p> <p>hasPValue 0.0010</p> |
| evi_13_pub_24251363_stu_1 | <p>isAcquiredFrom stu_1_pub_24251363</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some AchievingStableDose) and (isMeasuredAs some TimeRequiredToEvent))</p> <p>hasTimeFrameInDays 90</p> <p>hasEffectMetric some AbsoluteDifferenceGroupMedian</p> <p>hasEffectSizeUnit day</p> <p>hasEffectSize -15.0</p> |
| evi_14_pub_19106084_stu_1 | <p>isAcquiredFrom stu_1_pub_19106084</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyRef</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasFiveGeneticVariant some CYP2C19star2) and (hasFiveGeneticVariant some CYP2C19star3) and (hasFiveGeneticVariant some CYP2C19star4) and (hasFiveGeneticVariant some CYP2C19star5) and (hasFiveGeneticVariant some CYP2C19star8)))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some DefiniteOrProbableST) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 450</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 1.8</p> |
| evi_14_pub_20083681_stu_1 | <p>isAcquiredFrom stu_1_pub_20083681</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOf1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star17))</p> <p>hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MajorBleeding) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 30</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 0.5</p> |
| evi_14_pub_20801498_stu_1 | <p>isAcquiredFrom stu_1_pub_20801498</p> <p>hasComparison some ComparisonBetweenTreatmentWithinGenotype</p> <p>hasTwoGenotypeOI some (CarrierOfAtLeast1 and ((hasSixGeneticVariant some CYP2C19star2) and (hasSixGeneticVariant some CYP2C19star3) and (hasSixGeneticVariant some CYP2C19star4) and (hasSixGeneticVariant some CYP2C19star5) and (hasSixGeneticVariant some CYP2C19star6) and (hasSixGeneticVariant some CYP2C19star8)))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or MyocardialInfarction or Stroke)) and (isMeasuredAs some TimeToEvent))</p> <p>hasTimeFrameInDays 30</p> <p>hasEffectMetric some AdjustedHazardRatio</p> <p>hasEffectSize 0.73</p> <p>hasLower95PercentCI 0.52</p> <p>hasUpper95PercentCI 1.03</p> <p>hasPValue 0.078</p> |
| evi_14_pub_20979470_stu_2 | <p>isAcquiredFrom stu_2_pub_20979470</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasTwoGeneticVariant some CYP2C19star2) and (hasTwoGeneticVariant some CYP2C19star3)))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasFourComponent some (CVDeath or NonfatalMyocardialInfarction or Stroke or Thromboembolism)) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 1314</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 1.0</p> |
| evi_14_pub_22088980_stu_1 | <p>isAcquiredFrom stu_1_pub_22088980</p> <p>hasComparison some ComparisonBetweenTreatmentAndBetweenGenotype</p> <p>hasGeneticContrast some (CarrierOf2VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some e PRI) and (isMeasuredAs some PrimaryValue))</p> <p>hasTimeFrameInDays 14</p> |

| | |
|---------------------------|---|
| | hasEffectMetric some AbsoluteDifferenceGroupMean |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 20.3 |
| evi_14_pub_22431865_stu_1 | isAcquiredFrom stu_1_pub_22431865 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some AllINRTTest) and (isMeasuredAs some CountOfEvent)) |
| | hasTimeFrameInDays 90 |
| | hasEffectMetric some AbsoluteDifferenceGroupMean |
| | hasEffectSizeUnit countNumbers |
| | hasEffectSize 0.23 |
| | hasPValue 0.35 |
| evi_15_pub_19106084_stu_1 | isAcquiredFrom stu_1_pub_19106084 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyRef |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasFiveGeneticVariant some CYP2C19star2) and (hasFiveGeneticVariant some CYP2C19star3) and (hasFiveGeneticVariant some CYP2C19star4) and (hasFiveGeneticVariant some CYP2C19star5) and (hasFiveGeneticVariant some CYP2C19star8))) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some CVDeath) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 450 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 1.6 |
| evi_15_pub_20083681_stu_1 | isAcquiredFrom stu_1_pub_20083681 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved |
| | hasGeneticContrast some (CarrierOf2VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star17)) |
| | hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MajorBleeding) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 30 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 0.7 |
| evi_15_pub_20801498_stu_1 | isAcquiredFrom stu_1_pub_20801498 |
| | hasComparison some ComparisonBetweenTreatmentWithinGenotype |
| | hasSingleGenotypeOI some (Noncarrier and ((hasSixGeneticVariant some CYP2C19star2) and (hasSixGeneticVariant some CYP2C19star3) and (hasSixGeneticVariant some CYP2C19star4) and (hasSixGeneticVariant some CYP2C19star5) and (hasSixGeneticVariant some CYP2C19star6) and (hasSixGeneticVariant some CYP2C19star8))) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or MyocardialInfarction or Stroke)) and (isMeasuredAs some TimeToEvent)) |
| | hasTimeFrameInDays 30 |
| | hasEffectMetric some AdjustedHazardRatio |
| | hasEffectSize 0.96 |
| | hasLower95PercentCI 0.76 |
| | hasUpper95PercentCI 1.22 |
| | hasPValue 0.76 |
| evi_15_pub_20979470_stu_1 | isAcquiredFrom stu_1_pub_20979470 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star17)) |
| | hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MajorBleeding) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 0.5 |
| evi_15_pub_22088980_stu_2 | isAcquiredFrom stu_2_pub_22088980 |
| | hasComparison some ComparisonBetweenTreatmentAndBetweenGenotype |
| | hasGeneticContrast some (CarrierOf2VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2)) |
| | hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some PRI) and (isMeasuredAs some PrimaryValue)) |
| | hasTimeFrameInDays 14 |
| | hasEffectMetric some AbsoluteDifferenceGroupMean |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 15.5 |
| evi_15_pub_22431865_stu_1 | isAcquiredFrom stu_1_pub_22431865 |

| | |
|---------------------------|---|
| | <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some INRInTherapeuticRange) and (isMeasuredAs some TimeRequiredToEvent))</p> <p>hasTimeFrameInDays 90</p> <p>hasEffectMetric some AbsoluteDifferenceGroupMean</p> <p>hasEffectSizeUnit day</p> <p>hasEffectSize -0.36</p> <p>hasPValue 0.08</p> |
| evi_16_pub_19106084_stu_1 | <p>isAcquiredFrom stu_1_pub_19106084</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyRef</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasFiveGeneticVariant some CYP2C19star2) and (hasFiveGeneticVariant some CYP2C19star3) and (hasFiveGeneticVariant some CYP2C19star4) and (hasFiveGeneticVariant some CYP2C19star5) and (hasFiveGeneticVariant some CYP2C19star8)))</p> <p>hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MajorOrMinorBleeding) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 450</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize -0.1</p> |
| evi_16_pub_20083681_stu_1 | <p>isAcquiredFrom stu_1_pub_20083681</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyObserved</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star17))</p> <p>hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MajorBleeding) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 30</p> <p>hasEffectMetric some UnadjustedOddsRatio</p> <p>hasEffectSize 2.04</p> <p>hasLower95PercentCI 0.68</p> <p>hasUpper95PercentCI 6.12</p> |
| evi_16_pub_20801498_stu_1 | <p>isAcquiredFrom stu_1_pub_20801498</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyRef</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and ((hasSixGeneticVariant some CYP2C19star2) and (hasSixGeneticVariant some CYP2C19star3) and (hasSixGeneticVariant some CYP2C19star4) and (hasSixGeneticVariant some CYP2C19star5) and (hasSixGeneticVariant some CYP2C19star6) and (hasSixGeneticVariant some CYP2C19star8)))</p> <p>hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasTwoComponent some (CVDeath or MyocardialInfarction)) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 365</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 1.2</p> |
| evi_16_pub_20979470_stu_2 | <p>isAcquiredFrom stu_2_pub_20979470</p> <p>hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI</p> <p>hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star17))</p> <p>hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MajorBleeding) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 1314</p> <p>hasEffectMetric some AbsoluteDifferenceGroupRate</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize -1.4</p> |
| evi_16_pub_22088980_stu_3 | <p>isAcquiredFrom stu_3_pub_22088980</p> <p>hasComparison some ComparisonBetweenTreatmentAndBetweenGenotype</p> <p>hasGeneticContrast some (CarrierOf2VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star2))</p> <p>hasOutcomeMeasure some (PharmacodynamicsMeasure and (hasSingleComponent some PRI) and (isMeasuredAs some PrimaryValue))</p> <p>hasTimeFrameInDays 14</p> <p>hasEffectMetric some AbsoluteDifferenceGroupMean</p> <p>hasEffectSizeUnit percentagePoint</p> <p>hasEffectSize 10.8</p> |
| evi_16_pub_22431865_stu_1 | <p>isAcquiredFrom stu_1_pub_22431865</p> <p>hasComparison some ComparisonBetweenTreatmentWithoutGenotype</p> <p>hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MajorBleeding) and (isMeasuredAs some IncidenceOfEvent))</p> <p>hasTimeFrameInDays 90</p> |

| | |
|---------------------------|--|
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize -1.6 |
| | hasPValue 0.054 |
| evi_17_pub_19106084_stu_1 | isAcquiredFrom stu_1_pub_19106084 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyRef |
| | hasGeneticContrast some (CarrierOfAtLeast1 VsNoncarrier and ((hasFiveGeneticVariant some CYP2C19star2) and (hasFiveGeneticVariant some CYP2C19star3) and (hasFiveGeneticVariant some CYP2C19star4) and (hasFiveGeneticVariant some CYP2C19star5) and (hasFiveGeneticVariant some CYP2C19star8))) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some NonfatalMyocardialInfarction) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 450 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 2.6 |
| evi_17_pub_20801498_stu_1 | isAcquiredFrom stu_1_pub_20801498 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyRef |
| | hasGeneticContrast some (CarrierOfAtLeast1 VsNoncarrier and ((hasSixGeneticVariant some CYP2C19star2) and (hasSixGeneticVariant some CYP2C19star3) and (hasSixGeneticVariant some CYP2C19star4) and (hasSixGeneticVariant some CYP2C19star5) and (hasSixGeneticVariant some CYP2C19star6) and (hasSixGeneticVariant some CYP2C19star8))) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some DefiniteStentThrombosis) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 0.7 |
| evi_17_pub_20979470_stu_1 | isAcquiredFrom stu_1_pub_20979470 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI |
| | hasGeneticContrast some (CarrierOf1 VsNoncarrier and ((hasTwoGeneticVariant some CYP2C19star2) and (hasTwoGeneticVariant some CYP2C19star3))) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or NonfatalMyocardialInfarction or Stroke)) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize -1.4 |
| evi_17_pub_22431865_stu_1 | isAcquiredFrom stu_1_pub_22431865 |
| | hasComparison some ComparisonBetweenTreatmentWithoutGenotype |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some Thromboembolism) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 90 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize -3.1 |
| evi_18_pub_19106084_stu_1 | isAcquiredFrom stu_1_pub_19106084 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyRef |
| | hasGeneticContrast some (CarrierOfAtLeast1 VsNoncarrier and ((hasFiveGeneticVariant some CYP2C19star2) and (hasFiveGeneticVariant some CYP2C19star3) and (hasFiveGeneticVariant some CYP2C19star4) and (hasFiveGeneticVariant some CYP2C19star5) and (hasFiveGeneticVariant some CYP2C19star8))) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some NonfatalStroke) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 450 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 0.64 |
| evi_18_pub_20801498_stu_1 | isAcquiredFrom stu_1_pub_20801498 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyRef |
| | hasGeneticContrast some (CarrierOfAtLeast1 VsNoncarrier and ((hasSixGeneticVariant some CYP2C19star2) and (hasSixGeneticVariant some CYP2C19star3) and (hasSixGeneticVariant some CYP2C19star4) and (hasSixGeneticVariant some CYP2C19star5) and (hasSixGeneticVariant some CYP2C19star6) and (hasSixGeneticVariant some CYP2C19star8))) |
| | hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MajorBleeding) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 365 |

| | |
|---------------------------|--|
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 0.7 |
| evi_18_pub_20979470_stu_1 | isAcquiredFrom stu_1_pub_20979470 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI |
| | hasGeneticContrast some (CarrierOf2VsNoncarrier and ((hasTwoGeneticVariant some CYP2C19star2) and (hasTwoGeneticVariant some CYP2C19star3))) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or NonfatalMyocardialInfarction or Stroke)) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize -2.9 |
| evi_19_pub_20801498_stu_1 | isAcquiredFrom stu_1_pub_20801498 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyRef |
| | hasGeneticContrast some (CarrierOf2VsCarrierOf1OrNoncarrier and (hasSingleGeneticVariant some ABCB1_C3435T)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or MyocardialInfarction or Stroke)) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize -0.1 |
| evi_19_pub_20979470_stu_1 | isAcquiredFrom stu_1_pub_20979470 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyOI |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star17)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasThreeComponent some (CVDeath or NonfatalMyocardialInfarction or Stroke)) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize -2.3 |
| evi_20_pub_20801498_stu_1 | isAcquiredFrom stu_1_pub_20801498 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyRef |
| | hasGeneticContrast some (CarrierOf2VsCarrierOf1OrNoncarrier and (hasSingleGeneticVariant some ABCB1_C3435T)) |
| | hasOutcomeMeasure some (ClinicalEfficacyMeasure and (hasSingleComponent some DefiniteStentThrombosis) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize -0.3 |
| evi_21_pub_20801498_stu_1 | isAcquiredFrom stu_1_pub_20801498 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyRef |
| | hasGeneticContrast some (CarrierOf2VsCarrierOf1OrNoncarrier and (hasSingleGeneticVariant some ABCB1_C3435T)) |
| | hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MajorBleeding) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 0.1 |
| evi_22_pub_20801498_stu_1 | isAcquiredFromRef stu_1_pub_20801498 |
| | hasComparison some ComparisonBetweenGenotypeWithinDrugTherapyRef |
| | hasGeneticContrast some (CarrierOfAtLeast1VsNoncarrier and (hasSingleGeneticVariant some CYP2C19star17)) |
| | hasOutcomeMeasure some (ClinicalSafetyMeasure and (hasSingleComponent some MajorBleeding) and (isMeasuredAs some IncidenceOfEvent)) |
| | hasTimeFrameInDays 365 |
| | hasEffectMetric some AbsoluteDifferenceGroupRate |
| | hasEffectSizeUnit percentagePoint |
| | hasEffectSize 2.1 |